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ABSTRACT 
Emily Rose Smith: Point-of-Care HIV Testing for Early Infant Diagnosis During the Postpartum Period: 
Timing and Type of Test Matters  
(Under the direction of Annelies Van Rie) 
In the past decade, large gains have been made in reducing pediatric HIV infections during the 
prenatal or peripartum period. However, recent changes in the World Health Organization (WHO) 
breastfeeding guidelines will likely shift the majority of new infant HIV infections to the postnatal 
period
1,2
. Although breastfeeding guidelines have changed, early infant diagnosis (EID) recommendations 
have not been updated.  
In this dissertation, I evaluated the performance of two HIV rapid tests, Determine and Unigold, 
on a cohort of 121 Malawian HIV-exposed, breast-fed infants who were HIV negative at 6 weeks 
postpartum from 3 to 18 months of age. I also evaluated the cost-effectiveness for several EID strategies 
that varied in type, timing, and number of rapid tests, including an Alere test, a point-of-care virological 
assay, through Markov modeling. 
Among 121 HIV-exposed infants, the estimated specificity increased quicker for Unigold to 
100% (95% CI: 95.4, 100.0) by age 12 months compared with 95.6% (90.7, 100.0) by 15 months of age 
for Determine. Both tests failed to detect several incident HIV infections. Seroreversion occurred sooner 
with Unigold with an earlier mean time to seroreversion by 62 days (95% CI: 60, 64). Among 21 different 
EID strategies, the lowest costing strategy was testing once with Unigold at 9 months ($18.20 per infant) 
and testing twice with Alere at 6 and 15 months ($145.60 per infant). The strategies with the lowest and 
highest effectiveness were testing once with Unigold at 9 months (337,806 disability-adjusted-life years 
[DALYs]) and testing twice at 6 and 15 months with Alere (192,588 DALYs). After sequentially 
comparing all strategies in ranked order by costs, six remained cost-effective.  
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 Our findings highlight that the type and timing of rapid test matters greatly in regard to accurately 
identifying and ruling out pediatric HIV infections. Updated guidelines for use of rapid tests in young 
HIV-exposed children that explicitly takes the type of test and infant age into account are urgently needed 
to ensure optimal care for the 1.5 million HIV-exposed infants born annually, especially in light of the 
new breastfeeding guidelines. 
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CHAPTER 1: SPECIFIC AIMS 
 
 About 1.5 million HIV positive women become pregnant each year3, resulting in a 1.5 million 
infants at risk of HIV infection. In 2010, the Joint United Nations Programme on HIV/AIDS Global Plan 
set forth ambitious goals including reducing the mother-to-child transmission (MTCT) of HIV to less than 
5% by 2015. Efforts to scale up prevention of mother-to-child transmission (PMTCT) services for HIV 
positive mothers in low resource settings has yielded promising results, such as more widespread 
distribution of antiretroviral (ART) therapy and an increased uptake in PMTCT services. Despite these 
improvements, an estimated 260,000 children under 5 were infected with the virus in 2011
3
, almost all 
(90%) of these infections occurred in sub-Saharan Africa.   
 PMTCT guidelines recommend at least 4 antenatal care visits during pregnancy, provision of 
ARV prophylaxis to the infant during pregnancy and delivery, and virological testing at 4-6 weeks
4
. 
Under these guidelines and the widespread scale-up of ART services in resource-poor settings, MTCT of 
HIV is likely to be successful in further reducing vertical transmission of HIV during the antenatal, 
delivery, and early infancy (i.e., first 6 weeks) periods. However, the current PMTCT cascade 
inadequately captures the postpartum period as it typically stops after delivery or, at best, after the 4-6 
week infant virological test. In addition, postpartum transmission of HIV comprises 15% to 35% of new 
pediatric infections, suggesting current PMTCT strategies insufficiently capture the postpartum period 
and are not sufficient to eliminate HIV among infants
5-7
. Postpartum-acquired HIV is expected to increase 
given the recent changes in breastfeeding guidelines. HIV positive mothers are now encouraged to 
exclusively breastfeed for the first 6 months of life and continue breastfeeding for at least the first 12 
 2 
 
months of life
8. The extended duration of breastfeeding will increase the duration an infant’s exposure, 
which will increase the incidence of infant HIV acquisition through breastfeeding.   
 Early infant diagnosis (EID) of HIV infection is critical in the survival of HIV infected children
9
. 
The WHO currently recommends HIV-DNA/RNA polymerase chain reaction (PCR) and ultra-sensitive 
p24 antigen assays for EID
10
. In countries where the risk of infant HIV infection is the highest, the utility 
of virologic tests are hindered by significant financial and logistical challenges.  EID is also crucial in 
identifying seroreversion and seroconversion. Current PMTCT recommendations suggests testing infants 
with a rapid test 6 weeks after weaning but have not adequately addressed how to test infants in the 
interim period between 6 weeks of age and the cessation of breastfeeding. Rapid tests could be used in 
infants age 3 to 24 months, but their performance is hindered by the presence of maternal HIV antibodies. 
After  the age of 3 months, it is unclear when rapid tests are able to distinguish between an infant HIV 
infection and maternal antibodies in breastfeeding populations, severely inhibiting the utility of rapid tests 
during the postpartum period
8,11,12
 
13-17
. Furthermore, different rapid tests have been shown to perform 
differently in infants and have not been evaluated during the entire breastfeeding period.   
 The Global Plan towards the elimination of new HIV infections among children by 2015 and 
keeping their mothers alive will only be achievable if we redefine the PMTCT cascade to encompass the 
mother/infant dyad throughout the entire breastfeeding period. Changes in breastfeeding guidelines will 
increase the number of HIV-exposed infants after the 6 week virological test. Given the importance of 
early ART initiation, timely, cost effective, and accurate HIV testing strategies are critical for 
breastfeeding infants who escaped HIV infection during the first 6 weeks of life.  
 To evaluate the performance of two commonly used rapid tests (Determine and Unigold) in a 
breastfeeding, resource-limited population and identify testing algorithms to maximize rapid test 
performance during the first 2 years of life, we propose the following specific aims:  
  
 3 
 
Specific Aim 1:  
     Evaluate the performance of Determine and Unigold tests by: 
Aim 1a. Determining the sensitivity, specificity, positive predictive values, and negative predictive 
values of Determine and Unigold rapid tests for identifying incident HIV infections, compared with 
the PCR reference standard, among breastfeeding, HEU infants (i.e., PCR negative at 6 weeks). 
Aim 1b. Describing the Determine and Unigold rapid test results for all children with documented 
incident HIV infection during the breastfeeding period among infants who were PCR negative at 6 
weeks. 
Specific Aim 2:  
Determine the median time to seroreversion in a cohort of breastfeeding, HEU infants (i.e., PCR 
negative at 6 weeks) during the first 3 to 18 months of life. 
Specific Aim 3:  
Perform a modeling study to evaluate cost-effectiveness of various infant testing algorithms to 
accurately identify incident HIV infection in resource poor settings.   
 4 
 
CHAPTER 2: BACKGROUND 
 
2.1 Dramatic improvements in PMTCT to reduce prenatal and perinatal transmission 
 
 Large gains have been made in reducing infant HIV acquisition by the effective development and 
implementation of prevention of mother-to-child transmission (PMTCT) programs over the past two 
decades and most notably after 2010. In 2010, the Global Plan set forth ambitious goals including 
reducing the mother-to-child transmission (MTCT) of HIV to less than 5% by 2015
18
. Efforts to scale up 
PMTCT services for HIV positive mothers in 22 priority countries, 1 in India and 21 in Africa, has 
yielded promising results, such as an increase in HIV testing and counseling among pregnant women, 
more widespread distribution of antiretroviral (ARV) therapy and an overall uptake in PMTCT services
19
. 
Rapid scale up of PMTCT services has been dramatic over the last few years with over 60% of pregnant 
women receiving some PMTCT service
15,20
. Coverage of ART programs has increased from 10% in 
2004
21
 to 62% in 2012
19
. From 2009-2011, ART prophylaxis prevented an estimated 409,000 new infant 
infections in resource poor settings
22
. Since 2003, new infections in children worldwide dropped by 43% 
and in the last 4 years alone new infections declined by 24%
22
. New HIV infections among infants have 
been reduced by 50% in seven of the Global Plan’s priority countries1. Although the number of new 
infections among children is decreasing, the number of women newly infected with HIV has remained 
stable since 2009
1
.   
Current PMTCT guidelines  
 Current PMTCT guidelines recommend antenatal care visits during pregnancy, receiving HIV 
testing and counseling, provision of ARV prophylaxis for the HIV positive mother, and PMTCT 
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interventions during labor and delivery
4
. All pregnant women are encouraged to have at least 4 antenatal 
care visits with services for vaccinations, screening and treatment for infections, and early identification 
of warning signs. During the antenatal care visits, women are also offered HIV testing and counseling. If 
the woman is HIV positive, she is given offered an ARV regimen and encouraged to deliver in a facility 
equipped with PMTCT interventions. Postpartum PMTCT guidelines include following up of the infant 
and mother with HIV testing and linkage to HIV services if needed.  
Limitations of the current PMTCT guidelines 
 Although PMTCT guidelines have greatly increased the number of women on ART during 
antenatal care, there is a paucity of guidance on how to manage HIV-exposed infants during the 
postpartum period for two reasons.  
 #1: The PMTCT cascade is mainly maternal-centric. In 2010, the WHO defined a strategic plan 
aimed at achieving the Millennium Development Goals (MDG) 4, 5, and 6 (MDG 4: Reduce child 
mortality, MDG 5: Improve maternal health, and MDG 6: Combat HIV/AIDS, malaria and other 
diseases) through the use of the current PMTCT structure
23
. To aid in achieving these goals, the 
comprehensive strategic plan included 4 components: 1) Primary prevention of HIV infection among 
women of childbearing age; 2) Preventing unintended pregnancies among women living with HIV; 3) 
Preventing HIV transmission from a woman living with HIV to her infant, and 4) Providing appropriate 
treatment, care and support to mothers living with HIV and their children and families. Investment needs 
along the PMTCT cascade projected by the Global Plan from 2011-2015 also remained largely maternal-
centric with the largest increases in funding needed for more HIV testing and counseling, ARV therapy 
for mothers, and Option B+ availability (Figure 2)
18
. In contrast, increases in early infant diagnosis (EID) 
increased marginally.  
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Figure 1. Investment needs in 22 priority countries from Global Plan 
  
 ARV prophylaxis is recommended for the infant during labor and delivery and extended NVP is 
recommended while the mother is breastfeeding. However, there remains a paucity of recommendations 
on how to ensure the health and well-being of the HIV-exposed infant during the postpartum period.  
 #2: The PMTCT cascade typically stops after delivery or, at best, after the infant’s 4-6 week 
virological test. The 4-6 week virological test is vitally important as it allows for the early initiation of 
ART, which is linked to the survival of infected children. DNA/PCR testing remains the gold standard in 
diagnosing HIV infection at 4-6 weeks because of its high sensitivity and specificity. After 4-6 weeks, 
(Figure 3), breastfeeding children will remain exposed to HIV through for 6 to 24 months, per the updated 
WHO recommendations (see Section 2.3).  Although the guidelines recommend further testing during this 
time, this recommendation is rarely implemented and many HIV positive mothers and their infants are 
lost during the postpartum period
21,24
. 
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Figure 2. Early Infant Diagnosis Testing Cascade 
 
2.2 Early infant HIV diagnosis 
 
 Accurate and timely diagnosis of HIV is crucial for the survival of HIV infected children as early 
initiation of treatment is required given the risk of rapid progression of disease in young infants. Without 
ART, up to 60% of HIV-infected infants die by the second year
25,26
. Given that EID and early ART 
initiation, regardless if the disease has progressed clinically or immunologically, can dramatically 
increase an infected infant’s health outcomes, including mortality, timely detection should be a priority9.  
HIV testing methods for EID 
 The WHO recommends HIV-DNA or HIV-RNA PCR tests as well as ultra-sensitive p24 antigen 
assays for EID in resource limited settings
10
. A virological test is recommended at the first postnatal visit 
at 4-6 weeks and  a serological test is recommended after the initial 4-6 week test if the infant develops 
signs or symptoms suggestive of HIV or when the infant reaches 9 months of age (Figure 3)
27
. Virological 
testing in HEU infants occurs again 6 weeks after discontinuation of breastfeeding to rule out HIV 
infection. Polymerase chain reaction (PCR)-based HIV DNA and HIV RNA assays have become the most 
widely used diagnostic assays for EID worldwide
10
 and can detect most HIV-1 subtypes including A, B, 
C, D, E, G, and H. The specificity and sensitivity of HIV DNA PCR is 100% at 3 and 6 months
28-30
. HIV 
RNA assays have similar sensitivity and specificity values although they are not as widely used as a 
diagnostic tool for HEU infants.  
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Implementation of EID 
 Significant increases in EID have been seen worldwide through integrating EID with 
immunization services and scaling up virological testing using dried blood spots for PCR. However, these 
tests require samples to be transported from remote sites to centralized laboratory facilities. In developing 
countries where the risk of infant HIV infection is the highest, significant financial and logistical 
challenges hinder the utility of these tests.  
 EID is not only hindered by logistical factors but also greatly affected by attrition after delivery. 
Recent data shows that an alarming number of infants born to women with HIV do not receive testing 
within the first 2 months of life, with attrition numbers as high as 92%
21,24
. Recent studies in sub-Saharan 
Africa among lactating populations have documented attrition rates of up to 80% by 6 months, greatly 
impacting the utility and evaluation of virological diagnostic assays, particularly since the women have to 
return to the clinics a few weeks later to receive test results
31-42
.  
2.3 Increasing importance of MTCT during breastfeeding 
 
 Overall mortality of children with HIV before age 2 is substantially higher than children without 
HIV, irrespective of when they acquired the infection. However, among HIV-infected children, mortality 
is higher among infants who acquired the infection perinatally than among infants who acquired the 
infection postnatally, as summarized in a recent meta-analysis of clinical trials or cohort studies in sub-
Saharan African countries
43
. Overall, the 18-month post-infection mortality risk for perinatally infected 
children was 60% (57%-63) while the post-infection risk for postpartum-infected children was 36% 
(30%-42%). Within 12 months, the differential between mortality estimates for perinatally infected or 
postnatally infected infants did not substantially differ. An estimated 31% of infants infected after 4 
weeks had died within 12 months while 38% of infants perinatally infected died. Although the mortality 
associated with breastfeeding-associated infection was lower than the perinatally-infected mortality risk, 
we would expect both estimates to be higher in field settings. Most of the studies included in the meta-
analysis offered higher standards of care with clinical follow-up that is not often representative of real-
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world scenarios. Thus, it is likely the 36% breastfeeding-associated mortality risk is underestimated and 
highlights the need for timely and accurate detection of infection during the postpartum period. 
 Until recently, most of the reductions in infant HIV infections have occurred during pregnancy, 
delivery, and early infancy (i.e., birth to 6 week virological test)
1
. The current PMTCT guidelines of ARV 
interventions for pregnant and lactating women have been highly successful in reducing vertical 
transmission of HIV during antenatal, delivery, and early infancy (i.e., first 6 weeks) periods. As a 
consequence, it is estimated that over half of all new infections in high burden countries will occur during 
the breastfeeding period
1
. In areas with long breastfeeding, as many as 8 out of 10 newly acquired HIV 
infections will occur during the breastfeeding period 
1
. Recent changes in the WHO breastfeeding 
guidelines will likely increase the duration and intensity of breastfeeding in many countries and thus 
increase an infant’s recurrent exposure to HIV over a longer period of time, thereby increasing 
breastfeeding-associated MTCT. 
WHO Guidelines on HIV and infant feeding (Table 1) 
 In 2006, HIV infected women were to choose the most appropriate infant feeding option based on 
their individual circumstance. Exclusive breastfeeding was recommended for the first six months of life 
unless replacement feeding in the local setting was acceptable, feasible, affordable, and sustainable. When 
such a replacement feeding was found, HIV infected mothers were encouraged to avoid all breastfeeding. 
When replacement feeding was not acceptable, feasible, affordable, and sustainable, HIV infected 
mothers should continue breastfeeding with complementary foods. Breastfeeding should then be stopped 
once a nutritionally adequate diet without breast milk could be provided. No recommendations regarding 
the use of ARV during breastfeeding were given.  
 Between 2006 and 2009, substantial increases in programmatic experience and research evidence 
provided data regarding infant feeding, infant health, and HIV. Numerous studies in several high burden 
countries of Botswana, India, Malawi, South Africa, and Uganda found increased infant morbidity and 
mortality beyond the first six months of life associated with replacement feeding among HIV-exposed 
infants in the absence of ARV interventions
44-52
. Infants given replacement foods suffered increased 
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growth deficits and other severe infections, such as bouts of diarrhea and pneumonia
44,49-53
. Similarly, 
exclusive breastfeeding was found to improve HIV free survival in HEU infants
54,55
. Decreased HIV 
transmission within the first six months of life was also found to be associated with exclusive 
breastfeeding compared to mixed feeding
46,55,56
. 
 New research also highlighted that providing HIV infected mothers and/or their infants with ARV 
interventions could significantly reduce their risk of postnatal HIV transmission through breastfeeding. 
The provision of ARV along with breastfeeding through 12 months was found to prevent transmission 
and detrimental health benefits seen with mixed feeding
57-62
. In particular, HIV infected women who were 
given 3-drug antepartum ARV prophylaxis, regardless of CD4 count, through six months of study had 
lower rates of MTCT during breastfeeding
61
. Likewise, the Breastfeeding, Antiretrovirals and Nutrition 
(BAN) trial found 53% protective efficacy associated with providing 3-drug ARV prophylaxis during 
breastfeeding in women with CD4 > 250 cells/ul
60
. A 2011 systematic review also reported that the risk of 
HIV transmission during breastfeeding can be substantially reduced to 1-2% with ARV intervention
62
. 
These findings had profound implications for the HIV-infected mothers and their decision to breastfeed 
and how long to breastfeed for HIV positive mothers.  
 In 2010, the WHO changed the recommendations for HIV and infant feeding. HIV positive 
mothers are now encouraged to exclusively breastfeed for the first 6 months of life, introduce 
complimentary food thereafter, and continue breastfeeding for the first 12 months of life. Additionally, 
HIV positive mothers should receive lifelong ARV therapy or ARV prophylaxis interventions to reduce 
transmission during the 12 month breastfeeding period. Twelve months was chosen as the most beneficial 
cut-off point for breastfeeding among HIV infected mothers through modeling data since this represents 
the time in which breastfeeding provides the maximum survival benefit
8
. The benefit of breastfeeding 
until 12 months, in the presence of ARV interventions, was also found to be greater than the risk of HIV 
transmission. The new guidelines are recommended even in areas where ARVs are not yet available or 
distribution is being scaled up.  
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Table 1. 2006 and 2010 WHO recommendations on HIV and infant feeding. 
 
Maternal and infant interventions for prevention of HIV transmission during breastfeeding 
 Treatment recommendations for HIV positive pregnant and postpartum women have been 
streamlined since 2010 with the adoption of a single, universal regimen of ART for life 
4
. Since 2010, 
countries could choose between Option A, Option B, and Option B+ for pregnant, HIV positive women. 
Under Option A, women with CD4 counts ≤350 cells/mm receive triple ARVs starting as soon as 
diagnosed and infants receive a prophylactic regimen of daily nevirapine from birth through 1 week 
beyond the cessation of breastfeeding. Under Option B, women received triple ARVs as early as 14 
weeks gestation and continued after cessation of breastfeeding and infants receive daily nevirapine or 
AZT from birth through age 4-6 weeks regardless of infant feeding method. Under Option B+, women 
receive tripe ARVs starting as soon as diagnosed and continued through life and infants receive the same 
prophylactic therapy as Option B. The simplified approaches of Option B and Option B+ have greatly 
increased the number of HIV positive women who initiated ARV while pregnant.  
 Even though the simplified treatment approaches of Option B and Option B+ have significantly 
increased the number of HIV positive, pregnant women initiating ART, significant challenges remain. 
Only 4 of the 22 priority countries of the Global Plan achieved the goal of providing ARV to 90% of 
pregnant women living with HIV. Among women residing in sub-Saharan Africa, only 59% received 
ARV therapy or prophylaxis during pregnancy and delivery in 2011
19,63
. Only 58% of mothers
64
 and 29-
41% of HIV-exposed infants received antiretroviral (ARV) therapy in 2009
65,66
.  
2006 recommendations 2010 recommendations 
Based on clinical stage and CD4 cell count. 
 
Mothers known to be HIV-infected should be provided 
with lifelong ARV therapy or ARV prophylaxis 
interventions to reduce HIV transmission through 
breastfeeding. 
The most appropriate infant feeding option for an HIV-
infected mother depends on her individual circumstances. 
Exclusive breastfeeding is recommended for HIV-infected 
mothers for the first six months of life unless replacement 
feeding is acceptable, feasible, affordable, sustainable and 
safe for them and their infants before that time. All 
breastfeeding should stop once a nutritionally adequate and 
safe diet without breast milk can be provided. 
Mothers known to be HIV-infected (and whose infants are 
HIV uninfected or of unknown HIV status) should 
exclusively breastfeed their infants, regardless if ARVs 
are available, for the first 6 months of life, introducing 
appropriate complementary foods thereafter, and continue 
breastfeeding for the first 12 months of life. Breastfeeding 
should then only stop once a nutritionally adequate and 
safe diet without breast milk can be provided. 
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Problems with adherence to ART in the postpartum period 
 Among HIV positive women who initiated ART, high rates of non-adherence are observed in the 
prenatal and postpartum period (33% and 47%, respectively)
67
. Moreover, the highest rates of treatment 
default occur after 6 weeks postpartum and occurs progressively throughout the first 12 months
11
 
31,36,68,69
. 
Long-term ART adherence in PMTCT programs during the postpartum period has received less attention, 
even though the risk of nonadherence is higher
36,37,42
.  The large drop off in treatment throughout the 
postpartum period results in missed opportunities to improve the health of the HIV positive mother and 
exposed infant through appropriate testing and treatment, if needed. 
2.4 Monitoring of HIV infection during the breastfeeding period 
 
 Monitoring infant HIV infection status in the breastfeeding period is critical to timely identify 
HIV and to accurately rule out HIV infection. Early initiation of ART can dramatically increase the 
infant’s likelihood of survival, particularly among perinatally-infected children. Ruling out HIV infection 
(i.e., identifying the time of seroreversion) is also critical to breastfeeding, HIV positive mothers of HEU 
infants as this gives the mother peace of mind and increases the likelihood she will continue to breastfeed. 
 Ideally, virological tests should be used in the breastfeeding period to accurately determine the 
infant’s HIV infection status. As previously discussed, these tests are hindered by significant challenges 
in resource poor settings and repeat virologic tests throughout the breastfeeding period are not affordable 
in most settings. Rapid tests during the breastfeeding period could serve as a cost-effective and efficient 
tool for testing HIV. Repeat rapid tests are cheaper and allow for quick results that eliminate the loss-to-
follow-up often seen when using virological tests that require lab transportation time, batch testing, and 
longer waiting time for results
11,12
.  
Performance of rapid tests after the 4-6 week virological test 
 The availability of affordable, point of care HIV testing in adult populations has revolutionized 
diagnosis of the HIV worldwide. Over the past several decades, numerous rapid HIV tests that detect 
human antibodies against HIV-specific antigens have become commercially available. In adult 
populations, rapid tests have demonstrated similar accuracies to enzyme linked immunosorbant assays 
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(ELISA) in detecting HIV infection in low resource settings, although each test performs differently in 
clinical practice with varied sensitivities and specificities
70,71
.   
 Adults. Several rapid tests have been approved by the FDA for point of care HIV testing. In a 
study directly comparing all FDA approved rapid tests, the sensitivity and specificity of all tests exceeded 
95%
72
 although Unigold had the lowest sensitivity compared to Reveal G3, Multispot HIV-1/2, OraQuick 
Advance HIV-1/2, Stat-Pak, and Complete (96.8%, 98.9%, 99.6%, 99.5%, 98.3%, 100%, respectively)
72
.  
 Infants. Rapid tests have been evaluated in children, but there is a paucity of data regarding rapid 
tests performance among infants younger than 9 months. Table 2 summarizes the studies which examined 
sensitivities and specificities of two rapid tests, Determine and Unigold, in infants younger than 18 
months. All studies were conducted in resource-poor settings. Sensitivities and specificities are stratified 
by infant age. There were also instances where results were not stratified by infant age, making age-
specific interpretation of test performances difficult. Those sensitivities and specificities are noted at the 
bottom of the table under “Other time points”.  
 The estimates are limited by small sample sizes, attrition, and lack of testing among infants 
beyond 9 months of life
17,73-75
. Most of the studies were also conducted in non-breastfeeding populations, 
hindering interpretation for populations after the revised WHO breastfeeding guidelines where most 
women will breastfeed for longer durations. 
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Table 2. Sensitivity and specificity of Determine and Unigold rapid test 
 
  
 Determine Unigold 
Infant age Sensitivity  (95% 
CI) 
Specificity (95% 
CI) 
Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
<3 months 92.6 (75.7-99.1)
75
 
100.0 (NS)
73
 
99.3 (98.0-99.8)
17
 
8.0 (4.1-13.9) 
0.0 (NS)
73
 
97.0 (NS)
73
 4.0 (NS)
73
 
>3-6 
months 
88.9 (51.8-99.7) 33.3 (22.2-46.0)   
>6-9 
months 
100.0 (60.7-100.0) 
98.6 (?)
73
 (at 7 
months) 
97.2 (95.5-98.3)
17
 
90.0 (?)
74
 (at 9 
months) 
82.4 (65.5-93.2) 
4.0 (?)
73
 (at 7 
months) 
31.1 (NS)
73
 (at 7 
months) 
85.0 (NS)
73
 (at 7 
months) 
>9-12 
months 
100.0 (60.7-100.0) 
100.0 (NS)
73
 (at 12 
months) 
100.0 (87.3-100.0) 
55.0 (NS)
73
 (at 12 
months) 
21.9 (NS)
73
 (at 12 
months) 
99.0 (NS)
73
 (at 12 
months) 
>12-18 
months 
90.0 (55.5-99.7) 92.0 (74.0-99.0)   
>18 months     
Other time points 
3-18 months 98.2 (90.4-99.7)
76
 99.0 (98.4-99.4)   
1-20 months 95.3 (NS)
77
    
<18 months 95.5 (93.5-96.9)
17
 99.2 (95.6-99.9)
17
   
*NS-Not shown    
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Performance of alternative rapid tests  
 Fourth generation assays. Fourth generation assays have recently been developed and detect both 
HIV antibody and p24 antigen, antigen expressed in the seroconversion phase of HIV infection, providing 
an earlier detection of HIV infection than previous generation assays. 
 Adults. Field assessment of the fourth generation Determine HIV-1/2 Ag/Ab Combo rapid test 
was conducted among 1,009 participants in testing and counseling center in Malawi
78
. Although the test 
detected established HIV infection, it did not detect acute HIV infections better than the current testing 
algorithms of using Determine and Unigold tests. In a large study of 21,334 HIV positive persons in San 
Francisco, the potential for case finding of acute HIV cases was the highest for the 4
th
 generation 
ARCHITECT HIV Ag/Ab Combo (99.1%; [95% CI: 91.1, 100.0]) and lower for Determine (96.6%; 
[95% CI: 84.7, 100.0]), Unigold (94.3%; [95% CI: 82.4, 100.0]), OraQuick Advance on blood plasma 
(92.8%; [95% CI: 88.2, 97.3), and Clearview Stat-Pak (92.8%; [95% CI: 83.8, 100.0])
79
.  
 Infants. In theory, fourth generation rapid tests should be able to detect HIV infection sooner than 
third generation rapid tests because of early p24 antigen in infants. A recent study among infants in South 
Africa found that the fourth generation Determine Combo HIV-1/2 Ag/Ab Combo Test failed to detect 
p24Ag in 98% of HIV infected infants
80
. Even at 3 months of age, the sensitivity of the p24 antigen 
component was less than 10%. Among 13 infants with clinical symptoms and advanced stage disease, the 
test detection p24 antigen in one resulting in a sensitivity of 1.7%. The use of fourth generation rapid tests 
does not perform better than that of third generation HIV rapid tests, particularly among younger infants. 
 Oral rapid tests. Oral rapid tests serve as a less invasive option for sampling since the test requires 
oral fluid instead of blood. These tests are generally easier to perform and consume less time to perform. 
 Adults. Evaluation of the more recent OraQuick ADVANCE Rapid HIV-1/2 Antibody test also 
showed conflicting results. In field testing in several communities in Zambia, the test using oral fluid 
performed with sensitivity and specificity rates (98.7% and 99.8%, respectively) when compared with 
both a positive Determine and a positive Uni-Gold test
81
. Similar high sensitivity and specificity rates for 
the OraQuick oral rapid test have been reported in US settings
82,83
. However, another study evaluating the 
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performance of 4 rapid HIV tests among 21,234 HIV positive patients in San Francisco found OraQuick 
ADVANCE Rapid HIV-1/2 Antibody test using oral fluid was much lower (86.6%; [95% CI: 79.4-92.0]) 
than the other three rapid tests (OraQuick Advance using fingerstick blood, Vironostika HIV-1 
Microelisa, Genetic Systems HIV ½ Plus 0)
79
.  
 Infants. The performance of oral rapid tests among infants has not been as widely studied. A 
South African cross-sectional study among 597 HIV-exposed infants (birth-6 months of age) compared 
three oral rapid tests (OraQuick, Calypte, and Orasure)
84
.  OraQuick performed best in detecting and 
excluding HIV exposure but the test did not detect exposure in 12% of infants. Although this study is 
generally relevant to the literature, it is not the goal of the proposed study since all of our infants will be 
HIV-exposed already. No studies have been evaluated the performance of oral rapid tests among infants 
who have been exposed to the disease.  
2.5 The acquisition and decay of maternal antibodies  
 
 Rapid serological tests cannot distinguish between maternal antibodies and infant antibodies, 
making a definitive HIV diagnosis in the infant difficult
13,14
. Transfer of maternally acquired antibodies, 
particularly IgG antibodies, is crucial to an infant’s early defense of infectious agents. Of the five 
antibody classes, only significant amounts of IgG are transferred across the placenta, and, after birth, IgA 
becomes the predominant class transferred through colostrum and breast milk.  During the breastfeeding 
period, maternal antibodies are replaced by the child’s own antibodies. This progression of the transfer 
and decay of maternally-acquired IgG are affected by several factors, including maternal characteristics, 
pregnancy outcomes, and infant age and is depicted in Figure 4. 
In utero factors contributing to transplacental antibody transfer 
 Although the association between placental transfer of IgG and many factors, including maternal 
age,  socioeconomic conditions, maternal nutrition, parity, and type of delivery have been evaluated, it is 
well established the most significant contributors affecting placentally-transferred IgG in utero are length 
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of gestation, placental integrity, maternal IgG concentrations. 
 
Figure 3. The acquisition and decay of maternal antibodies 
 
 Length of gestation: The most significant factor directly associated with total IgG transfer in 
newborns length of gestation. Maternal transfer of IgG occurs in a linear fashion beginning as early as 13 
weeks, with the largest amount transferred in the last trimester
85-88
. During the second trimester, fetal IgG 
concentrations are only 5%-10% of maternal levels, and concentrations reach 50% of maternal levels 
during weeks 28-32. The largest total IgG amount acquired by the fetus occurs during the last 4 weeks of 
pregnancy. The association between length of gestation of IgG levels in newborns has been observed for 
specific antibodies against measles, mumps, diphtheria, tetanus, pertussis, influenza, rubella, and E. 
Coli
86,89-92
. 
 Low birth weight: Reduced IgG transfer efficiency has been observed among low birth weight 
babies
87,91
. In a cohort of infants in Sri Lanka, infants with low birth weights demonstrated low levels of 
antibody transfer, even after adjusting for gestational age
93
. It should be noted that all mothers with low 
birth weight infants in the Sri Lankan study were anemic. Although birth weight may have a direct effect 
on IgG transfer, length of gestation serves as a more significant contributor since IgG transfer is greatly 
dependent on weeks in utero than the infant’s weight at birth. Thus, birth weight may serve as a proxy for 
length of gestation. 
Maternal IgG concentrations 
Transfer of antibodies to fetus 
Delivery 
Transfer of antibodies to 
infant through colostrum and 
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 Total maternal IgG concentrations: Newborn IgG levels typically correlate with maternal ones
94
. 
However, IgG levels can be saturated and depend on the amount of cell surface receptors present in the 
infant. After a saturation point, there is an inverse relationship between maternal IgG concentrations and 
IgG transfer to the infant, resulting in lower neonatal IgG values than maternal ones
87
. This phenomenon 
of lower IgG transfer is observed in certain regions in Africa where high maternal IgG values are 
common
87,95,96
. Specifically for HIV, mean levels of maternal IgG concentrations for all antibodies except 
HSV are significantly higher in HIV-infected mothers than non-infected mothers, thereby lowering the 
transfer of IgG to the infant
97,98
. 
 Maternal IgG concentrations and transfer of IgG to the infant are impacted by ART exposure, 
both in utero and prophylactically. In a European study, infants with ART exposure in utero through 
maternal ART or neonatally through prophylactic therapy had lower IgG levels than infants with no ART 
exposure. Similarly, ART reduced the number of circulating IgG in chronically infected individuals in 
New York
99
. The majority of women in the European and New York studies had lower IgG levels than 
women in Africa, rendering it difficult to deduce if this relationship is observed in women with higher 
baseline maternal IgG concentrations typically seen in Africa. High baseline maternal IgG concentrations 
among HIV-infected women in Africa (i.e., above the saturation point) are correlated with lower IgG 
transfer. Thus, ART administration to HIV-infected women with high baseline IgG concentrations, as in 
Africa, would reduce the activation of the chronically-activated immune system, thereby increasing the 
amount of IgG transferred to the infant. 
 Placental integrity: Certain conditions, such as hypergammaglobulinaemia, malaria, and HIV, can 
cause pathological changes to placental tissue, thereby damaging IgG-specific Fc receptors (hRcRn) that 
mediate transplacental transfer to some pathogens (measles, tetanus, varicella-zoster virus, streptolysin O, 
pertussis, Streptococcus pneumonia, and HIB)
87,96,100,101
. Significant decreases in antibody transfer for 
pertussis, Haemophilus influenzae type B, pneumococcus, poliovirus, and tetanus have been reported in 
cases of maternal HIV infection or malaria in developing and developed countries
97,98,100-104
. The transfer 
impairment is even more pronounced among mothers with high IgG serum levels, a clinical indication of 
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a higher severity of disease, displaying the inverse relationship between maternal IgG levels and IgG 
transfer to the infants
87,97,98,105
.  
 Clinical indicators of HIV severity, including viral load and CD4 count, are associated with 
placental IgG transfer. In a cohort of HIV positive, pregnant women in Nairobi, a strong inverse 
association between placental IgG transfer and HIV-1 viral load in the third trimester or at delivery has 
been observed 
105,106
. In addition, women with CD4 counts less than 200 had reduced placental transfer of 
IgG compared with women with CD4 counts above 500. Controlling HIV viremia and boosting 
production of CD4 counts through effective ART at the end of a woman’s pregnancy, the time where the 
majority of transfer of IgG occurs, could increase the efficiency of placental transfer. 
 Other: Although gestational age, maternal IgG concentrations, and placental integrity are noted 
most consistently in the literature as significant contributors to IgG transfer to the infant, other 
characteristics may also impact IgG transfer. Among women in Kenya, transfer of tetanus-specific 
antibodies was lower in women with low BMI, transfer of measles- and tetatnus-specific antibodies was 
lower in women with preterm delivery, transfer of measles-specific antibodies was lower in younger 
ages
101,106
. However, the majority of other studies do not find an association between BMI, maternal age, 
preterm delivery, and parity once gestational age, maternal IgG concentration, and co-morbidities are 
adjusted for
90,101
. 
Persistence of maternal antibodies during the postpartum period 
 Maternal HIV Immunoglobulin G (IgG) antibody can be detectable up to 18 months but usually 
become undetectable by 9 months of age. Studies from industrialized countries have reported median ages 
at seroreversion of 7-12 months
107-109
 and an estimated 1%-2% of HEU US and European infants do not 
serorevert until 15 months of age
109
. In developing countries, however, there is a lack of data on 
seroreversion and in studies where it was evaluated the time of maternal antibody loss in infants is highly 
variable. Among Vietnamese HEU infants, only 22% seroreverted by 12 months
110
 while 60% of South 
African HEU infants had seroreverted by 12 months
73
. In a recent study, the proportion of HEU South 
African infants who seroreverted was 20% at 4 months of age, 50% at 6 months, and 100% at 8 months of 
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age
17
. Maternal antibodies decline slowly throughout the first year of life in the postpartum period with a 
half-life of 28 to 30 days in non-breastfed infants
13,15-17
. However, there are minimal data on the 
persistence of maternal antibodies in breastfed populations. Of the studies describing persistence of 
maternal antibodies, three of the studies were in industrialized countries among non-breastfeeding 
populations
107-109
 and three studies occurred prior to the WHO guidelines changing that encouraged 
breastfeeding for HIV-pregnant/lactating women and were among non-breastfeeding populations
13,15,17,73
. 
There were two studies which examined a mixed population of breastfeeding and non-breastfeeding HIV 
positive women, although the percentage of breastfeeding women was not provided
1516
. Only one study 
describing seroreversion documented the percentage of breastfeeding HIV positive women but this 
percentage was very low at 4%
110
. 
Postpartum factors affecting waning of placentally-acquired antibodies 
 After birth, IgA becomes the predominant antibody class transferred through colostrum and 
breast milk
111
. In addition, maternally-acquired IgG decay during the postpartum period, with the most 
rapid waning occurring before 9 months of age. During the first few days after delivery, colostrum is the 
predominant form of nutrition given to an infant and contains many protective properties, including 
antiviral and immunological substances. The immunoglobulin content, particularly IgG , in colostrum is 
much higher than that in breast milk
111
. Contributions of IgM and IgG are produced but in minuscule 
quantities
112-116
. Over 92%-95% of IgG is transferred in utero while the remaining 5%-8% is transferred 
mainly through colostrum from day 0 to day 6 and in very small quantities thereafter through breast 
milk
113-116
. Breast milk antibodies do not enter the infant circulation in substantial amounts and, of the 
five immunoglobulin classes, the most significant transfer is IgA. Although the relationship between 
antibody decay during the postpartum period and a myriad of maternal and infant characteristics have 
been examined, the most significant contributors consistently noted in the literature are infant age and 
maternal IgG concentrations.  
 Infant age: Infant total IgG acquired in utero is subjected to an exponential decay rate with a 
half-life of 35-50 days
112
. In a Swiss cohort, by 9 to 12 months of age, less than 6% of infants were 
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antibody positive to mumps or rubella while 9% were antibody positive to measles
117
. Similarly, other 
studies have found the concentration of passively-acquired IgG for measles, mumps, and rubella 
decreased rapidly within the first six months of life
118
 and the concentration of pertussis-specific IgG 
decreased rapidly within the first two months of life
119
. 
 Other than infant age, very few infant-related characteristics have been identified that impact 
waning of placentally-transferred antibodies. A study among rural Bangladeshi infants found measles-
specific antibody concentrations decreased with age and the child’s length, weight, gestational age, and 
parity were not associated
120
. Similarly, a Congolese study found age was the only factor influencing 
decay of measles antibody, even after adjusting for infant gender, birth weight, weight-for-age, maternal 
age, and parity
121
. 
 Maternal IgG concentrations. Maternal IgG concentrations not only affect the transfer of 
antibodies in utero but also impact the clearance of antibodies in infants after delivery
87,94,95,120,122-124
. 
Elevated maternal IgG concentration reduces transplacental efficiency for the infant, resulting in lower 
infant IgG levels acquired in utero. Thus, the rate of infant antibody decay after delivery is faster among 
infants born to women with elevated IgG concentrations than infants born to women with lower IgG 
concentrations. 
 ART therapy. Mean time to seroreversion seems to be shorter in studies performed earlier in the 
HIV epidemic, particularly, before the usage of PMTCT or ART. An analysis on 3 MTCT prevention 
trials in Malawi found that infants born from 1989 to 1996 had a significantly shorter time to 
seroreversion than infants born from 2000 through 2003
16
. Similar results were noted in the US where the 
time to seroreversion was 4 months longer in 1990 than in 1994
125
. The most recent study evaluating 
differences in time to seroreversion was conducted among US infants born between 2000 to 2007
126
. The 
median age of antibody loss was 13.9 months among children born between 2000 to 2007 compared to 
9.4, 10.3, and 10.9 months from earlier cohorts during the late 1980s and early 1990s when women did 
not receive ART during pregnancy
109,125,127
. Additionally, the median age of seroreversion from this study 
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was 3 months longer than the median ages seen in Malawi during the same time period, again indicating 
ART treatment could delay clearance of antibodies since ART usage was higher in the US than Malawi
16
. 
 Although historical data, as noted above, seems to suggest maternal ART contributes to 
seroreversion delays, to date there have been no studies to explicitly evaluate how ART/HAART affects 
the time of seroreversion in infants. A small case analysis of 14 infants less than 12 months who initiated 
ART therapy in rural India observed that the majority of these infants did not develop sufficient 
antibodies for detection on rapid test due to ART
128
. However, this paper did not provide what type of 
rapid test was used, the number of tests performed per time period, and the ages of the children.  
 Other factors complicating the utility of rapid tests. Another risk factor contributing to time to 
seroreversion is birth weight as children with higher birth weights were more likely to serorevert at a 
younger age
16. Gender, gestational age, mother’s clinical stage of AIDS, breastfeeding status, and child’s 
health history have not been found to be associated with time to seroreversion
16,109
.  
2.6 Current recommended HIV testing algorithms for HIV-exposed infants with a negative 4-6 
week virological test 
 
 Currently, there are three main HIV testing algorithms used worldwide: 1) the 2010 WHO 
recommendations on the diagnosis of HIV infection in infants and children (Figure 5); 2) the CDC testing 
algorithm for HIV-exposed infants in settings with ART, PCR availability, and resources permit either 
replacement feeding or two tests per infant; and 3) the CDC testing algorithm in settings without 
widespread ART, limited resources for virological testing, and where most women breastfeed.  
WHO Recommendations 
 Figure 5 describes the current WHO early infant HIV testing algorithm
27
. The group of interest 
given the current breastfeeding guidelines (see Section B.3), is represented in the red circle. Infants that 
tested negative on the 4-6 week virological test and continued to be breastfeed remain at risk for acquiring 
HIV until cessation of breastfeeding occurs. According to the WHO algorithm, after a negative 
virological test at 4-6 weeks rapid antibody testing should begin at 9 months unless signs and symptoms 
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suggestive of HIV occur prior to 9 months. The following two scenarios could ensue among breastfeeding 
infants who tested negative on a virological test at age 4 to 6 weeks: 
 Scenario 1: Infants who remain well are to receive an HIV antibody test beginning at 9 months 
of age. If the antibody test at 9 months is negative the child is assumed uninfected. A repeat antibody test 
is to be given six weeks after the cessation of breastfeeding and/or at 18 months of age. 
 Scenario 2: If infants develop signs or symptoms suggestive of HIV between 4-6 weeks and 9 
months, they are to be given a virological test. If a viral test is not available, an HIV antibody test is to be 
performed at 9 months.  
 
Figure 4. WHO early infant HIV testing algorithm 
   
 The testing algorithm in both scenarios  recommend sparse HIV testing of HEU infants during the 
time between the 4-6 week virological test and 18 months of age or cessation of breastfeeding unless the 
infant is sick, in which it may be too late. Between age 4-6 weeks and 9 months of age, no testing is 
recommended unless the child is sick. This time period is approximately 7 months. A test is 
recommended at 9 months of age and then again 6 weeks after cessation of breastfeeding or until 18 
months of age.  This second risk period after age 9 months is approximately 2-9 months depending on 
At birth or 4-6 weeks 
9 months 
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when the child weans. The entire risk period from the 4-6 week virological test to the cessation of 
breastfeeding is 11 to 16 months. It is not adequate enough to ensure early initiation of ART if the child 
does become infected through breastfeeding to simply test HIV-exposed infants a few times during the 
breastfeeding risk period. Another pitfall of the algorithm is that the algorithm does not describe what 
tests or combination of rapid tests to use at any timepoint. As previously discussed (Section B.4), these 
tests have widely different performances when used among infant populations in resource limited settings.  
CDC testing algorithm for HIV-exposed infants in settings with ART, PCR availability, and resources 
permitting either replacement feeding or two tests per infant 
129
  
 
 The only recommendation for an HEU infant who is younger than 9 months is to conduct PCR 
virological testing. If the HEU infant is 9 months of age or older, a rapid HIV antibody test is to be 
conducted. If the rapid test is positive, a PCR should be conducted. If the rapid test is negative and the 
infant has not been breastfed within the last 6 weeks, the child is considered HIV negative. If the rapid 
test is negative and the infant has been breastfed within the last 6 weeks, the infant is “probably” not 
infected but is still at risk and a repeat rapid test should be conducted 6 weeks after cessation of 
breastfeeding. Similar to the WHO EID testing recommendations, there is no information regarding what 
test to use and the frequency of and accuracy of each test. Additionally, testing occurs infrequently during 
the breastfeeding exposure period, placing the HEU infant at risk of late diagnosis.  
CDC testing algorithm in settings without widespread ART, limited resources for virological testing, and 
where most women breastfeed
129
  
 
  Infants less than 6 months of age  are encouraged to exclusive breastfeed. Clinical assessments 
are to be performed. If the child becomes ill, referral for HIV care is to occur. No mention of testing 
during this HIV exposure breastfeeding is given. Among children who are 6 months of age or older, a 
rapid HIV test is to be performed six weeks after weaning. If the antibody test is negative, the infant is 
considered not infected and the mother is encouraged not to breastfeed. If the antibody test is positive, the 
child is to continue preventive measures until definitive diagnosis can occur. If virological testing is not 
available, a repeat rapid test is to occur at 12-15 months of age and, if positive, definitive diagnosis is 
made at another repeat test at 18 months.  
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 Similar to the WHO EID testing recommendations and the CDC testing algorithm for settings 
with ART, PCR availability, and resources permitting either replacement feeding or two tests per infant, 
there is no information regarding what test to use and the frequency for each test. Additionally, testing 
occurs even more infrequently than the other testing algorithms during the breastfeeding exposure period, 
placing the HEU infant at risk of late diagnosis.  Given increasing access to virologic testing for EID, the 
utility of this algorithm is outdated for most settings. Nonetheless, testing recommendations are briefly 
outlined. 
2.7 Significance of the proposed project: The intersection of the current PMTCT structure, current 
EID testing algorithms, and 2010 WHO breastfeeding recommendations 
 
 Current testing algorithms do not adequately describe how to optimally follow HEU infants, 
including what specific rapid test to use and when to administer the test, during the time between the 4-6 
week virological tests through the cessation of breastfeeding. Given the effectiveness of early ARV 
initiation, it is unacceptable to test an infant only a few times during the high risk period of repeated 
exposure through breastfeeding or to wait until the child develops symptoms suggestive of HIV..  
 Highlighting the need for updated testing algorithms further are the recent changes in 
breastfeeding guidelines. The duration of breastfeeding will increase an infant’s recurrent exposure to 
HIV over a longer period of time, which will increase the proportion of infant HIV acquired during the 
breastfeeding period, especially given that this risk period is not adequately captured in the current 
PMTCT structure. Studies evaluating rapid tests performance in resource poor settings among 
breastfeeding populations are especially important now that women will breastfeed for longer periods of 
time, increasing the risk of postnatal infection through exposure of HIV via breast milk. 
 The Global Plan will only be achievable if we redefine the PMTCT cascade to encompass the 
mother/infant dyad throughout the entire breastfeeding period. Given the importance of early ART 
initiation, novel testing algorithms that incorporate this risk period and are acceptable in resource limited 
settings are more critical now than ever among those that escaped HIV infection during the first 6 weeks 
of life.  
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CHAPTER 3: DESCRIPTION OF THE STUDY POPULATION AND DATA COLLECTION 
 
3.1 Study setting 
 
 The data used for this study came from a community-based cohort study examining the effects of 
HIV on pediatric neurodevelopment. The study was conducted at two healthcare centers in the Blantyre 
region of Malawi between May 2008 and March 2012. Both clinics have PMTCT programs which 
provide HIV counseling and testing of all pregnant women, and offered nevirapine treatment for 
prevention of mother to child transmission of HIV.  
 In Malawi an estimated 57,000 (13%) pregnant women and 90,000 children were living with 
AIDS in 2008
66
. In 2010, Malawi was one of the 21 African priority countries targeted in the Global Plan 
to reduce MTCT of HIV to less than 5%, increase PMTCT services, and provide more widespread 
distribution of ARV therapy
18
.  Since then, new HIV infections among infants have been reduced by 50% 
in seven of the Global Plan’s priority countries, including Malawi1. Despite these significant advances, 
Malawi continues to have one of the highest rates of HIV positive women who did not receive effective 
ARV regimens. In 2012, an estimated 69%-77% of HIV positive women did not receive ARVs while 
50% of women globally did not receive their ARVs
19
. 
 In Malawi, breastfeeding practices are widespread with an estimated 94% to 95% of women 
initiating breastfeeding within the first hour of birth and 93% to 97% of women initiating within the first 
day of birth
130
. Additionally, 93% of infants are exclusively breastfed for the first month and 71% among 
all infants for the first six months. The median duration of exclusive breastfeeding was 4 months and 24 
months for any breastfeeding. Among HIV positive women attending antenatal clinics in Blantyre and 
Lilongwe, Malawi, one study the estimated median duration of breastfeeding was 26 weeks and 22% of 
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women reported breastfeeding after 6 months
131
. In the study population, 78% of HIV positive women 
were breastfeeding at 6 months, 52% at 9 months, and 36% at 12 months.  
3.2 Study population 
 
Study population for the parent study  
 Inclusion criteria for the parent study included infants born to mothers greater than 15 years of 
age and included both HIV positive and HIV negative mothers. Exclusion criteria included mothers with 
active maternal alcohol or drug abuse or maternal chronic illness other than AIDS. All children, without 
congenital malformations or severe chronic illness, who were born to HIV infected mothers at the two 
participating health centers were screened for HIV infection at 4-6 weeks of age after appropriate HIV 
counseling and obtaining oral consent.  
Study population for the proposed study 
 Of the 556 children enrolled in the parent study, 96 perinatally infected infants, 170 children were 
born to HIV negative mothers, and 290 children born to HIV positive mothers. Children enrolled in the 
proposed study were eligible for inclusion if they were born to an HIV infected mother, had a negative 
PCR test at 4 to 6 weeks of age, and had a Determine or Unigold rapid test performed after 4 to 6 weeks 
of age. Rapid testing in the parent study began 9 months after the start of the study and children without 
any rapid testing before this 9 month period were excluded. Children were also excluded if they had a 
rapid test performed but the type of rapid test (Determine or Unigold) was not collected. The final dataset 
for the proposed study includes 121 children born to an HIV positive mother and were deemed HIV 
negative at 4 to 6 weeks by PCR. 
3.3 Data Collection for the parent study 
 
Procedures 
 Data was collected at two health centers in Blantyre, Malawi. Procedures for HIV-exposed 
infants from study enrollment and throughout the breastfeeding period are outlined in Table 3. HIV DNA 
PCR testing using version 1.5 of the Amplicor HIV-1 DNA test kit (Roche, Basel, Switzerland) was 
performed at 4-6 weeks or closest to that time to determine infant HIV infection. Confirmation of a 
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positive PCR result was sought through a second PCR or through HIV RNA viral load testing. Children 
enrolled in the study were asked to visit the clinic at 10 weeks and every 3 months between age 14 weeks 
and 18 months, and every 6 months between age 18 and 42 months. Blood was collected at all time 
points, unless HIV seroconversion was documented at one of these time point. At ages 14 weeks, 6,  9, 12 
and 15 months blood was collected for storage for biomarkers and HIV DNA PCR testing. Blood was 
taken for hemoglobin at each visit. HIV rapid tests using Unigold
®
 and Determine
®
 test kits were 
performed at 6, 9, 12, 15, and 18 months.  
Table 3. Procedures for HIV-exposed infants 
  
 Data collection procedures for the mother or primary caregiver, if no biological mother, are 
outlined in Table 4. Maternal or primary caregiver clinical history and sociodemographic information was 
collected at enrollment and updated at each follow-up visit. Sociodemographic data collected included 
marital status, level of education, employment status, caregiving responsibilities, members living in the 
household, household characteristics (i.e., toilet facilities, availability of electricity, building materials of 
the house and roof), assets and finances, utility of a mobile phone, and health of the child’s father. 
Clinical history included ARV regimen, usage of nevirapine at birth (maternal and infant), co-morbidity 
 
 
Age 6 weeks 
Routine 
vaccination visit 
Age 10 weeks 
Routine 
vaccination visit 
Age 14 weeks, 
6, 9, 12 & 15 
months 
Age  
18, 24, 30 
months 
Age 36 and 
42 months 
 Care First Study Visit Follow up study visits Follow-up 
visits 
Oral parental permission for 
HIV test of child   
√   √   
HIV DNA PCR testing √     
Post test Counseling   √    
Obtain parental permission for 
study participation 
  √    
Socio-economic & demographic 
questionnaire 
 √ √ √ √ 
Clinical history  √ √ √ √ 
Clinical exam   √ √ √ √ 
Neurological exam   √ √ √ √ 
Bayley Scales of Infant 
Development III 
 √ √ √ √ 
Hemoglobin  √ √ √  
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assessment, disruptions in work due to illness, and hospitalizations. Changes in maternal/primary 
caregiver contact information, primary caregiver status and clinical history were updated throughout the 
follow-up period. Missed visit date and attempts to contact the primary caregiver were recorded as 
needed. Unscheduled visit dates, reason for the unscheduled visit, and diagnoses at the unscheduled visit 
were recorded as needed. Selected infant blood samples collected in the parent study were shipped from 
Malawi to the University of North Carolina at Chapel Hill (UNC).  
Table 4. Procedures for HIV positive mothers or primary caregivers 
 
 
Rapid test results for the parent study 
 There were 121 children that were followed from their 4-6 week negative PCR test. Table 5 
describes the rapid testing that was completed on the 121 children from 2 months through 24 months.  
According, these children would return to the clinic for rapid testing every 3 months until 18 months of 
Form Description Age 10 weeks 
(Enrollment) 
Follow up 
Visits 
Unscheduled 
visits 
Used as 
needed  
Patient Contact 
Information Form 
Used to record phone number, address 
and tracing permission 
√ Update   
Study Summary 
Sheet 
Used to track dates of lab procedures 
and changes in HIV status 
√ Update Update  
Immunization 
Record Form 
Used to record immunization history 
of the child 
√ Update   
Maternal Clinical 
History and Socio-
demographics OR 
Primary Caregiver 
Clinical History and 
Socio-demographics  
Form  
Records information on the child’s 
home environment, health of the 
caregiver and parents. 
√    
Clinical Form Records clinical history of the child, 
clinical examination, neurological 
examination and AIDS staging 
√ √   
Primary Caregiver 
Clinical History and 
Socio-demographics 
follow-up  
Updates information on the 
caregiver’s health and the child’s 
home environment 
 √   
Change in Primary 
Caregiver 
Used to record changes in primary 
caregiver if there is a change 
   √ 
Missed Visit Form Used to record information when a 
child misses a visit and attempts to 
contact the family and reschedule. 
   √ 
Unscheduled Visit 
Form 
Used to record information about an 
unscheduled visit to the study clinic 
  √  
ARV treatment Log Log to record treatment with ARVs     √ 
Inactivation of 
Study Participation 
Form 
Used if a child discontinues the study 
or dies before the end of the study 
   √ 
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age and then again at age 24 months. However, there were many times when the children were brought 
into the clinic earlier or later than these timepoints due to various reasons, such as missed visits or coming 
earlier/later to a scheduled appointment.  
 Throughout the follow-up period for each child at each timepoint, four scenarios could have 
occurred:  
 1) Both rapid tests were run and the results agreed between the two tests (DT+/UN+, DT-/UN-), 
 2) Both rapid tests were run but the results were discordant (DT-/UN+, DT+/UN-), 
 3) Only one rapid was conducted (DT- or +/UN missing, DT missing/UN- or +), and  
 4) Neither rapid test was conducted (DT missing, UN missing). 
 Table 5 describes the number of times each scenario occurred throughout the follow-up period. In 
total, there were 737 Determine and Unigold tests conducted in the parent study and, of these, 392 were 
Determine tests and 345 were Unigold tests. There were 53 study visits in which Unigold was conducted 
but Determine was not and 152 study visits in which Determine was collected and Unigold was not. 
Missing data for these visits were a result of rapid tests being out of stock, typically resulting in only one 
test being conducted, or the child did not come to the appointment, resulting in both tests not being 
conducted. Missing data due to stock-outs totaled 53 Determine and 152 Unigold tests needing to be 
conducted. Missing data due to a child not coming to a study visit totaled 85 Determine and 85 Unigold 
tests, resulting in 138 Determine tests and 237 Unigold tests not conducted in Malawi.  
 
  
 
3
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           Table 5. Rapid test results for parent study during follow-up period 
 
Collected data from  
parent study 
(n=737 rapid test results) 
 Missing data from parent 
study 
(n=152 rapid test results) 
    
 
 
        
Timepoint 
(month) 
Results agree Results discrepant 
Determine missing, 
Unigold complete 
Determine collected, 
Unigold missing 
 
Timepoint 
(month) 
Missing 
both DT 
and UN 
 DT+/DT+ DT-/UN- DT+/UN- DT-/UN+ DT?/UN+ DT?/UN- DT+/UN? DT-/UN?   DT?/UN? 
2 0 0 0 0 0 0 0 0  2  
3 0 0 1 0 0 3 0 0  3 37 
4 0 0 0 0 0 0 0 0  4  
6 6 34 27 1 0 18 1 0  6 11 
7 0 0 1 0 0 0 0 0  7  
8 0 0 1 0 0 0 0 0  8  
9 2 39 22 0 0 10 0 1  9 8 
10 0 0 0 0 0 2 0 0  10  
12 2 43 1 0 1 7 0 7  12 12 
15 1 34 0 0 0 4 0 17  15 4 
18 2 29 1 0 0 5 1 22  18 2 
21 1 2 0 0 0 0 0 2  21  
22 0 1 0 0 0 0 0 0  22  
24 0 19 0 0 0 3 4 27  24 2 
>24 0 18 1 0 0 3 3 18  >24  
Total DT 14 219 55 1 0 0 9 94  Missing 
DT 
76 
Total UN 14 219 55 1 1 55 0 0  Missing 
UN 
76 
Total tests 28 438 110 2 1 55 9 94  Total 
missing 
152 
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3.4 Data collection for proposed study 
 
 Per study protocol, children were scheduled to visit the study clinic at age 6, 9, 12, 15, 18, 21, and 
24 months. However, data was collected when the mothers and children came for a visit, which was not 
always at the time of the scheduled appointment. Some children also missed scheduled visits, resulting in 
missing rapid test data for that timepoint. To address the issue of missing rapid test data and investigate 
the discordant results between Determine and Unigold results, we conducted 100 Determine and 100 
Unigold rapid tests on a select group of stored samples. We prioritized samples according to the following 
criteria summarized in Table 6:  
1. Obtain results that would provide us with the shortest seroreversion time.  
 Priority for testing of samples was given to earlier timepoints or timepoints that would result in a 
shorter seroreversion observation window. For example, if an infant was positive on both rapid tests at 3 
months, did not have tests run at 6 months, and tested negative at 9 months, we wanted to obtain the test 
results at 6 months. The initial window to observe seroreversion would be 6 months (3 months to 9 
months) while the second window with the new sample would be a shorter observation window of 3 
months (3 months to 6 months). Of the 53 study visits in which Unigold was conducted but Determine 
was not, we obtained 14 Determine results. Of the 152 times in which Determine was collected and 
Unigold was not, we obtained 2 results. Of the times when both Determine and Unigold was missing, we 
obtained 55 Determine results and 62 Unigold results. 
2. Investigate a sample of discordant rapid test results.  
 Of the 55 discordant results, 53 were at the 9 month timepoint or prior. We reran the discordant 
pairs in 33 occurrences. Of the 33 discrepant results that were retested, 27 agreed with the parent study 
results and were not altered in the dataset. Retesting of the remaining 8 discordant pairs resulted in 
different rapid tests results than the original parent study data. Results of these 8 were originally positive 
for Determine and negative for Unigold. After retesting, the Determine and Unigold results tested 
positive. Three of the 8 discrepant results had a very faint Unigold test. However, it was agreed upon by 
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the two laboratory managers and the other reviewer that these faint results should be considered positive, 
per Unigold manufacturer instructions.  
3. Investigate questionable test results.  
 There were occasions where an infant had a 6 negative test but had a 9 month positive rapid test. 
This would seem like a seroconversion but was not classified as one by study investigators throughout the 
follow-up period. We reran these tests at 6 months and found one to be positive and one to be negative. 
Table 6. Summary of UNC rapid testing 
 
 
 
 
 
 
 After this first round of retesting, we received funding from the University of North Carolina 
Center for AIDS Research to test all available samples needed.  This resulted in a total of 492 Determine 
and 504 Unigold tests conducted. We compared the population with missing data versus complete data, 
by timepoint and by test, for characteristics including infant factors (gender, breastfeeding, nevirapine at 
birth) and maternal factors (maternal age, marital status, education level, and socioeconomic variables). 
(see Appendix A). There were no factors consistently different between the two populations. We therefore 
concluded the missing data population was similar to the complete case population and proceeded with 
the missing data population for analyses. 
 
Reason for retesting DT UN 
Missing both DT and UN results 55 62 
Missing DT results 14 0 
Missing UN results 0 2 
Discrepancy between initial DT/UN testing 27 25 
Discrepancy between initial DT/UN testing 8 9 
Other questionable test results. 2 5 
*DT-Determine; UN-Unigold 
  
3
4
 
               Table 7. Description of collected or missing rapid test data throughout follow-up, stratified by type of rapid test. 
 
  3m 6m 9m 12m 15m 18m Total 
Collection 
site 
DT UN DT UN DT UN DT UN DT UN DT UN DT UN 
Malawi 1 1 66 66 63 62 52 52 56 56 57 57 295 294 
UNC 75 76 31 39 29 29 35 38 20 17 7 11 197 210 
Total  76 77 97 105 92 91 87 90 76 73 64 68 492 504 
Total 
missing 
45 
(37%) 
44 
(36%) 
25 
(20%) 
16 
(13%) 
29 
(24%) 
30 
(25%) 
34 
(28%) 
31 
(26%) 
45 
(37%) 
48 
(40%) 
57 
(47%) 
53 
(44%) 
234 
(32%) 
222 
(31%) 
DT: Determine, UN: Unigold 
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CHAPTER 4: METHODS 
 
4.1 Specific Aim 1 
 
4.1.1 Study Sample and Data Collection 
 
 We collected data on the performance of Unigold® and Determine® rapid tests as part of a 
community-based cohort study examining the effects of HIV on neurodevelopment in infants receiving 
care at two healthcare centers in the Blantyre region of Malawi between May 2008 and March 2012. 
During that period, both clinics provided HIV counseling and testing to all pregnant women and offered 
single dose nevirapine or zidovudine treatment to women who were HIV infected. The study included 
infants born to HIV-positive mothers (age ≥ 15 years) who did not have a history of alcohol or drug abuse 
or chronic illness other than AIDS. For the analysis presented here, only children who were negative by 
HIV DNA PCR at the time of enrollment were included. 
HIV DNA PCR testing using version 1.5 of the Amplicor HIV-1 DNA test kit (Roche, Basel, 
Switzerland) was performed at enrollment, which took place at approximately 6 weeks of age (median 
age 6.4 weeks, interquartile range [IQR] 4.3-15.1 weeks). Children were scheduled to visit the study 
clinic at age 10 weeks and every 3 months between age 14 weeks and 18 months. At all timepoints, 
clinical and sociodemographic information were collected, a fingerprick was performed for hemoglobin 
testing, dried blood spots were collected for storage for HIV DNA PCR assays, and a venous whole blood 
sample was taken for storage at ≤ -70 degrees Celsius. Confirmation of infant HIV infection detected by a 
positive HIV DNA PCR result was done through a second HIV DNA PCR assay or a HIV RNA viral load 
assay.  
Starting in February 2009, an additional fingerprick was performed at point-of-care for Unigold
®
 
and Determine
®
 rapid HIV tests at age 6, 9, 12, 15, and 18 months. In addition, to obtain data on rapid test 
performance at age 3 months, the Unigold
®
 and Determine
®
 rapid tests were performed on stored blood 
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collected at age 3 months. If data were missing at other timepoints due to failure to perform the rapid test 
at point-of-care or assay stock outs, rapid HIV tests were also performed on stored blood when available. 
Rapid testing on stored blood was conducted at a research laboratory at the University of North Carolina. 
Stored samples were thawed per manufacturer’s instructions, and both rapid tests were performed 
simultaneously by a single operator. Weakly positive rapid tests results were reported as positive.  
 The University of Malawi College of Medicine Research and Ethics Committee and the 
University of North Carolina at Chapel Hill Institutional Review Board approved the study protocol. All 
mothers provided written informed consent and permission for participation of their infant. 
4.1.2 Statistical Analysis 
 The 18-month cumulative incidence of infant HIV infection was estimated using an extension of 
the Kaplan-Meier estimator that allows for competing risks of death or loss to follow-up
132
 Sensitivity and 
specificity were estimated in a cross-sectional manner at each timepoint (3, 6, 9, 12, 15 and 18 months), 
separately for Determine and Unigold. A two-week window around each timepoint was used to define a 
visit. Data occurring outside of the two-week window were discarded. Sensitivity for each rapid test was 
estimated by the proportion of infants diagnosed as HIV infected by the rapid test among all infants with 
confirmed infection (by PCR) at the timepoint of interest. Specificity for each rapid test was estimated by 
the proportion of infants diagnosed as HIV negative by the rapid test among all infants with confirmed 
free of HIV infection (by PCR) at the timepoint of interest. 
 The positive predictive value (PPV) was estimated by the proportion of infants with confirmed 
HIV infection among all infants who tested positive on the rapid test. The negative predictive value 
(NPV) was estimated by the proportion of infants free of HIV infection among all infants who tested 
negative on the rapid tests. PPV and NPV were determined for a range of population infant HIV 
incidence. To depict the levels of HIV incidence during the postpartum period currently seen throughout 
Africa, we used a range of 1-5% for the incidence of infant HIV infection for each of the 3-month 
periods. This range was selected based on data reported in two trials of antiretroviral prophylaxis in the 
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first two years of life among infants in Malawi, a meta-analysis to estimate incidence of postpartum HIV 
infection in multiple African sites, and data from the present study
133,134
.  
 The reference standard was one positive PCR test plus a confirmatory PCR test, one positive HIV 
DNA PCR plus one positive HIV RNA assay before age 18 months of age, or one positive HIV rapid test 
at age 18 months. If a PCR test could not be performed at a specific timepoint, the result of the next 
available PCR result was assessed and, if negative, the infant was assigned a HIV uninfected status at the 
timepoint of interest. If positive, the earlier timepoint was excluded from analyses. Exact methods were 
used to calculate 95% confidence intervals (CIs) for sensitivity and specificity estimates. Analyses were 
conducted using SAS software, version 9.4 (SAS Institute).  
4.2 Specific Aim 2 
 
4.2.1 Study Sample and Data Collection 
 The study sample and data collection methods for Specific Aim 2 were the same as Specific Aim 
1. 
4.2.2 Statistical Analysis 
 The primary endpoint, time to seroreversion, was defined as the first occurrence of a negative 
HIV rapid test. Because rapid tests were performed at 3-month intervals, the exact time of seroreversion 
was not observed but known to have occurred in the time interval between the last positive rapid test and 
the first negative rapid test. The distribution of age of seroreversion was estimated using the extension of 
the Kaplan-Meier product limit estimator which allows for interval censored data via SAS PROC 
ICLIFETEST
135-137
 (SAS Institute). Observations were right censored at the first occurrence of an incident 
HIV infection, death, loss to follow-up, or at the end of the 18 month follow-up period. We accounted for 
competing risks of death or HIV infection. Bootstrap sampling was used to calculate a corresponding 95% 
confidence interval. As each infant contributed a result for both Determine and Unigold, paired survival 
curves were generated. To compare the paired survival curves, the difference in mean survival times were 
estimated by computing the area under each curve.   
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4.3 Specific Aim 3 
 
4.3.1 Analytic overview 
 We compared three point-of-care diagnostic assays, of which two were antibody tests (Determine 
and Unigold) and one was a newly developed virological assay (Alere Q HIV PCR), for several early 
infant testing strategies during the postpartum period. Using Markov models, we simulated each infant’s 
trajectory from the 4 to 6 week timepoint through the lifetime.  
 We projected outcomes, including cost, effectiveness measured in DALYs, and overall cost-
effectiveness, for a cohort of HIV-exposed infants, following a negative HIV PCR DNA test at 4 to 6 
weeks postpartum, among several early infant diagnosis testing strategies in Malawi. Clinical outcomes 
included delayed HIV diagnoses, number of false negative, false positive, true negative, and true positive 
rapid tests, and infant mortality. Economic outcomes included testing costs associated with each strategy, 
HIV pre- and post-test counseling costs, and healthcare and treatment costs for HIV infected persons. We 
calculated incremental cost-effectiveness ratios (ICERs) in $/DALY: difference in testing strategies costs 
between two strategies divided by the difference in DALYs between the two strategies. For ICERs, all 
outcomes were discounted at 3%/year
138
. We examined variations in test sensitivity, specificity, loss-to-
follow up rates, healthcare and treatment costs, and mortality associated with HIV infection through one-
way, deterministic sensitivity analyses. We also conducted multiway sensitivity analyses, varying test 
performance (i.e., sensitivity and specificity), Alere costs, healthcare and treatment costs, and mortality 
associated with HIV infection simultaneously. 
4.3.2 Early infant diagnosis algorithms 
 We evaluated 21 EID strategies based on a combination of three POC assays and seven timings of 
HIV testing (Table 8). We evaluated different timing scenarios: 1) testing at the WHO recommended time 
points (i.e. at 9 months and either at 6 weeks after cessation of breastfeeding or at age 18 months), 2) 
testing only once at 6, 9, 12 or 15 months, and 3) testing twice during the postpartum period (testing at 6 
months and then either 12 or 15 months). For each timing strategy, we evaluated Determine and Unigold, 
two antibody assays, and Alere q HIV 1/2, a qualitative POC nucleic acid test that does not require a 
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laboratory or extensive training. For all strategies, all positive POC tests are to be followed up with a PCR 
test to confirm the HIV diagnosis. 
Table 8. Description of early infant HIV diagnosis testing strategies 
EID Algorithm Testing timepoints Point-of-care test 
Current WHO 
recommendation 
2 tests at 9 and 18 months or 6 
weeks after BF cessation 
1. Determine 
2. Unigold 
3. Alere q HIV 1/2  
EID strategies 
with 1 testing 
timepoint 
1 test at 6 months 
4. Determine 
5. Unigold 
6. Alere q HIV 1/2 
1 test at 9 months 
7. Determine 
8. Unigold 
9. Alere q HIV 1/2 
1 test at 12 months 
10. Determine 
11. Unigold 
12. Alere q HIV 1/2 
1 test at 15 months 
13. Determine 
14. Unigold 
15. Alere q HIV 1/2 
EID strategies 
with 2 testing 
timepoints 
2 tests at 6 and 12 months or 6 
weeks after BF cessation 
16. Determine 
17. Unigold 
18. Alere q HIV 1/2 
2 tests at 6 and 15 months or 6 
weeks after BF cessation 
19. Determine 
20. Unigold 
21. Alere q HIV 1/2 
*BF-Breastfeeding; EID-Early infant diagnosis 
 
 
 
WHO recommended strategies:  
 According to the WHO algorithm, HIV-exposed infants with a negative virological test at 4 to 6 
weeks of age should be tested at 9 months and 18 months, or 6 weeks after cessation of breastfeeding, 
with a rapid test, unless the infant has signs and symptoms suggestive of HIV
27
. Thus, the WHO 
recommended strategies included 2 testing timepoints at 9 months and 18 months, or 6 weeks after 
cessation of breastfeeding. 
Testing strategies with only one timepoint 
  Attrition during the postpartum period affects an overwhelming majority of PMTCT programs in 
resource-limited settings and even impacts randomized clinical trials where losses are closely 
monitored
67,139-143
. Furthermore, losses to follow-up (LTFU) are greater in the postpartum period than 
during the antenatal period
35,144,145
. Recent data shows that an alarming number of infants born to women 
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with HIV do not receive HIV testing within the first 2 months of life, with attrition numbers as high as 
92%
21,24
. Likewise, other studies in sub-Saharan Africa among pregnant populations have documented 
attrition rates of up to 80% by 6 months
31-42
. A recent systematic review of studies evaluating LTFU along 
the entire PMTCT cascade found extensive heterogeneity in findings with LTFU at 3 months ranging 
from 4.8 to 75.2% and ranging from 50.2 to 85.1% at 12 months postpartum
146
. The overall pooled 
estimate at 3 months was 33.9% (95% CI: 27.6, 41.5). It is of note that many of these studies were 
conducted when the PMTCT programs were first being implemented and only used single dose 
nevirapine.  
 The recent introduction of the WHO Option B and Option B+ programs throughout Africa, in 
which all women receive antiretroviral drugs, shows encouraging retention rates of nearly 80% after 12 
months on the program
147
. It should be noted that the majority of women in the program were already on 
ART for their own health and had significantly lower LTFU rates than women initiating ART to prevent 
mother-to-child transmission. Thus, the results are not entirely generalizable to all populations unless 
mothers are already on ART. As more countries move to the similar programs and continue to 
disseminate more widespread availability of PMTCT services, we expect the LTFU proportions to 
gradually reduce, although probably not as rapidly as in the Malawian study.  
 Most of the maternally-acquired HIV antibodies in HIV-exposed, uninfected infants will have 
seroreverted by 9 months of age
13,15-17,107-109
. In our data, 86% of infants had seroreverted according to the 
Determine test and 99% of infants had seroreverted according to the Unigold test by 9 months of age. The 
testing timepoint of 9 months was chosen as one strategy as this is the recommended vaccination time 
according to the WHO vaccination schedule
148
.  Additionally, we evaluated testing only at 6 months or 
testing only at 12 months. 
Testing strategies with two timepoints  
 Because attrition affects a large majority of PMTCT postpartum follow-up programs in many 
resource limited settings, we defined the worst case strategy as simply returning to the clinic at 18 months 
or 6 weeks after a mother ceased breastfeeding. This scenario, although not ideal, may reflect the current 
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reality of many PMTCT programs, especially those with the highest loss to follow-up rates. Although we 
do not recommend this strategy, we evaluated the cost-effectiveness to reflect the worst case scenario that 
could occur in HIV-prevalent countries. Furthermore, we do not anticipate this strategy to prove 
beneficial but we expect doing more than 1 testing timepoint will greatly improve the effectiveness of an 
early infant diagnosis program, thereby encouraging countries to focus efforts on at least one testing 
timepoint for HIV-exposed infants. Evaluating the worst case strategies allowed us to evaluate conducting 
at least 1 rapid test before 15 months of age as opposed to none. Furthermore, it is likely the 15 month 
postpartum timepoint represents 6 weeks after most women discontinue breastfeeding. The updated 
breastfeeding guidelines encourage women to breastfeed for 12 months and the current WHO testing 
guidelines advise a rapid test 6 weeks after cessation of breastfeeding. Thus, 15 months is a logical testing 
that represents the end of postpartum HIV risk period. 
 Postpartum breastfeeding-associated transmission of HIV to the infant is greatest within the first 
6 weeks of life and between 6 and 12 months of age (Table 9).  
Table 9. Cumulative incidence of postpartum HIV infant infection. 
  
Two trials of antiretroviral prophylaxis in the first two years of life among infant in Malawi, a meta-
analysis among HIV-exposed infants in multiple African countries, and our data found incident levels of 
1.6% to 9.4% between birth and 3 months and levels of 2.8% and 4.9% between 6 and 12 months of 
age
133,134
.  If the goal of any early infant diagnosis program is to timely identify new cases and promptly 
initiate treatment, testing timepoints corresponding to the highest levels of incidence are ideal.  However, 
rapid testing at 3 months will result in most infants testing false positive since the majority of maternally-
acquired antibodies have not waned by this time. Thus, we chose the next testing timepoint of 6 months 
 Time period  
Study Birth  0- 1.5 1.5-3 3-6 6-9 9-12 12-15 15-18 Overall 
Our data  1.6 2.6 1.8 1 0.2 2.1 17.2 
Coutsoudis, 2004 5 4.2 2.8 0.2 2.1 9.3 
Taha, 2007  8.43 1.22 4.05 3.48 17.2 
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as the first timepoint. We chose 12 months, or 6 weeks after breastfeeding cessation, as the second 
timepoint as this corresponds to another time of highest risk of HIV acquisition in the postpartum period.  
 We also evaluated a testing strategy with timepoints 6 months and 15 months. Women are 
encouraged to exclusively breastfeed for 6 months and continue through 12 months. The 15 month 
timepoint would then allow women 6 weeks of breastfeeding cessation, the recommended time between 
cessation of breastfeeding and infant HIV testing. 
4.3.3 Model structure 
 Using Markov modeling we simulated the economic and clinical outcomes of a hypothetical 
cohort of 10,000 HIV-exposed, uninfected infants from 6 weeks postpartum through the first 18 months 
of life as well as over a lifetime horizon. The 6 week time point was chosen as the starting point since 
HIV-exposed infants are to be tested with a PCR test at 4 to 6 weeks of age according to WHO EID 
testing guidelines
10
. We defined the follow-up period in 3 month cycles, beginning at 3 months of age and 
extending through 18 months. The model structure over a lifetime horizon was stratified as 0 to 2 years, 2 
to 5 years, 5 to 10 years, 10 to 20 years, and 20 to 60 years. Figure 5 shows the health states a child could 
occupy during each three month cycle and the transition probabilities of moving to another health state or 
remaining in the same health state.  
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Figure 5. Model structure 
 
 Health states were mutually exclusive and defined as the POC test result at each time point (false 
negative, false positive, true negative, or true positive results), using the result of the HIV DNA PCR test 
as the reference standard. The transition probabilities of going from one state to another were allowed to 
vary over the breastfeeding period, according to data from 3-month time cycles, which required repeated 
Markov structures specific to each 3-month cycle. Age-specific risk of death was modeled at every time 
period and was considered an absorbing health state. The transition matrix consisted of 20 probabilities, 
per time cycle, and is summarized in Table 10.  
 
TN 
Rapid test - / PCR - 
TP 
Rapid test + / PCR + 
FP 
Rapid test + / PCR - 
FN 
Rapid test - / PCR + 
pa 
pc 
pi 
pm 
pn 
pp 
pb 
pd pj 
Death 
pl 
pk 
po 
pe pf 
pg 
ph 
ps 
pq 
pp pr 
*FN-false negative; FP-false positive; TN-true negative; TP-true positive 
 
Health states were mutually exclusive and defined as the POC test result at each time 
point, including false negative, false positive, true negative, or true positive results. A 
false negative result was defined as testing negative on the POC test but testing positive 
on HIV DNA PCR test. A false positive result was defined as testing positive on a POC 
test but testing negative on HIV DNA PCR test. A true negative result was defined at 
testing negative on a POC test and a HIV DNA PCR test. A true positive result was 
defined as testing positive on a POC test and a HIV DNA PCR test. Age-specific risk of 
death was modeled at every time period and was considered an absorbing health state. We 
defined the transition probabilities of moving from one health state to the other according 
to input parameters at each time point.  
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 Table 10. Markov model transition matrix 
 State (Time 2)  
State (Time 1) State A: 
TP 
State B: 
FP 
State C: 
TN 
State D: 
FN 
Death 
State A: TP pm pi pb pg pt 
State B: FP pj pn pd pk pu 
State C: TN pa pc pp pe pv 
State D: FN ph pl pf po pw 
FP: false positive; FN: false negative; TP: true positive; TN: true negative 
 
 As a central assumption of Markov models, transition probabilities are assumed to be constant 
over time. However, in our analyses we did not expect the transition probabilities between states to 
remain constant over the breastfeeding period. Seroreversion occurs more rapidly in the first few months 
after birth, affecting both the sensitivity and specificity of each rapid test. Thus, the transition 
probabilities of going from one state to another state were assumed to not be the same over the 
breastfeeding period. Thus, Markov models and corresponding transition matrices for each 3 month time 
cycle were built (Figure 6). 
 
  
4
5
 
 
 
 
 
 
 
 
*FN-false negative; FP-false negative; TN-true negative; TP-true positive 
Figure 6. Markov model and transition matrices for each 3 month time cycle 
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4.3.4 Model input parameters for the base case model: Clinical input parameters (Table 11) 
Overview 
Where possible and relevant, we based clinical input parameters on data from a cohort of HIV-
exposed infants who were HIV PCR negative (version 1.5 of the Amplicor HIV-1 DNA test kit, Roche, 
Basel, Switzerland) at age 6 weeks (median age 6.4 weeks, range 10.6 weeks), and in whom we measured 
the performance of HIV serological rapid tests. The study took place between 2008 and 2012 at two 
healthcare centers in the Blantyre region of Malawi. During the study period, PMTCT programs provided 
HIV counseling and testing to all pregnant women and offered single dose nevirapine or zidovudine for 
PMTCT. We prospectively collected data on 121 HIV-exposed infants, of which half (51%) were female 
and 80% received nevirapine at birth, which is similar to the current PMTCT uptake in Malawi seen in 
other studies, even in the Option B+ era
149,150
. Exclusive breastfeeding declined throughout the 
postpartum period, from 54% at month 3, to 18% at month 6, 1% at months 9 and 12, and 0% at months 
15 and 18. Any breastfeeding declined from 87% of mothers at month 3, to 69% at month 6, 45% at 
month 9, 39% at month 12, 26% at month 15, and 17% at month 18. Maternal antiretroviral treatment 
(ART) use prior to birth was low (29%) and postpartum ART use and adherence was not recorded. We 
therefore based maternal ART use and adherence on published literature from sub-Saharan Africa and 
assumed that 88% of breastfeeding women will use ART at 6 weeks postpartum
151
, 80% at 3 months 
postpartum
152
 and 56% of these women will be adherent to ART at 12 months postpartum
147,152,153
.  
 Our model structure was stratified according to age (0 to 2 years, 2 to 5 years, 5 to 10 years, 10 to 
20 years, and 20 to 60 years). Mortality estimates, life expectancies, disability weights, and duration of 
HIV infection were defined for each time period and POC test result (i.e., true positive, true negative, 
false positive, or false negative). The observed mortality estimates in the first 24 months of life among 
HIV positive and HIV negative infants in our cohort correspond to what is found in the existing 
literature9,25,153,154. Thus, mortality estimates by age and by rapid test result were obtained from our data 
and the existing literature. For each infant, the most recent rapid test result prior to death was used to 
calculate the transition probability from the rapid test result at that time point to death in the following 
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time cycle. Mortality estimates for HIV-exposed, uninfected infants after 24 months were based on 2013 
WHO Global Health Observatory Data Repository estimates for Malawi and a pooled analysis of several 
studies in Africa that included HIV-exposed, uninfected infants
131,155
. The average age of death for HIV 
infected infants age 24 months and older were based on a pooled analysis of 12 studies examining age-
specific survival
154
. The average age of death was assumed to be the midpoint of the time period. Life 
expectancies for HIV infected and HIV-exposed, uninfected infants were based on a study in South Africa 
that had 56% PMTCT uptake, 87% linkage to postnatal care, Option B+ provision, and 36% pediatric 
ART adherence, which mimics the current reality in Malawi
156
. Disability weights associated with 
HIV/AIDS were estimated from the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 
(GBD)
157-159
, which assigned a disability weight of 0.12 to diagnosed HIV. A disability weight of 0.50 
was assigned to undiagnosed HIV, assuming these infants did not receive treatment and rapidly 
progressed to AIDS. A disability weight of 0.01 was assigned to persons uninfected with HIV. The 
duration of disease a person contributed within each time period was the number of years within that time 
period, assuming they lived to the end of the period. The duration of disease among persons who died was 
half of the time of that interval, assuming death occurred at the midpoint of the respective period. 
Details of clinical input parameters 
1. Mortality estimates, by age and rapid test result  
Birth to 2 years 
Background and input parameters 
 HIV positive: true positive on rapid test: Among infants infected with HIV during the postpartum 
period, no study has reported mortality risks based on whether the infant tested positive or negative 
according to a rapid test. Therefore, we based the mortality estimates within the first two years for HIV 
infected infants who tested positive from a rapid test on our data. In our data, 20% of infants who tested 
positive, thereby defining a true positive rapid test result, died by year 2. However, this estimate is likely 
overestimated given these infants used single dose nevirapine and did not have access to PI-based ART, a 
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combination that can lead to poor outcomes due to resistance. Therefore, we lowered the mortality 
estimate to 15%. 
 HIV positive: false negative on rapid test or missed on rapid test: A Zimbabwean study found 
16% of infants infected postpartum died before 12 months and an additional 16% between 12 and 24 
months
160
. Additionally, a pooled analysis of 12 studies with known timing of pediatric HIV infection 
found mortality among infants with postnatal HIV infections was 38% at year 2
154
. We can assume most 
of the infants did not receive any type of treatment in the 12 studies as most of the studies analyzed were 
conducted prior to widespread distribution of ART. In our data, 35% of infants who tested false negative 
died during-follow-up. 
 HIV-exposed, uninfected: Among infants not infected with HIV, mortality rates were based on 
for a pooled analysis of several studies in Africa that included HIV-exposed, uninfected infants
131
.  
Input parameters 
 Based on our data, we assumed mortality risks of 20% among HIV-exposed, infected infants who 
tested positive on a rapid test and 38% among HIV-exposed, infected infants who tested negative on a 
rapid test or were a missed infection. We assumed mortality of 8% among infants who were exposed, but 
uninfected. 
Sensitivity parameters 
 HIV positive: true positive on rapid test: Sensitivity analyses were conducted around the 
mortality parameter for 0-2 year old HIV positive infants who tested positive (15%). The lower bound 
was calculated by assuming all infants received ART directly after diagnosis, which can reduce mortality 
by 75% if initiated early. The upper bound was based on a recent meta-analysis of 12 studies with known 
timing of pediatric HIV infection. Mortality among infants with postnatal HIV infections was 38% at year 
2
154
. We can assume most of the infants did not receive any type of treatment in the 12 studies as most of 
the studies analyzed were conducted prior to widespread distribution of ART. The mortality proportion of 
38% is similar to mortality of infants in our study who were a false negative by a rapid test, thus 
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hindering any type of treatment. Thus, the upper bound was set at 40% and assumed a majority of infants 
did not receive treatment. 
 HIV positive: false negative on rapid test, missed infection or delayed diagnosis: Sensitivity 
parameters were conducted around the mortality parameters for infants that tested false negative and 
infants that had missed infections. We did not expect the lower bound to be reduced dramatically for these 
infants as disease progression in infants occurs very rapidly
25,26
.  However, in the Option B+ era, women 
taking HAART will deliver in better health (i.e., increased CD4 counts), which is associated with 
improved survival of their infants
131
. Thus, the lower bound was set at 15% to reflect improved health of 
mothers on HAART. The upper bound was calculated based on previous research showing that up to 60% 
of infants infected with HIV die by the age of 2 if untreated
25,26
. However, this estimate was lowered to 
45% since the previous literature included both perinatal and postnatal infections and mortality among 
perinatally infected infants is higher than postnatally infected infants
25,43,154
. 
2 to 5 years 
Background 
 HIV positive, true positive on rapid test: Mortality estimates attributable to HIV are limited and 
are usually aggregated for ages 0 to 14 years. In a pooled analysis examining age-specific survival in 12 
studies that collected pediatric HIV mortality data, Marston and colleagues estimated a cumulative 
mortality among postnatally-infected infants by year 5 at 42%
154
. Thus, the proportion of infants dying 
with the first 2 years of life was estimated at 38% with the additional 4% dying between years 2 and 5. If 
we assume the cumulative mortality by year 5 is similar in our study, where 20% died in the first two 
years of life, an additional 22% would die between years 2 and 5. The cumulative mortality in the 
Marston study, however, was among studies without widespread provision of ART. Thus, we assumed 
the cumulative mortality in our study was lower due to the provision of ART.  
 HIV positive, false positive on rapid test: We did not expect false positive results from rapid test 
since the majority of placentally-acquired antibodies will have waned by 2 years.  
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 HIV positive, missed infection or delayed diagnosis: Among children who but had a delayed or 
missed diagnosis, we assumed mortality to be lower after 2 years of age since disease progression slows 
after infancy
25,26
.  
 HIV-exposed, uninfected: Among infants not infected with HIV, mortality rates were based on 
2013 WHO Global Health Observatory Data Repository estimates for Malawi and a pooled analysis of 
several studies in Africa that included HIV-exposed, uninfected infants
131,155
. 
Input parameters 
 We assumed 10% of HIV positive infants who tested rapid test positive, 30% of HIV positive 
with missed or delayed infections, and 1% of HIV negative infants died between years 2 and 5 of age. 
Sensitivity 
 Since data is limited, sensitivity parameters were assumed. The lower mortality bound was 
estimated assuming treatment was promptly initiated among HIV positive infants who tested rapid test 
positive. The upper bound was estimated assuming a minimal percentage of HIV positive infants initiated 
treatment. 
5 to 10 years 
Background 
 HIV positive, true positive on rapid test: In a meta-analysis examining age-specific survival in 12 
studies that collected pediatric HIV mortality data, Marston and colleagues estimated mortality by year 10 
at 53%
154
. The proportion of infants dying with the first 5 years of life was estimated at 42% with the 
additional 11% dying between years 5 and 10. Since most of the studies in the pooled analysis did not 
provide child PMTCT, we assumed morality among ages 5 to 10 years was lower than 11%. 
 HIV positive, missed infection or delayed diagnosis:  Among children who a delayed or missed 
diagnosis, we assumed mortality to be lower after 2 years of age since disease progression slows after 
infancy, but similar to mortality during younger ages of 2 to 5 years
25,26
.  
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 HIV-exposed, uninfected: Among infants not infected with HIV, mortality rates were based on 
2013 WHO Global Health Observatory Data Repository estimates for Malawi and a pooled analysis of 
several studies in Africa that included HIV-exposed, uninfected infants
131,155
. 
Input parameters 
 We assumed 8% of HIV positive infants who tested rapid test positive, 30% of HIV positive who 
with delayed or missed infections, and 0.8% of HIV negative infants died between ages 5 and 10. 
Sensitivity 
 Since data is limited, sensitivity parameters were assumed. The lower mortality bound was 
estimated assuming treatment was promptly initiated among HIV positive infants who tested rapid test 
positive. The upper bound was estimated assuming a minimal amount initiated treatment and was similar 
to the estimate in the Marston pooled analysis. 
10 to 20 years 
Background 
 HIV positive, true positive: Marston and colleagues estimated mortality by year 20 at 84%
154
. The 
proportion of infants dying with the first 10 years of life was estimated at 53% with the additional 31% 
dying between years 10 and 20. Since most of the studies in the pooled analysis was prior to the 
implementation of Option B+ and prior to the availability of resistance testing and second and third line 
treatment regimens, we assumed morality among ages 10 to 20 years was lower than 31% since a higher 
majority of HIV positive persons initiate and adhere to treatment due to Option B and Option B+.  
 HIV positive, missed infection or delayed diagnosis: Among children acquiring HIV infections 
between ages 10 to 20 years, we assumed mortality to be lower after 2 years of age since disease 
progression slows after infancy, but slightly higher to mortality during younger ages of 2 to 10  years
25,26
. 
We increased mortality during this time period among HIV positive persons who tested rapid test 
negative or were a missed infection to correspond with the increase seen among HIV positive persons 
who tested rapid test positive. 
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 HIV-exposed, uninfected: Among infants not infected with HIV, mortality rates were based on 
2013 WHO Global Health Observatory Data Repository estimates for Malawi and a pooled analysis of 
several studies in Africa that included HIV-exposed, uninfected infants
131,155
. 
Input parameters 
 We assumed 20% of HIV positive infants who tested rapid test positive, 35% of HIV positive 
with missed infections or delayed diagnoses, and 0.8% of HIV negative children died between ages 5 and 
10. 
Sensitivity 
 Since data is limited, sensitivity parameters were assumed. The lower mortality bound was 
estimated assuming treatment was promptly initiated among HIV positive infants who tested rapid test 
positive. The upper bound was estimated assuming a minimal amount initiated treatment. 
20 to 60 years 
Background 
 HIV positive, true positive: Marston and colleagues estimated mortality by year 20 at 84%
154
. The 
proportion of infants dying with the first 20 years of life was estimated at 84% with the additional 16% 
dying between years 20 and 60. However, we assumed the cumulative mortality to be lower since the 
studies in the pooled analysis were prior to widespread distribution of treatment. The assumed cumulative 
mortality from birth to 20 years for our analysis was 64% with the additional 36% of persons dying by 
age 60. 
 HIV positive, missed infection: We assumed mortality to be lower after 2 years of age since 
disease progression slows after infancy, but slightly higher than mortality during younger ages of 2 to 20 
years
25,26
.  
 HIV-exposed, uninfected: Among infants not infected with HIV, mortality rates were based on 
2013 WHO Global Health Observatory Data Repository estimates for Malawi and a pooled analysis of 
several studies in Africa that included HIV-exposed, uninfected infants
131,155
. 
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Input parameters 
 We assumed 36% of HIV positive infants who tested rapid test positive, 35% of HIV positive 
persons were missed infections or delayed diagnoses, and 15% of HIV negative persons died between 
ages 20 and 60. 
Sensitivity 
 Since data is limited, sensitivity parameters were assumed. The lower mortality bound was 
estimated assuming treatment was promptly initiated among HIV positive infants who tested rapid test 
positive. The upper bound was estimated assuming a minimal amount initiated treatment. 
2. Life expectancy, average age of death, and number of years lost by age and rapid test result 
Life expectancy 
Background and input parameters 
 Life expectancy for all infants, regardless of HIV infection, in Malawi was based on the 2013 
WHO Global Health Observatory Data Repository estimates for Malawi
155
. Life expectancy, in years, was 
stratified by ages of less than 2 years, 2 to 5 years, 5 to 10 years, 10 to 20 years, and 20 to 60 years.   
 Average age of death 
0 to 2 years  
Background and input parameters 
 The average age of death for HIV positive infants less than 2 years of age was based on our data 
and the average age of death for HIV negative infants less than 2 years of age was assumed to be 1 year, 
based on the midpoint of the time period. The average age of death for HIV positive infants was based on 
our data and previous research evaluating cost-effectiveness and clinical outcomes of several WHO 
recommended PMTCT strategies in Zimbabwe
161
. The cohort of pregnant, HIV infected women 
resembled our cohort of women with an average age of 24 years and average breastfeeding duration of 15 
months. The Zimbabwe study examined several PMTCT strategies, included Option B, Option B+, ART 
provision and adherence to the infant after pediatric infection, and linkage to care during the postpartum 
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period.  The average age of death was assumed to be 0.9 months for HIV positive infants and 12 months 
for HIV negative infants. 
2 to 5 years and 5 to 10 years 
 The average age of death for children older than 2 but less than 10 was based on a previous study 
in South Africa
156
. The average age of death of 21.41 years was based on an assumption of 56% PMTCT 
uptake, 87% linkage to postnatal care, Option B+ provision, and 36% pediatric ART adherence, which 
mimics the current reality in Malawi.  
10 to 20 years and 20 to 60 years 
 It is of no surprise that ART can dramatically affect life expectancy in HIV positive persons. A 
Ugandan study among 22,315 patients receiving combination ART found life expectancy increased by 
26.7 (25.0, 28.4) years if ART was initiated at age 20 and by 27.9 (26.7, 29.1) years if ART was initiated 
at age 35
162
. Although, the study did not provide estimates of ART adherence during the follow-up period, 
59% of persons initiated ART at WHO stage 2 and 30% initiated ART at WHO stage 3. Thus, we assume 
treatment was not initiated directly after infection but rather after the acute infection period was over in 
the majority of patients.  A more recent modeling study was conducted among HIV infected patients who 
were older than 15 years and treatment naïve in South Africa
163
. The average life expectancy among 
patients who initiated ART at age 25 years was increased 31.4 years (26.7, 36.2) and was 25.9 (22.2, 
30.0) if ART was initiated at age 35 years. Similar to the Ugandan study, ART adherence was not 
provided in the South African study. The Malawi HIV epidemic resembles the Ugandan epidemic more 
closely than the South African epidemic, where provision of treatment is more widespread. Assuming 
ART adherence will likely continue to increase in low income countries, due to widespread dissemination 
and provision of treatment, we assumed an average duration of 27 years for adults ages 10 to 20 years and 
24 years for adults older than 20 years, similar to the Ugandan study.  
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3. Disability weights 
Background 
 Disability weights associated with HIV/AIDS were estimated from the Global Burden of 
Diseases, Injuries, and Risk Factors Study 2010 (GBD)
157-159
. In the 2010 GBD study, a disability weight 
of 0.12 was assigned to undiagnosed HIV without symptoms. A disability weight of 0.50 was assigned to 
undiagnosed HIV, assuming these infants did not receive treatment and rapidly progressed to AIDS.  
Input parameters 
 Assuming most infants will be diagnosed without symptoms, otherwise the infants would have 
been brought in for early testing, a disability weight of 0.12 was assigned to infants who tested true 
positive. A disability weight of 0.50 was assigned to infants who tested false negative or were missed 
infections, on the assumption they would be untreated. A disability weight of 0.01 was assigned to HIV-
exposed, uninfected infants (i.e., infants who tested false positive and true negative on a rapid test). 
4. Number of incident cases 
Background and input parameters 
 The incident number of cases by rapid test result type was calculated according to our data from 
Malawi. The transition probabilities for each 3 month cycle was used to estimate the number of cases if 
an infant tested true positive or false negative according to a rapid test in the cohort of 10,000 infants.  
 The incident number of cases for HIV-exposed, negative infants (i.e., those that tested false 
positive and true negative on a rapid test) between ages 0 to 2 years was calculated based on our data, 
with 17% of infants becoming infected during that time period. The incident number of cases for all other 
age ranges was based on previous pooled data from sub-Saharan Africa
161,164
. 
Sensitivity parameters 
 Among HIV-exposed, uninfected infants, we explored the lifetime incidence rate assumption 
through sensitivity analyses with a range of 2% to 50% to account for dissemination of pre-exposure 
prophylaxis, contributing to a lower lifetime risk, and high-risk behaviors, contributing to a higher 
lifetime risk of HIV. 
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5. Duration of disease (years), by age 
 Our model structure was stratified by time periods throughout a person’s life (i.e., 0 to 2 years, 2 
to 5 years, 5 to 10 years, 10 to 20 years, and 20 to 60 years. Thus, the duration of disease a person 
contributed within each time period was the number of years within that time period, assuming they lived 
to the end of the period. If a person died within that interval, we assumed the death occurred in the middle 
of the period. Thus, the duration of disease among persons who died was half of the time for that interval. 
4.3.5 Model input parameters for the base case model: Economic input parameters (Table 11) 
Overview 
 The cost of a Determine and Unigold test was set at $1.50 and $5.00, respectively. An additional 
$1.60 was added to each serological rapid test for sample preparation costs and personnel. The cost of the 
Alere Q HIV test was set at $25.00 per test and included equipment costs, sample preparation and 
personnel
165
. The costs of a PCR was set at $35.00 and included costs of the tests, sample preparation, and 
personnel
166
. HIV pre- and post-test counseling costs were determined based on research conducted in 
Uganda
75
. The costs of providing ART to HIV infected children were based on cost-effectiveness research 
conducted in Rwanda
167
. 
 The costs of a false positive POC test included the cost of the POC test, costs of pre- and post-test 
HIV counseling, cost of a follow-up PCR, and costs of counseling after a negative PCR test. The costs of 
a true positive POC test included the cost of the POC test, costs of pre- and post-test HIV counseling, cost 
of a follow-up PCR, costs of counseling after a positive PCR test, and treatment costs. The costs of a false 
negative and true negative POC test were the same and included the cost of the POC test and costs of pre- 
and post-test HIV counseling.  
Details of economic input parameters 
Testing costs 
 The costs of each rapid test and the costs associated with PCR were estimated based on our data 
sources in Malawi and previous research conducted in Uganda75. The costs of a Determine test was $1.50 
and the costs of a Unigold test was $5.00. An additional $1.60 was added to each rapid test for sample 
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preparation costs and personnel. The costs of the Alere Q HIV test was estimated to be $25.00 per test 
and included equipment costs, sample preparation and personnel
165
. Each Alere Q HIV machine costs 
$10,000 and can perform 7,000 tests per year. The costs of a PCR was estimated at $35.00 and includes 
costs of the tests, sample preparation, and personnel
166
. 
Counseling costs 
 HIV pre and post test counseling costs were determined based on previous research conducted in 
Uganda
75
. Costs associated with a negative rapid test or a negative PCR test was $1.40 per test and costs 
associated with a positive rapid test or a positive PCR test was $1.50 per test. 
Infant HIV infection costs 
 The costs of providing ART to HIV infected children were based on previous cost-effectiveness 
research conducted in Rwanda
167
. For children less than 12 months of age, the cost of treatment for each 
HIV infected infant was $558.32. For children older than 12 months of age, the cost of treatment for each 
HIV infected child was $527.52. For simplicity, the costs were combined for the follow-up period 
resulting in $542.92 per year for each infected children from 3 months to 18 months of age. 
Test result costs 
 The costs of a false positive rapid test or false positive Alere PCR test included the cost of the 
point-of-care test, costs of pre and post test HIV counseling after a positive point-of-care test, cost of a 
follow-up PCR, and costs of pre and post test HIV counseling after a negative PCR test. The costs of a 
true positive rapid test or true positive Alere PCR test included the cost of the point-of-care test, costs of 
pre and post test HIV counseling after a positive point-of-care test, cost of a follow-up PCR, costs of pre 
and post test HIV counseling after a positive PCR test, and treatment costs for the infected infant. The 
costs of a false negative rapid test or false negative Alere PCR test included the cost of the point-of-care 
test and costs of pre and post test HIV counseling after a negative point-of-care test. The costs of a true 
negative rapid test or true negative Alere PCR test included the cost of the point-of-care test and costs of 
pre and post test HIV counseling after a negative point-of-care test. 
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Sensitivity parameters 
 The cost of providing ART varies from country to country. A recent cost-effectiveness analysis 
conducted among four countries found discounted costs for infant ART ranging from $801 in Zambia, 
$759 in Kenya, $404 in Vietnam, and $279 in South Africa
168
. Based on these estimates, we varied our 
costs of infant ART from $300 to $800. These ranges were incorporated in the total costs if the test result 
was a true positive. 
4.3.6 Model input parameters for the base case model: Test performance parameters (Table 11) 
 In our cohort study, serological rapid HIV tests were performed at POC in Malawian HIV-
exposed uninfected infants at ages 3, 6, 9, 12, 15, and 18 months postpartum at 6 weeks. At missing data 
points (approximately 30%), rapid tests were conducted on stored blood at a University of North Carolina 
research laboratory. To account for missing data due to unavailable stored blood and not collected in 
Malawi, we used multiple imputation methods using Markov chain Monte Carlo methods
169
 and Proc MI 
in SAS to impute the missing values for five datasets
101,102
. HIV DNA PCR was considered the gold 
standard and performed at each time a rapid test was done. Confirmation of infant HIV infection detected 
by a positive HIV DNA PCR result was done through a second HIV DNA PCR assay or a HIV RNA viral 
load assay. Using HIV DNA PCR as the reference standard, we calculated the sensitivity and specificity 
of Determine and Unigold in 3 month intervals, from month 3 to month 18 postpartum (Table 2). The 
corresponding transition probabilities were averaged over the five datasets to create the final transition 
probabilities for each rapid test at each time cycle.  
 Transition probabilities between health states for the Alere q HIV1/2 test for each 3 month cycle 
were calculated based on test results from two African studies
170,171
. The sensitivity of the Alere test in a 
South African study of 1,098 infants with a median age of 47 days (IQR: 42-177 days) was 95.5% (95% 
CI: 91.7 to 97.9) and specificity was 99.8% (95% CI: 99.1 to 100.0) among all infants. Age-specific 
estimates were not provided
45
. The sensitivity and specificity of the Alere test in a Mozambique study of 
827 infants with a median age of 42 days (IQR: 30-90 days), were 97.3% (95% CI: 85.8 to 99.9) and 
99.9% (95% CI: 99.2 to 100.0), respectively, among infants younger than 6 months and was 99.9% (95% 
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CI: 76.8 to 100.0) and 100.0% (95% CI: 92.1 to 100.0) among infants age 6 to 18 month
46
. Based on these 
two studies, we used values for sensitivity and specificity of 97.0% and 99.8%, respectively, between 
months 3 and 9, and sensitivity and specificity values of 99.0% and 100.0%, respectively, between 
months 9 and 18 to calculate the transition probabilities. 
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  Table 11. Model input and sensitivity parameters 
Parameters Base-case value Sensitivity parameters Data source 
Clinical model assumptions and input parameters 
Test performance 
Sensitivity    
Determine   
Our data 
3 month 100.0 47.8, 100.0 
6 month 100.0 39.8, 100.0 
9 month 66.7 22.3, 95.7 
12 month 100.0 69.2, 100.0 
15 month 87.5 47.4, 99.7 
18 month 100.0 63.1, 100.0 
Unigold   
3 month 100.0 47.8, 100.0 
6 month 100.0 39.8, 100.0 
9 month 75.0 19.4, 99.4 
12 month 81.8 48.2, 97.7 
15 month 87.5 47.4, 99.7 
18 month 100.0 63.1, 100.0 
Alere    
3 month-9 
month 
97.0 91.7, 100.0 
170, 171 
12 month-18 
month 
99.0 91.7, 100.0 
Specificity    
Determine    
3 month 7.0 2.3, 15.7 
Our data 
6 month 34.4 24.8, 44.9 
9 month 46.5 35.9, 57.1 
12 month 88.3 81.1, 95.5 
15 month 95.6 90.7, 100.0 
18 month 94.6 88.8, 100.0 
Unigold   
3 month 19.4 11.1, 30.5 
6 month 83.7 74.4, 89.9 
9 month 97.7 94.6, 99.7 
12 month 100.0 95.4, 100.0 
15 month 100.0 94.5, 100.0 
18 month 100.0 94.0, 100.0 
Alere    
3 month - 9 
month 99.8 
99.1, 100.0 
170, 171 
12 month - 18 
month 99.9 
99.1, 100.0 
Parameters needed to calculate DALYs 
 0-2 2-5 5-10 10-20 20-60 0-2 2-5 5-10 10-20 20-60  
Mortality estimates (%) 
HIV 
positive, TP 
15 10 8 20 36 4, 40 4, 16 5, 11 10, 31 31, 41 
154, 
our 
data 
HIV 
positive, FN 
38 - - - - 15, 45 - - - - 
154, 
our 
data 
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HIV 
positive, 
missed 38 30 30 35 35 20, 40 20, 40 15, 35 25, 45 25, 45 
154, 
our 
data 
HIV 
negative, FP 
or TN 8 1 0.8 0.8 15 - - - - - 172 
Life 
expectancy      
      
HIV 
positive, TP 
20.51 18.91 13.91 27.0 27.0 - - - - - 
155,1
61-
163 
HIV positive 
FN or 
missed 20.51 32.50 27.50 45.00 27.00 - - - - -  
Number of 
incident cases 
(%) 17 2 2 30 1 2, 25 1.8, 3.0 1.8, 3.0 10, 45 0.9, 1.5 
161,1
64 
Duration of 
HIV/AIDS 
(years) 2 3 5 10 40 
- - - - -  
Economic model input parameters 
Testing costs (includes test and sample prep)   
Determine $3.10 - Our data, 75 
Unigold $6.60 - Our data, 75 
Alere PCR $25.00 - 165 
PCR $35.50 - Our data, 166 
Counseling costs    
Pre/post with negative 
result $1.40 - 75 
Pre/post with positive  
result $1.50 - 75 
Costs for HIV infected 
child    
ART per year  $542.92 $300-$800 167 
Costs associated with test 
results    
False positive Determine $41.00 - Our data, 75,166 
False positive Unigold $44.50 - Our data, 75,166 
False positive Alere $72.90 - 165,166 
True positive Determine $584.02 $341.10-$841.10 Our data, 75,166,167 
True positive Unigold $587.52 $344.60-$844.60 Our data, 75,166,167 
True positive Alere $615.92 $373.00-$873.00 165-167 
False negative Determine $4.50 - Our data, 75 
False negative Unigold $8.00 - Our data, 75 
False negative Alere $36.40 - 165 
True negative Determine $4.50 - Our data, 75 
True negative Unigold $8.00 - Our data, 75 
True negative Alere $36.40 - 165 
*ART-Antiretroviral treatement; EBF-Exclusive breastfeeding; MTCT-Mother-to-child transmission; NVP-Nevirapine; 
PMTCT-prevention of mother to-child transmission; PCR-polymerase chain reaction 
 
Note:  Costs assumed a triangular distribution and all other parameters assumed beta distributions. 
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4.3.7 Outcomes 
 
 We projected the clinical and economic outcomes of each strategy, and the incremental cost-
effectiveness. Economic outcomes included testing costs, HIV pre- and post-test counseling costs, 
healthcare and treatment costs, and total costs.  
 Clinical outcomes included missed pediatric HIV infection, number of false negative, false 
positive, true negative, and true positive rapid test results, and Disability Adjusted Life Years (DALYs). 
A missed pediatric HIV infection was defined as any infection that occurred but was not detected by the 
HIV rapid test used as well as any infection occurring six months or more before the testing time point, as 
both negatively impacts the benefits of early treatment initiation. For example, missed infections for the 
EID strategy 7 (test once at 9 months with Determine) would include all infections after 9 months and any 
infections between age 6 weeks and 3 months but not identified by Determine at the 9 month testing time 
point. DALYs were expressed as the number of years lost due to early death, disability, or ill-health, 
thereby combining mortality and morbidity into a single metric
173,174
. Years of life lost (YLL) to an HIV 
infection was calculated from the number of deaths in the population, the standard life expectancy at age 
of death, and a discount rate
174
. 
 
  Years of life lost to disability (YLD) from HIV infection was calculated from the number of 
incident cases, disability weights, duration of disease, and a discount rate
174
.  
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YLL and YLD were calculated for each age group and for each health state. Health benefits were 
discounted at 3% annually throughout the lifetime horizon
138
.  
 We assessed the relative value of each EID strategy to the next most expensive strategy using the 
incremental cost-effectiveness ratio (ICER) by ranking all EID strategies in sequential order by total 
costs
175,176
. The incremental effectiveness of each EID strategy was evaluated as DALYs averted, 
compared with the next most expensive strategy. Strategies were considered dominated (i.e., cost-
effective) if DALYs were not averted in the next most expensive strategy. After the initial comparisons of 
all strategies in sequential order, dominated strategies were eliminated from the ranking, and the 
incremental effectiveness of the remaining strategies were evaluated again as DALYs averted, compared 
with the next most expensive strategy. This iterative process continued until all remaining strategies were 
undominated by the next most expensive strategy, resulting in the final ICER calculations. ICER results 
from the base case were compared with a willingness-to-pay threshold of 1 or 3 times the per capita 
Malawi gross domestic product (GDP) per DALY averted. The WHO considers interventions that cost 1 
to 3 times the per capita GDP per DALY averted as cost-effective, with interventions that costs less than 
1 times the per capita GDP considered very cost-effective
177,178
. 
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CHAPTER 5: RESULTS. PERFORMANCE OF HIV RAPID TESTS AMONG BREASTFEEDING, 
MALAWIAN INFANTS  
 
 In the past decades, large gains have been made in reducing the burden of infant HIV infection 
through implementation of effective prevention of mother-to-child transmission (PMTCT) programs, 
primarily in the prenatal and delivery period
19,221
. However, implementation of the 2010 World Health 
Organization (WHO) breastfeeding guidelines may shift the timing of infant HIV infection to the 
postnatal period as HIV positive mothers are now encouraged to exclusively breastfeed for the first 6 
months of life and continue breastfeeding for at least the first 12 months of life, increasing the duration of 
the infant’s recurrent exposure to HIV compared to the previous guidelines8. In areas with a tradition of 
prolonged breastfeeding, it is estimated that as many as 8 out of 10 pediatric HIV infections may occur 
during the breastfeeding period
1
. 
 The WHO recommends HIV-DNA/RNA polymerase chain reaction (PCR) and ultra-sensitive 
p24 antigen assays for diagnosis of infant HIV infections
10
. These tests, however, are limited in resource 
poor settings by logistical and financial constraints and high loss to follow-up during the breastfeeding 
period since mothers are required to return for test results
11,12
. Rapid HIV tests are cheaper and allow for 
quick results (i.e., 20 minutes) but these tests detect HIV antibodies and the presence of circulating 
placentally-transferred maternal HIV antibodies, complicating their interpretation in young infants
13,14
. 
The time of seroreversion, or decay of maternal antibodies, ranges between 9 to 18 months, with the most 
significant decay occurring by 12 months of age
17,73,107-110
. The WHO therefore recommends rapid tests as 
a screening assay to determine HIV exposure in children less than 18 months of age or as a diagnostic 
assay in children older than 18 months of age
27
. 
 In previous studies of the persistence of maternal HIV antibodies among infants younger than 18 
months of age, children were aggregated regardless of age and were mainly comprised only infants older 
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than one year
13,15-17
. Thus, the utility of rapid tests in infants in high HIV burden settings during early 
infancy and throughout the postpartum period, particularly in relation to the decay of placentally-acquired 
antibodies, is not yet well understood. We aimed to evaluate the performance of two commonly used 
rapid tests in the public sector at 6 timepoints during the first 18 months of life in Malawian, breastfed 
HIV-exposed children.  A detailed description of the methods is available in section 4.1 of this document. 
5.1 Results 
 
 Overall, 121 HIV-exposed infants contributed 996 HIV rapid test results between 3 months and 
18 months of age. Of the 996 rapid tests, 295 Determine and 294 Unigold were conducted in real-time in 
Malawi; 197 Determine and 210 Unigold were conducted at UNC. The 3 month tests were performed 
almost exclusively (99%) at UNC on stored blood. Approximately two-thirds of tests at the 6, 9, and 12 
month timepoints were performed in real-time in Malawi. After 12 months, over 75% of all tests were 
performed in real-time in Malawi.   
 Of the 121 mother-infant pairs, half of the infants were female, 98 (81%) of the infants received 
single dose nevirapine at birth, and 24 (20%) of the mothers reported taking daily antiretrovirals prior to 
birth (Table 12). Most (69%, 84/121) infants breastfed up to 6 months, but only 22 (18%) infants were 
exclusively breastfed through month 6. Of the 21 infants infected during follow-up, 9 (43%) were still 
breastfeeding at 18 months; only 17 of the 100 (17%) non-infected infants were still breastfeeding at 18 
months.  
Among the cohort of 121 HIV-exposed infants who were HIV negative at age 6 weeks, 21 
became infected, corresponding to a cumulative incidence of HIV infection of 17.2% (95% CI: 11.1, 
24.5) over 18 months. Of the 21 infants who became infected with HIV between 6 weeks and 3 months, 
1.6% of infants became infected between birth and 3 months, 4.1% between 3 and 6 months, 0.8% 
between 6 and 9 months, 5.0% between 9 and 12 months, 4.9% between 12 and 15 months, and 0.8% 
between 15 to 18 months.  
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Excluding HIV infection  
The specificity estimates of both tests increased with infant age, but the estimated specificity of 
the Unigold assay was higher than that of the Determine assay at all ages (Figure 7, Table 13). For 
Unigold, the estimated specificity increased from 19.4% (95% CI: 11.1, 30.5) at 3 months to 83.7% (74.4, 
89.9) at 6 months, reaching 100 (95% CI: 95.4, 100.0) by age 12 months. The specificity estimates of the 
Determine test increased from 7.0% (2.3, 15.7) at 3 months to 34.4% (24.8, 44.9) at age 6 months, 
leveling off at 95.6% (90.7, 100.0) by 15 months of age. 
Diagnosing incident HIV infection  
The estimated sensitivity, defined as true incident HIV infection, of both tests displayed a U-
shaped curve with 100% sensitivity before age 6 months, low sensitivity (around 70%) at age 9 months, 
after which sensitivity increased again, reaching 100% for both rapid tests at age 18 month. Due to the 
low event rates, sensitivity estimates were imprecise, with broad 95% confidence intervals (Table 13).  
 Among the 21 infants, we observed 4 different infection scenarios: (1) incident HIV infection 
prior to seroreversion, (2) seroreversion followed by detection of an incident infection by a rapid test, (3) 
incident HIV infection with false negative HIV rapid test due to the window period, and (4) all other 
scenarios with insufficient information necessary to characterize (Figure 8). The first scenario, incident 
infection prior to seroreversion, occurred in six children (A-F). The second scenario, seroreversion 
followed by detection of an incident infection by a rapid test, occurred in four children (F-I) for 
Determine and in three children for Unigold (G-I). In all four children, incident infection occurred 
between 9 and 12 months. For three children (G-I), we were able to observe seroreversion followed by 
identification of an incident infection at age 12 months with both rapid tests. In one child (H), we 
observed seroreversion prior to incident infection for both tests, but identification of an incident infection 
was only documented by Determine. The third scenario, incident infection with a false negative rapid test 
most likely representing the window period, occurred in four children (H, J, K, L). In two children (J, L), 
incident infection occurred between 6 and 9 months of age, but either Determine (L) or both rapid tests (J) 
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were false negative at age 9 months. In the remaining nine children (M-U), insufficient data was available 
to classify them.  
Positive and negative predictive values of rapid test results 
 The estimated PPV was low at most ages for both tests and decreased with decreasing population 
incidence of HIV infection (Table 14). The estimated PPV of Unigold was substantially higher than that 
of Determine at all ages except for age 3 months, an age at which the PPV was extremely low (≤ 7%) for 
both rapid tests. The estimated PPV for Determine never reached more than 52%, independent of age or 
population infant HIV incidence. An estimated PPV greater than 80% was reached for Unigold at age 12 
months or older in settings with HIV incidence ≥5%. 
 The estimated NPV was very high (≥99%) for both rapid tests at all ages regardless of the 
population infant HIV incidence, except for age 9 months in settings with ≥4% risk of HIV acquisition, 
where the estimated NPV value of Determine was slightly lower (96-97%).   
5.2 Discussion 
 
 Even in the era of option B+, monitoring infant HIV infection status in the breastfeeding period is 
critical for timely identification of HIV infection, rapid initiation of antiretroviral treatment and accurately 
ruling out HIV infection. For all HIV-exposed infants with negative virological tests at age 4 to 6 weeks, 
the WHO currently recommends a rapid test at 9 months and, if negative, again at 18 months or 6 weeks 
after the cessation of breastfeeding without providing guidance regarding what type of rapid test to use. 
We show that performance of rapid tests in young infants depends on the infant’s age and the type of 
rapid test. Thus, recommendations for rapid testing should incorporate age-specific guidelines and 
information on what type of test to best use during the postpartum period.  
 At 3 months of age, rapid HIV tests have minimal clinical value since recent infection cannot be 
distinguished from circulating maternal antibodies. Between 6 and 12 months of age, however, screening 
by rapid tests could play a role in the follow up of HIV-exposed infants, but the clinical utility depends on 
the type of rapid test used, with Unigold outperforming Determine at these timepoints. At age 12 months 
and beyond, the type of test is less important, as both tests identifed HIV-free children, although both 
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tests failed to detect some incident infections. Finally, as we observed no difference in test performance 
between ages 15 to 18 months, it may be possible to change the current recommendation to test HIV-
exposed, uninfected infants at 18 months to the earlier timepoint of 15 months. From a mother’s 
perspective, this would reduce the stressful waiting time regarding her child’s HIV status. 
 The “worse” performance of the Determine rapid test is not surprising as Determine is a more 
sensitive test compared to the Unigold test in adult populations
179,180
. The Determine test has a lower 
threshold for HIV antibodies than Unigold. Consequently, maternal antibodies will continue to be 
detected longer with Determine than Unigold. Thus, the proportion of false positives will be higher for 
Determine, reducing the specificity of Determine in this context. Although test sensitivity may have been 
inflated due to testing on stored blood, 
17,73,181
, we do not expect this to impact the results substantially as 
60% of all testing was conducted in Malawi in real-time.  
 Our study was the first to prospectively compare two rapid tests at multiple timepoints, including 
very young ages, in a cohort of predominantly breastfeeding infants in a resource limited setting. Our 
results are consistent with previous studies
22,23 
in regard to test sensitivity but not specificity, though 
comparisons with other data are difficult given the scarcity of rapid test performance data among young 
infants
17,73
. In mainly formula-fed South African children, the estimated specificity for Determine was 
82% at 6 to 9 months and 100% at 9 to 12 months
73
, compared to 46.5% at 9 months and 88.3% at 12 
months in our cohort of mainly breast-fed Malawian children. Other studies evaluating tests performance 
aggregated all infants less than 18 months of age, making comparisons difficult
17,74
. . While many more 
rapid tests are commercially available and used in resource limited settings, we only evaluated those two 
that are commonly used in the public sector in Malawi and did not include any fourth generation rapid 
tests. One small study showed that fourth generation tests did not perform better in infants compared to 
third generation tests
80
. 
Based on our findings, the use of Unigold, or another rapid test with similar performance 
characteristics, throughout the entire postpartum period could be advocated for, particularly given the 
outperformance of Unigold at all timepoints, including the younger ages where timely identification of 
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infection and prompt treatment initiation is important. Although Determine is cheaper than Unigold, the 
lower percentage of false positives with Unigold would result in fewer unnecessary follow-up PCR tests, 
thereby reducing overall costs in an early infant diagnosis program. Another option for testing during this 
time period are point-of-care virological assays, which distinguish between true infections and 
placentally-acquired HIV antibodies at young ages. While preliminary data from studies in early infant 
diagnosis programs are promising, 
170,171
 the cost of these novel point-of-care virological assays are 
expected to be nearly seven times the costs of a rapid test
165
, likely too expensive for repeated use during 
the first 18 months of life in the 1.5 million HIV-exposed children born annually in high burden 
countries
3
. It is therefore likely that a potential role for rapid tests in the repeat screening of HIV-exposed 
infants remains.  
 In conclusion, timely, accurate, and affordable testing algorithms at point-of-care are critical for 
effective early infant diagnosis in the postpartum period. Our findings that the performance of rapid tests 
differed by age, test type, and for different population infant HIV incidence levels, warrants evaluation of 
the use of rapid tests in large cohorts of HIV-exposed children. Updated guidelines for use of rapid tests 
in HIV-exposed infants that explicitly take timing and test type into account are urgently needed to ensure 
optimal care for the 1.5 million HIV-exposed infants born annually.  
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Table 12. Characteristics of cohort of HIV-exposed infants with negative PCR test at 6 weeks in Malawi  
 
All 
(N=121) 
HIV-exposed, 
uninfected (N=100) 
HIV-exposed, 
infected*  
(N=21) 
 
Infant characteristics 
N (%) 
Median (IQR) 
Mean (SD) 
N (%) 
Median (IQR) 
Mean (SD) 
N (%) 
Median (IQR) 
Mean (SD) 
 
p-value 
Gender 
Female 
Male 
 
61 (51) 
60 (49) 
49 (50) 
51 (50) 
12 (57) 
9 (43) 
 
 
0.53 
Exclusive Breastfeeding 
status (month) 
3 
6 
9 
12 
15 
18 
 
 
66 (54) 
22 (18) 
1 (1) 
1 (1) 
0 (0) 
0 (0) 
56 (56) 
18 (18) 
1 (1) 
1 (1) 
0 (0) 
0 (0) 
10 (48) 
4 (19) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 0.62 
Any Breastfeeding status 
(month) 
3 
6 
9 
12 
15 
18 
 
 
106 (87) 
84 (69) 
55 (45) 
47 (39) 
32 (26) 
21 (17) 
87 (87) 
70 (70) 
40 (40) 
35 (35) 
24 (24) 
12 (12) 
19 (90) 
14 (67) 
15 (71) 
12 (57) 
9 (43) 
9 (43) 0.16 
NVP at birth 
Yes 
No 
Unknown 
 
97 (80) 
6 (5) 
18 (15) 
80 (80) 
6 (6) 
14 (14) 
17 (81) 
0 (0) 
4 (19) 0.26 
Weight-for-age z-score  
(mean) 
-1.05 (1.25) 
-1.84 (1.10) -0.69 (0.87) NA 
Maternal characteristics     
Age (median) 27 (IQR: 18-40) 27 (IQR: 18-40) 29 (IQR: 20-39) 0.65 
Maternal ARV use prior to 
birth 
No 
Yes 
Unknown 
 
87 (72) 
24 (20) 
10 (8) 
69 (69) 
22 (22) 
9 (9) 
17 (81) 
1 (5) 
3 (14) 0.08 
Marital status 
Single (divorced, 
widowed) 
Married (married, living 
with partner) 
Unknown 
 
17 (14) 
99 (82) 
5 (4) 
12 (12) 
85 (85) 
3 (3) 
2 (10) 
17 (80) 
2 (10) 0.82 
Education level 
Completed > secondary 
level 
Completed < secondary 
level 
Unknown 
 
62 (51) 
54 (45) 
5 (4) 76 (76) 
21 (21) 
3 (3) 
14 (66) 
5 (24) 
2 (10) 0.66 
*HIV infection occurred after 6 weeks 
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Table 13. Sensitivity and specificity of Determine and Unigold assays during the postpartum period 
 
 
 
 
  Results   
 
Total 
tested 
True 
positive 
(PCR+, 
rapid 
test+) 
False 
Negative 
(PCR+, 
rapid test-
) 
False 
positive 
(PCR- 
,rapid 
test+) 
True 
negative 
(PCR-, 
rapid  
test-) 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
Infant age N n (%) n (%) n (%) n (%)   
3 months        
Determine 76 5 (7) 0 (0) 66 (86) 5 (7) 100.0 (47.8, 100.0) 7.0 (2.3, 15.7) 
Unigold 77 5 (7) 0 (0) 58 (75) 14 (18) 100.0 (47.8, 100.0) 19.4 (11.1, 30.5) 
6 months        
Determine 97 4 (4) 0 (0) 61 (63) 32 (33) 100.0 (39.8, 100.0) 34.4 (24.8, 44.9) 
Unigold 105 4 (4) 0 (0) 17 (16) 84 (80) 100.0 (39.8, 100.0) 83.7 (74.4, 89.9) 
9 months*        
Determine 92 4 (4) 2 (2) 46 (50) 40 (43) 66.7 (22.3, 95.7) 46.5 (35.9, 57.1) 
Unigold 91 3 (3) 1 (1) 2 (2) 85 (94) 75.0 (19.4, 99.4) 97.7 (94.6, 99.7) 
12 months        
Determine 88 10 (11) 0 (0) 9 (11) 68 (77) 100.0 (69.2, 100.0) 88.3 (81.1, 95.5) 
Unigold 91 9 (10) 2 (2) 0 (0) 79 (88) 81.8 (48.2, 97.7) 100.0 (95.4, 100.0) 
15 months        
Determine 76 7 (9) 1 (1) 3 (4) 65 (86) 87.5 (47.4, 99.7) 95.6 (90.7, 100.0) 
Unigold 73 7 (10) 1 (1) 0 (0) 65 (89) 87.5 (47.4, 99.7) 100.0 (94.5, 100.0) 
18 months        
Determine 64 8 (13) 0 (0) 3 (4) 53 (83) 100.0 (63.1, 100.0) 94.6 (88.8, 100.0) 
Unigold 68 8 (12) 0 (0) 0 (0) 60 (88) 100.0 (63.1, 100.0) 100.0 (94.0, 100.0) 
Abbreviations: CI, confidence interval;  
*Of the 6 HIV incident infections detected at 9 months, 4 were tested with Determine and Unigold and 2 were tested only with Determine due to 
Unigold stock-out at the testing site. 
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Table 14. Positive and negative predictive values of Determine and Unigold assays during the postpartum period with varying                                    
pediatric HIV incident infections 
Positive predictive value 
Incidence* 3m 95% CI 6m 95% CI 9m 95% CI 12m 95% CI 15m 95% CI 18m 95% CI 
5%             
Determine 5.3 (0.0, 10.7) 7.4 (1.1, 13.8) 6.2 (0.0, 12.9) 31.0 (8.4, 53.7) 51.1 (20.2, 82.1) 49.4 (19.8, 78.9) 
Unigold 6.1 (0.0, 12.1) 24.4 (6.0, 42.8) 63.2 (20.9, 100.0) 81.1 (49.9, 100.0) 82.2 (53.8, 100.0) 84.0 (58.7, 100.0) 
4%             
Determine 4.3 (0.0, 9.1) 5.9 (1.1, 11.7) 4.9 (0.0, 11.0) 26.3 (4.7, 47.8) 45.3 (14.5, 76.2) 43.5 (14.3, 72.9) 
Unigold 4.9 (0.0, 10.3) 20.4 (3.1, 37.6) 57.6 (14.3, 100.0) 77.3 (43.8, 100.0) 78.5 (48.0, 100.0) 80.6 (53.3, 100.0) 
3%             
Determine 3.3 (0.0, 0.7) 4.5 (0.0, 9.5) 3.7 (0.0, 9.0) 20.9 (0.0, 40.8) 38.1 (7.9, 68.1) 36.4 (7.9, 64.8) 
Unigold 3.7 (0.0, 8.4) 15.9 (0.0, 31.6) 50.2 (6.4, 94.0) 71.7 (35.6, 100.0) 73.0 (40.1, 100.0) 75.6 (45.8, 100.0) 
2%             
Determine 2.1 (0.0, 5.6) 3.0 (0.0, 7.2) 2.5 (0.0, 6.8) 14.9 (0.0, 32.2) 28.9 (0.0, 56.9) 27.4 (1.1, 53.8) 
Unigold 2.5 (0.0, 6.4) 11.1 (0.0, 24.6) 39.9 (0.0, 82.9) 62.5 (23.8, 100.0) 64.1 (28.6, 99.6) 67.1 (34.6, 00.7) 
1%             
Determine 1.1 (0.0, 3.5) 1.5 (0.0, 4.5) 1.2 (0.0, 4.4) 7.9 (0.0, 21.2) 16.7 (0.0, 39.9) 15.7 (0.0, 37.3) 
Unigold 1.2 (0.0, 4.0) 5.8 (0.0, 15.9) 24.7 (0.0, 62.6) 45.2 (5.4, 85.1) 46.9 (9.9, 83.9) 50.2 (15.6, 84.9) 
Negative predictive value 
Incidence* 3m 95% CI 6m 95% CI 9m 95% CI 12m 95% CI 15m 95% CI 18m 95% CI 
5%             
Determine 99.3 (97.2, 100.0) 99.8 (98.9, 100.0) 96.4 (91.1, 100.0) 99.9 (98.8, 100.0) 99.3 (94.2, 100.0) 99.9 (98.6, 100.0) 
Unigold 99.7 (98.4, 100.0) 99.9 (98.9, 100.0) 98.7 (88.6, 100.0) 99.0 (91.2, 100.0) 99.4 (93.3, 100.0) 99.9 (98.3, 100.0) 
4%             
Determine 99.4 (97.6, 100.0) 99.9 (99.0, 100.0) 97.1 (92.4, 100.0) 99.9 (98.9, 100.0) 99.5 (94.9, 100.0) 99.9 (98.7, 100.0) 
Unigold 99.8 (98.6, 100.0) 99.9 (98.9, 100.0) 98.9 (89.9, 100.0) 99.2 (92.2, 100.0) 99.5 (94.1, 100.0) 99.9 (98.5, 100.0) 
3%             
Determine 99.6 (97.9, 100.0) 99.9 (99.2, 100.0) 97.8 (93.8, 100.0) 99.9 (99.0, 100.0) 99.6 (95.7, 100.0) 99.9 (98.9, 100.0) 
Unigold 99.8 (98.8, 100.0) 99.9 (99.1, 100.0) 99.2 (91.4, 100.0) 99.4 (93.4, 100.0) 99.6 (94.9, 100.0) 99.9 (98.7, 100.0) 
2%             
Determine 99.7 (98.4, 100.0) 99.9 (99.3, 100.0) 98.6 (95.2, 100.0) 99.9 (99.2, 100.0) 99.7 (96.5, 100.0) 99.9 (99.1, 100.0) 
Unigold 99.9 (99.1, 100.0) 99.9 (99.3, 100.0) 99.5 (93.2, 100.0) 99.6 (94.7, 100.0) 99.7 (95.6, 100.0) 99.9 (98.9, 100.0) 
1%             
Determine 99.8 (98.9, 100) 99.9 (99.5, 100.0) 99.2 (96.9, 100.0) 99.9 (99.5, 100.0) 99.8 (94.2, 100.0) 99.9 (98.6, 100.0 
Unigold 99.9 (99.4, 100.0) 99.9 (99.5, 100.0) 99.7 (95.3, 100.0) 99.8 (96.4, 100.0) 99.9 (97.2, 100.0) 99.9 (99.3, 100.0) 
Abbreviations: NPV, negative predictive value; PPV, positive predictive value 
*Incidence was defined as HIV infant incident infections occurring within the specified time period. For example, the PPV calculated at 6 months included infant infections 
  
7
3
 
which occurred between 3 and 6 months. 
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Figure 7. Specificity of Determine and Unigold assays during the postpartum period 
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Figure 8. Results of rapid tests in 21 children with negative HIV DNA PCR at age 6 weeks and subsequent confirmed HIV infection 
 
 
Results of rapid tests in 21 children with negative HIV DNA PCR at age 6 weeks and 
subsequent confirmed HIV infection. Rapid tests were performed concurrently at each time 
point. Some results are missing due to stock-outs of rapid tests or data collection error. No 
new infections were documented at 18 months. Seroconversion was confirmed by HIV DNA 
PCR. Scenario 1: Incident infection before seroreversion. Scenario 2: Seroreversion 
followed by incident infection; Scenario 3: Incident infection with false negative HIV rapid 
test due to window period; Scenario 4: Insufficient information available. 
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CHAPTER 6: RESULTS. TIMING OF HIV SEROREVERSION AMONG HIV-EXPOSED, 
BREASTFED INFANTS IN MALAWI: TYPE OF RAPID TEST MATTERS 
 
 The need for an accurate rapid HIV test for breastfeeding infants at point-of-care in resource-
limited settings is now needed more than ever, given the recommendation for prolonged breastfeeding 
and increasing access to life-saving treatment for HIV-infected infants. Since 2010, the World Health 
Organization (WHO) breastfeeding guidelines
8
 encourage women to exclusively breastfeed for the first 
six months of life and continue breastfeeding throughout the first two years of life, whereas before HIV 
positive mothers were encouraged to use formula feeding starting at age 6 months
182
. Results of studies 
led to a consensus that a prompt and definitive HIV diagnosis is crucial for timely initiation of life-saving 
antiretroviral treatment
9,183,184
.  
For early infant diagnosis (EID) of HIV infection, the WHO recommends a virological assay. Use 
of virological assays in resource-limited settings is limited by high costs and logistical constraints, as 
these assays require transportation to a centralized laboratory and thus a return visit by the mothers for 
test results. Rapid serological tests could be a cheaper, point-of-care alternative but they cannot 
distinguish between maternal and infant antibodies
13,14
. The lack of data on the timing of decay of 
maternal antibodies in young infants hinders the potential use of rapid tests for screening breastfeeding 
infants for mother to child transmission of HIV. 
We aimed to determine the time to seroreversion for two commonly used rapid tests in a cohort of 
HIV-exposed breastfeeding infants age 3 to 18 months of life. A detailed description of the methods is 
available in section 4.2 of this document 
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6.1 Results 
 
 Of the 121 infants included in the analysis, 51% were female and 49% were male. The median 
age of the mother at the time of delivery was 27 years, most women were married (81%), only half 
completed the primary level of education or less. Most women self-reported no PMTCT for themselves 
(71%), and 80% of infants receiving single dose nevirapine or AZT, the regimens in use and available 
during the study period. Approximately 54% of infants were exclusively breastfed at month 3, only 18% 
were exclusively breastfed at month 6. Any breastfeeding, including mixed feeding, progressively 
declined with 87% of infants breastfeeding at 3 months, 69% at 6 months, 45% at 9 months, 39% at 12 
months, 26% at 15 months, and 17% at 18 months of age. During follow-up, 21 infants were diagnosed 
with incident HIV infection. Twelve infants were censored due to an HIV infection or death occurring 
prior to seroreversion detected through Determine and 7 were censored due to an HIV infection or death 
occurring prior to seroreversion detected through Unigold.  
 The probability of seroreversion between age 3 and 18 months, stratified by rapid test, is 
presented in Table 15. At three months of age, 3% of infants had seroreverted according to Determine and 
7% had seroreverted according to Unigold. About one in four infants had achieved seroreversion by 4 
months using Unigold, but only by 6 months when using Determine. More than 95% of all infants had 
seroverted by 7 months according to Unigold and by 12 months according to the Determine assay.  
6.2 Discussion 
 
 Circulating maternal HIV antibodies in HIV-exposed, uninfected infants complicates the 
interpretation of rapid serological tests due to the difficulty in distinguishing between a true positive (HIV 
antibodies produced by the HIV-infected infant) and a false positive (maternal HIV antibodies in the 
HIV-exposed, uninfected infant) result. In this cohort of HIV-exposed infants, we show that the time of 
seroreversion depends greatly on the type of test used, with time of seroreversion occurring at a much 
younger age for the Unigold assay compared to the Determine assay.  
The WHO EID guidelines only recommend rapid tests for diagnostic purposes starting at age 18 
months. Our data suggest that the Unigold assay could be used from month 7 onwards to exclude infant 
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HIV infection in HIV-exposed, breastfeeding infants, as maternal antibodies could no longer be detected 
by the Unigold assay in 98.9% (95% CI: 96.9, 100.0) of 7-month old infants. From a mother’s 
perspective, an HIV negative diagnosis in her infant is emotionally important and could motivate her to 
adhere to her antiretroviral therapy during the remaining breastfeeding period. For healthcare providers, 
the documented time of seroreversion could increase confidence in screening for incident infant infections 
during the subsequent months of breastfeeding, as a positive rapid test after documented seroreversion 
will have a high positive predictive value and a negative test will have a high negative predictive value. 
While data are limited, data on time to seroreversion greatly differs between different rapid tests, 
but also between studies using the same rapid test. Studies in industrialized countries using Western Blot 
assays reported median ages at seroreversion of 7 to 12 months
107-109
. A cross-sectional study of 12-month 
old South African infants documented seroreversion in 90% for Unigold and 55% for Determine
73
, lower 
than the 99% for Unigold and 95% for Determine we observed at age 12 months. In another cross-
sectional South African study, the proportion of HIV-exposed uninfected infants who seroreverted 
according to Determine was 20% at 4 months of age, 50% at 6 months, and 100% at 8 months of age
17
, 
higher than the 8%, 25%, and 72% we observed in our cohort at the respective ages. Reasons for the 
marked differences between studies may be attributable to differences in postmenstrual age at delivery, 
maternal HIV immunoglobulin G (IgG) concentrations, maternal HIV severity, and maternal viral load 
and CD4 count, as these factors are strong determinants of the amount of placental immunoglobulin G 
(IgG) transfer
85-88
 
105,106
. 
 In conclusion, our results highlight the need for recommendations to specify the timing and type 
of test used in the context of infant HIV detection in resource-poor settings, and base the interpretation of 
test result on knowledge of time to seroreversion of the selected test. Further research is needed in 
different resource poor settings to estimate the time of seroreversion, identify the optimal rapid test for 
repeat screening of breastfeeding infants, and better understand the determinants of seroreversion in this 
population. 
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Table 15. Estimated probability of seroreversion at a certain age, by rapid test 
Age 
(month) 
Determine 
Probability (95% CI) 
Unigold 
Probability (95% CI) 
3 3.1 (0.0, 6.7) 7.4 (1.0, 13.7) 
4 8.1 (1.0, 14.5) 23.9 (14.5, 33.4) 
5 16.5 (9.1, 23.9) 33.3 (30.0, 36.4) 
6 24.9 (17.6, 32.3) 67.3 (61.7, 72.9) 
7 72.4 (71.3, 73.4) 98.9 (96.9, 100.0) 
8 72.4 (71.3, 73.4) 99.2 (97.1, 100.0) 
9 85.5 (82.3, 88.7) 99.3 (97.3, 100.0) 
10 90.4 (87.3, 93.6) 99.4 (97.4, 100.0) 
11 92.3 (89.4, 95.1) 99.5 (97.6 (100.0) 
12 95.1 (92.2, 97.9) 99.7 (97.7, 100.0) 
*CI-confidence interval 
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CHAPTER 7: EVALUATION OF POINT-OF-CARE EARLY INFANT HIV DIAGNOSIS 
ALGORITHMS AMONG HIV-EXPOSED INFANTS DURING THE BREASTFEEDING PERIOD: A 
COST-EFFECTIVENESS ANALYSIS 
 
Recent changes in the World Health Organization (WHO) breastfeeding guidelines will likely 
shift the majority of new infant HIV infections to the postnatal period. Based on research findings that 
exclusive breastfeeding improves HIV free survival and decreased HIV transmission in exposed infants
44-
52,54-56
, the WHO now encourages all HIV positive mothers to exclusively breastfeed for six months and 
then continue breastfeeding throughout the first or second year of the infant’s life2. As this extends the 
duration of HIV exposure, it is estimated that 8 out of 10 new pediatric HIV infections will occur during 
the postpartum period
1
.  
 Timely and accurate early infant diagnosis (EID) testing among HIV-exposed infants is critical 
during the first two years of life as disease progression occurs rapidly in young children
9,25,26
. EID testing 
recommendations have not yet been updated to incorporate the extended exposure risk period following 
implementation of the revised breastfeeding guidelines. Current EID guidelines recommend the use of 
virological assays
10
 but their use is limited by financial and logistical constraints in resource limited 
settings
21,24
. Serological rapid tests are a cheaper, point-of-care (POC) alternative but cannot distinguish 
between maternal and infant antibodies at young ages and perform differently depending on the type of 
rapid test
13,14
. Qualitative virological POC tests are being developed
185,186
, but they will most likely be 
much more expensive than serological rapid tests. 
Using Markov models, we aimed to assess the clinical and economic outcomes, and cost-
effectiveness of different POC-based EID strategies that can be incorporated within existing PMTCT 
structures and vaccination schedules. 
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7.1 Base case results (see Appendix B, Table 20 for full results) 
 
Economic outcomes 
 Table 16 outlines the total costs of the 21 EID testing strategies. Testing only once with Unigold 
were the three least expensive options, at $18.20, $23.37, and $30.62 per HIV-exposed infant for testing 
at 9, 12 and 6 months, respectively. Testing twice with Alere were the three most expensive strategies, at 
$145.60, $142.70, and $131.00 per HIV-exposed infant for testing at 6 and 15 months, 6 and 12 months, 
and 9 and 18 months, respectively. For each of the time points assessed (i.e., WHO recommended time 
points, testing only once, and testing twice) Unigold was the least expensive and Alere the most 
expensive.  
Clinical outcomes 
 The strategy with the lowest effectiveness, measured as the highest accumulated DALYs, was 
testing only once at 9 months with Unigold (337,806), followed by testing at 9 months with Determine 
(327,377) or testing at 6 months with Unigold (310,881) (Table 16). The strategy with the greatest 
effectiveness was testing twice at 6 and 15 months with Alere at 6 and 15 months (192,588), followed by 
testing at 9 and 18 months or 6 and 12 months with Alere (197,025 and 198,132, respectively). 
Cost-effectiveness 
 All EID strategies were ranked in sequential order by total costs, from lowest to highest total 
costs and the effectiveness of each alternative strategy was compared with the next more expensive 
strategy in terms of DALYs averted. After eliminating dominated strategies with higher DALYs in the 
next more expensive strategy, four alternative strategies remaining cost-effective (Table 17 and Figure 9). 
Testing only once at 12 months with Unigold had an incremental cost-effectiveness of an additional $1.53 
per DALY averted as compared to testing only once at 9 months with Unigold. Testing only once at 12 
months with Determine had an ICER of $3.94 per DALY averted as compared to testing only once at 12 
months with Unigold. Testing only once at 15 months with Determine had an ICER of $3.02 per DALY 
averted as compared to testing only once at 12 months with Determine. Testing only once at 15 months 
with Alere had an ICER of $15.20 per DALY averted as compared to testing only once at 15 months with 
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Determine. Testing twice at 6 and 15 months with Unigold had an ICER of $6.37 per DALY averted as 
compared to testing only once at 15 months with Alere. Lastly, testing twice at 6 and 15 months with 
Alere had an ICER of $91.98 per DALY averted as compared with testing twice at 6 and 15 months with 
Unigold.  All six undominated strategies were lower than the willingness-to-pay threshold of the per 
capita Malawi GDP value of $275.00
187
. 
7.2 Discussion 
 
 Cost-effective EID strategies are needed to reduce the burden of pediatric HIV in sub-Saharan 
Africa, particularly given the predicted relative increase in HIV infections due to breastfeeding following 
the recent WHO recommendation that all HIV positive women breastfeed their infant for at least 12 
months. The current EID recommendations were made prior to these changes in breastfeeding guidelines. 
We assessed the cost-effectiveness of 21 EID strategies that varied in test type, number of testing 
timepoints, and timing of test. All strategies used POC tests in infants who tested HIV negative on a PCR 
test at age 4 to 6 weeks, in line with the WHO EID recommendations, and all strategies confirmed a 
positive POC test with a HIV DNA PCR assay or a HIV RNA viral load assay. Six strategies were 
deemed cost-effective: a single Unigold rapid test at 12 months was the most cost-effective strategy, 
followed by a single Determine test at 12 months, testing once at 15 months using Determine, a single 
POC qualitative virological Alere assay at 15 months, two Unigold tests at 6 and 15 months, or two Alere 
tests at 6 and 15 months. All six dominant EID strategies were highly cost-effective according to the 
commonly accepted WHO standards of  <1 times or <3 times GDP per capita
187
. 
 The factors contributing the most to the cost-effectiveness of EID strategies were the costs, 
performance of the assays evaluated, and testing timepoints. Although testing once at 9 months with 
Unigold was the lowest costing strategy, the DALYs were the highest. Conversely, the strategies with the 
lowest DALYs, or highest effectiveness, were some of the most expensive strategies (i.e. testing twice at 
6 and 15 months with Alere or Unigold or testing twice at 9 and 18 months with Alere). The other factors 
significantly contributing to the costs of each strategy were the number of false positive and true positive 
test results. For each false positive result, a follow-up PCR, at an estimated $35 per test, and an extra pre- 
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and post-test counseling session was required. Since the number of false positive results was highest for 
Determine, these strategies had higher testing and counseling costs than Unigold or Alere. The number of 
true positive results increased healthcare and treatment costs. Consequently, most of the strategies using 
Alere had higher healthcare costs than strategies using Determine and Unigold.  
 Low effectiveness (i.e. high DALY’s) was mostly due to missing HIV infections due to testing at 
early time points or due to low test sensitivity. Most of infections in our cohort occurred between 6 weeks 
and 3 months or after 6 or 9 months. Thus, strategies testing only once at time points before 12 months 
had higher numbers of missed infections and thus higher DALYs since we assumed these infections 
would be diagnosed at a later stage of disease. Furthermore, strategies with two testing strategies reduced 
the likelihood of a missed infection which, in turn, reduced overall DALYs. At any time point, lower test 
sensitivity resulted in a higher number of false negative results, and thus lower effectiveness. The highest 
number of false negative results occurred when testing only once at 9 months with Determine, which is 
not surprising as the Determine assay capture maternal HIV-antibodies at an older age than Unigold
179,180
. 
Strategies using the virological Alere assay had the lowest number of false positive test results, regardless 
of when testing occurred.  
  Our study was the first to evaluate the cost-effectiveness of EID strategies for several POC rapid 
tests in a cohort of predominantly breastfeeding infants in resource-limited settings. Thus, comparisons 
with other studies cannot be made. While there are more POC HIV tests commercially available and used 
in high burden countries, we only evaluated two serological rapid tests that are commonly used in the 
public sector in Malawi. We also evaluated a virological assay that is new and has not been extensively 
studied in resource-limited settings. However, the results from both studies examining the Alere were 
similar highlighting the strong performance in the field. The validity of any model greatly depends on the 
accuracy of parameter values used. Given the recent implementation of option B+ and the 2010 WHO 
guidelines, few prospective cohort data on infant outcomes under these policies is available. To refine the 
model and improve accuracy, data on postpartum maternal and infant ART adherence and other rapid 
tests data, including further studies with POC virological assays, should be incorporated once available.  
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Conclusion 
 The goal of any EID program is to both promptly identify pediatric incident HIV cases, thereby 
quickly initiating treatment to reduce HIV-related infant morbidity and mortality
9
, and accurately rule out 
HIV infection in uninfected infants, thereby comforting women that their infant is free of HIV infection. 
In addition, EID programs need to be caregiver-friendly by limiting the number of times a caregiver has 
to return to the clinic. From a country-level standpoint, EID strategies need to be both cost-effective and 
affordable since the settings with the highest number of HIV-exposed infants are typically highly limited 
in their public health resources. 
 The current EID guidelines are outdated for the new WHO breastfeeding guidelines, which 
increase the duration infants born to HIV positive mothers are exposed to HIV. Furthermore, even though 
it has been demonstrated that different assays perform differently in young infants
17,73-75
, the guidelines do 
not aid countries in determining which type of test should be used in their EID program. Our analyses 
show that the type of test and timing of test matters greatly to the cost-effectiveness of EID strategies, 
with the lowest costing cost-effective strategy being a single Unigold rapid test at age 12 months. Among 
the six cost-effective strategies, testing twice at 6 and 15 months with Alere was the most effective but 
also the most expensive. For maximum impact from an EID strategy in terms of the lowest DALYs, a 
low-cost qualitative virological assay at POC would be the ideal assay during the breastfeeding period in 
high burden countries.   
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Table 16. Base case results: POC test results, total costs, and pediatric outcomes for early infant diagnosis 
algorithms 
(See Appendix B: Table 20 for complete results) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
Economic outcomes 
EID  
algorithm 
Testing 
month 
Test 
type 
Testing Counseling 
Healthcare
/ treatment 
Total Costs 
Costs per 
infant 
Current 
WHO 
recomme-
ndations 
9, 18 
DT $98,337.53 $12,130.56 $568,126.05 $1,031,287.06 $103.13 
UN $94,149.19 $12,818.95 $666,698.70 $818,084.13 $81.81 
Alere $266,774.51 $10,836.54 $449,417.75 $1,310,070.88 $131.00 
EID 
strategies 
with 1 
testing 
timpeoint 
6 
DT $220,839.44 $18,052.14 $231,283.92 $470,175.50 $47.02 
UN $93,030.41 $11,364.86 $201,760.81 $306,156.08 $30.62 
Alere $249,780.17 $10,075.04 $223,104.99 $482,960.20 $48.30 
9 
DT $179,615.78 $16,109.78 $121,062.78 $316,788.34 $31.68 
UN $56,904.26 $10,164.89 $115,514.89 $182,584.04 $18.20 
Alere $259,293.25 $10,448.69 $204,539.60 $474,281.54 $47.43 
12 
DT $69,379.84 $11,860.47 $252,520.93 $333,761.24 $33.38 
UN $56,346.84 $10,158.83 $167,187.68 $233,693.35 $23.37 
Alere $249,681.72 $10,076.25 $237,820.59 $497,578.57 $49.76 
15 
DT $55,716.61 $11,939.74 $318,324.43 $385,980.78 $38.60 
UN $69,730.75 $11,509.08 $305,966.19 $387,206.01 $38.72 
Alere $291,582.00 $11,801.72 $373,726.37 $677,110.09 $67.71 
EID 
strategies 
with 2 
testing 
timepoint
s 
6, 12 
DT $123,627.85 $14,749.07 $530,144.61 $1,197,966.48 $119.80 
UN $111,432.50 $13,390.03 $469,544.76 $969,934.18 $96.99 
Alere $307,975.62 $12,509.76 $514,047.55 $1,427,732.29 $142.70 
6, 15 
DT $113,145.90 $13,944.13 $613,104.75 $1,269,639.73 $126.96 
UN $113,746.67 $12,978.91 $510,876.32 $1,013,168.78 $101.32 
Alere $318,243.18 $12,927.28 $532,419.63 $1,456,789.45 $145.60 
*DALY-disability-adjusted life years; DT-Determine; FN-false negative; FP-false positive; TN-true 
negative; TP-true positive; UN-Unigold4 
 
Note: Costs were ranked from low to high by total costs of each EID strategy. DALYs were ranked 
from low to high by total DALYs for each EID strategy. Costs ranking were used in sequential 
comparisons to compute the ICERs. DALY rankings are presented here to describe the base case results 
and were not used for sequential comparisons for ICER calculations.  
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 Table 16 (continued). Base case results: POC test results, total costs, and pediatric outcomes for early infant 
diagnosis algorithms (See Appendix B: Table 20 for complete results) 
 
 
 
 
  
Clinical outcomes 
Rank 
(low to high) 
EID  
algorithm 
Testing 
month 
Test 
type 
TP FN FP TN 
Missed 
infections 
DALY Cost DALY 
Current 
WHO 
recommend-
ations 
9, 18 DT 1,046 0 163 6,084 584 273,521 18 13 
  UN 1,228 0 0 6,525 503 252,403 15 11 
  Alere 828 0 0 5,967 473 197,025 19 2 
EID 
strategies 
with 1 
testing 
timepoint 
6 DT 426 0 5,286 1,031 1,293 297,705 8 15 
  UN 372 0 1,047 5,152 1,402 310,881 3 19 
  Alere 411 5 16 6,277 1,353 307,921 10 18 
 9 DT 223 257 4,322 1,818 1,321 327,377 6 20 
  UN 213 142 213 5,798 1,507 337,806 1 21 
  Alere 377 4 16 6,619 1,190 273,279 9 12 
 12 DT 465 0 899 5,612 1,163 278,726 4 14 
  UN 308 243 0 6,353 1,151 304,094 2 17 
  Alere 438 4 14 6,226 1,313 303,634 11 16 
 15 DT 586 147 342 6,417 733 243,559 7 9 
  UN 564 141 0 6,872 704 233,526 5 6 
  Alere 688 1 8 6,938 689 219,955 12 5 
EID 
strategies 
with 2 
testing 
timepoints 
6, 12 DT 976 0 919 6,540 462 237,607 16 8 
  UN 865 159 0 7,552 483 250,767 13 10 
  Alere 947 11 14 6,867 459 234,281 20 7 
 6, 15 DT 1,129 97 338 6,742 160 217,992 17 4 
  UN 941 98 0 7,156 163 198,132 14 3 
  Alere 981 4 14 7,099 228 192,588 21 1 
*DALY-disability-adjusted life years; DT-Determine; FN-false negative; FP-false positive; TN-true 
negative; TP-true positive; UN-Unigold4 
 
Note: Costs were ranked from low to high by total costs of each EID strategy. DALYs were ranked from 
low to high by total DALYs for each EID strategy. Costs ranking were used in sequential comparisons to 
compute the ICERs. DALY rankings are presented here to describe the base case results and were not used 
for sequential comparisons for ICER calculations. 
 87 
 
Table 17. Incremental cost-effectiveness ratio (ICER) comparison of EID strategies ranked by total EID costs 
EID strategy 
EID strategy 
cost 
EID strategy 
DALY 
Incremental 
cost 
Incremental 
DALY averted 
ICER 
9m UN $182,140.26 337,806.02 - - - 
12m UN $233,724.16 304,093.94 $51,703.28 33,712.08 $1.53 
6m UN $306,364.94 310,880.97 $72,462.73 (6,787.03) Dominated 
8m DT $316,775.96 327,376.78 $10,632.26 (16,495.81) Dominated 
12m DT $333,682.30 278,726.36 $16,972.90 48,650.42 $3.94 
15m DT $385,795.72 243,559.47 $52,219.54 35,166.89 $3.02 
15m UN $387,206.01 316,942.63 $1,225.23 (73,383.16) Dominated 
6m DT $470,158.02 297,645.18 $82,696.12 19,297.44 Dominated 
9m Alere $474,445.44 273,278.99 $4,379.42 24,366.19 Dominated 
6m Alere $482,974.32 307,920.81 $8,678.65 (34,641.81) Dominated 
12m Alere $497,565.56 303,633.79 $14,618.37 4,287.01 Dominated 
15m Alere $676,912.75 219,954.99 $179,531.53 83,678.80 $15.20 
6m, 12m UN $918,166.50 252,402.55 $140,974.04 (32,447.56) Dominated 
6m, 15m UN $950,461.22 250,766.65 $151,850.05 1,635.90 $6.37 
9m, 18m UN $1,063,564.22 198,131.88 $43,234.61 52,634.78 Dominated 
9m, 18m DT $1,135,204.22 273,521.20 $18,118.28 (75,389.32) Dominated 
6m, 12m DT $1,152,777.98 237,606.58 $166,679.42 35,914.62 Dominated 
6m, 15m DT $1,191,265.56 217,991.71 $71,673.24 19,614.87 Dominated 
9m, 18m Alere $1,290,269.64 197,024.92 $42,777.34 20,966.79 Dominated 
6m, 12m Alere $1,429,630.58 234,281.34 $114,578.70 (37,256.42) Dominated 
6m, 15m Alere $1,458,109.54 192,588.02 $29,046.50 41,693.32 $91.98 
*DT-Determine; EID-early infant diagnosis; UN-Unigold 
 
Note: We assessed the relative value of each EID strategy to the next most expensive strategy using the 
incremental cost-effectiveness ratio (ICER) by ranking all EID strategies in sequential order by total costs. 
The effectiveness of each EID strategy was evaluated as DALYs averted compared with the next most 
expensive strategy. Strategies were considered dominated if DALYs were not averted in the next most 
expensive strategy. After the initial comparisons of all strategies in sequential order, dominated strategies 
were eliminated from the cost rankings and the effectiveness of the remaining strategies were evaluated 
again as DALYs averted, compared with the next most expensive strategy. This iterative process continued 
until all remaining strategies were undominated by the next most expensive strategy, resulting in the final 
ICER calculations.  
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*DT-Determine; EID-early infant diagnosis; UN-Unigold 
  
Note: We assessed the relative value of each EID strategy to the next most expensive strategy using 
the incremental cost-effectiveness ratio (ICER) by ranking all EID strategies in sequential order by 
total costs. The effectiveness of each EID strategy was evaluated as DALYs averted compared with 
the next most expensive strategy. Strategies were considered dominated if DALYs were not averted 
in the next most expensive strategy. Dominant strategies are labeled and are connected with the 
dotted line. All dominant strategies tested only once at the specified timepoint with specified POC 
test. 
     Figure 9. Cost-effectiveness efficiency frontier 
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CHAPTER 8: CONCLUSION 
 
 The current PMTCT cascade has resulted in dramatic reductions in pediatric HIV infections, 
particularly during the prenatal or delivery period
1,19,22
, but guidelines and PMTCT activities are lacking 
for the postpartum period
4
. Recent changes in the WHO breastfeeding guidelines will increase the HIV 
exposure period for infants since all HIV positive women are now encouraged to breastfeed for the first 
one to two years of the infant’s life2. It is estimated that, in breastfeeding populations, up to 80% of all 
new infections will occur in the postpartum period
1
. Updated PMTCT and early infant diagnosis (EID) 
guidelines are thus needed in light of the extended breastfeeding period to ensure prompt identification of 
infant infection and initiation of life-saving antiretroviral treatment. 
 Although ART can significantly reduce the risk of transmission associated with mixed feeding
57-
62
, ART adherence during the postpartum period is generally lower than during the prenatal period, 
especially in women who are first diagnosed with HIV during their pregnancy
147,188-190
. Poor adherence to 
ART in the postpartum period is thus likely to remain a problem, even in the Option B+ era .
147,149,191
  EID 
after 9 or 12 months of life will thus remain critical to optimal care for HIV-exposed infants. 
Type of test used for EID matters 
 Serological rapid tests are a cheaper alternative than virological tests and eliminate the need for a 
breastfeeding mother to return to the clinic for results. The WHO recommendations include using a rapid 
test but only for diagnosis of HIV infection after age 18 months or to determine if a child has been 
exposed to HIV. Furthermore, the guidelines do not provide guidance on which one to use
10
.  
Our data showed that rapid tests perform differently depending on the type and timing of the test.
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Starting at age 6 months, the Unigold test could be used as a screening tool in the follow-up of HIV-
exposed infants, which is earlier than the current recommended time of 9 months of age. Additionally, we 
showed the type of rapid test matters and differs greatly in regards to sensitivity and specificity 
particularly during the early infancy months. Unigold outperformed Determine in regard to specificity at 
all timepoints, thus reducing the likelihood of a mother receiving a false positive result. This may 
encourage the mother to adhere to treatment while she continues breastfeeding her HIV uninfected infant. 
Strictly looking only at specificity, our data suggests using Unigold for EID testing, especially prior to 12 
months of age. However, specificity is only one part of what matters for EID. 
 In regards to sensitivity, both rapid tests missed pediatric HIV infections beginning at 9 months of 
age. Since is it critical to timely identify an incident infection as disease progression occurs rapidly in 
young infants, these missed infections are associated with poorer prognosis and higher mortality than 
infections accurately identified
25,26
. New virological assays for use at point of care that are highly 
sensitive and specific are being developed but will be significantly more expensive than serological rapid 
tests
185,186
. 
Timing and type of test greatly determine the cost-effectiveness of EID strategies  
The current WHO recommendations include testing at 9 and 18 months of age or 6 weeks after 
breastfeeding cessation
27
. Our data suggests that testing at 9 months may be too early or too late to begin 
EID testing since most infections occur prior to 3 months or after 9 months. The higher rate of infections 
after 9 months may be due to the switch from exclusive breastfeeding to mixed feeding at age 6 months, 
as mixed feeding is known to increase the risk of HIV transmission to her infant through 
breastfeeding
46,55,56,192
. Other studies, including two trials of ART prophylaxis in the first two years of life 
among Malawian infants and a meta-analysis among HIV-exposed infants in multiple African countries, 
similarly found that the risk of postpartum, breastfeeding-associated HIV transmission was greatest 
within the first 6 weeks of life and after 9 months of age
133,134
.  Testing at later months (i.e., 12 and 15 
months) in our data therefore resulted in reductions in missed infections and increases in DALYs, 
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regardless of type of rapid test. Among the 21 EID strategies evaluated, four cost-effective strategies with 
single testing timepoints implemented testing after age 9 months. The remaining two cost-effective 
strategies with two testing timepoints tested early at 6 months, which would have timely diagnosed 
infections prior to 3 months, and again after 9 months, which would have diagnosed later infections 
occurring after 9 months. 
 Our data suggests that a low-cost POC virological assay could become the most attractive EID 
strategy for high burden countries. Until such tests are available, four cost-effective EID strategies using 
rapid tests that are more cost-effective than the current EID guidelines could already be implemented: 
testing once at 12 months with Unigold or Determine, testing once at 15 months with Determine, and 
testing twice at 6 and 15 months with Unigold. 
Redefining the PMTCT cascade in the option B+ era: a mother-infant dyad approach to incorporate the 
postpartum period 
 
 Even though the simplified treatment approaches of Option B and Option B+ have significantly 
increased the number of HIV positive, pregnant women initiating ART, significant challenges remain. 
Only 4 of the 22 priority countries identified in the Global Plan achieved the goal of providing ART to 
90% of pregnant women living with HIV. Among women residing in sub-Saharan Africa, only 59% 
received ART therapy or prophylaxis during pregnancy and delivery in 2011
19,63
. Additionally, only 58% 
of mothers
64
 and 29-41% of HIV-exposed infants received ART therapy in 2009
65,66
. Thus, EID will 
remain a key component of the PMTCT cascade for the near future unless innovative approaches 
significantly improve ART adherence.  
 Even among mothers with access to Option B+, attrition in the postpartum period has been worse 
than in the prenatal period, in part due to PMTCT scale-up being focused towards pregnant women, 
frequent maternal HIV non-disclosure, and lack of care engagement
67,193
. The highest rates of treatment 
default occurs after 6 weeks postpartum and increases progressively throughout the first 12 
months
11,31,36,37,42,68,69
. These missed opportunities affect both the health of the breastfeeding HIV positive 
mother and their infant. If mothers do not return for care, their infants are also not returning for EID. 
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Thus, the PMTCT cascade should be focused on the mother-infant dyad and include clear guidelines for 
EID testing and linkage and engagement in care among breastfeeding, HIV positive mothers,  
Conclusion 
 It is critical to advocate for an EID testing regimen that is mother-friendly, by being at the point-
of-care, and accurate, by reducing the number of false positive and false negative results. EID strategies 
that are more likely to result in a true negative or a true positive result will give a breastfeeding mother 
peace-of-mind about her infant’s HIV exposure and encourage continued adherence to her ART regimen 
until she ceases breastfeeding, which in turn will reduce the infant’s risk of HIV transmission. From a 
country’s perspective, high burden settings are often tasked with weighing the benefits of a specific 
intervention with the costs of implementation. Our data helps guide countries toward cost-effective, 
mother-friendly EID strategies from both the individual (i.e., HIV positive mother and her breastfeeding 
infant) and population (i.e., high burden setting) perspective. 
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APPENDIX A. COMPARISON BETWEEN DEMOGRAPHIC CHARACTERISTICS IN COMPLETE 
CASE VERSUS MISSING POPULATION 
 
 
Table 18. Comparison of demographic characteristics in complete case population versus missing population: 
Determine 
 3 months 6 month 9 month 
 CC Missing  CC Missing  CC Missing  
 N (%) N (%) 
p-
value N (%) N (%) 
p-
value N (%) N (%) p-value 
Infant characteristics 
Gender 
Female 
Male 
 
37 (49) 
39 (51) 
 
24 (53) 
21 (47) 
 
 
0.62 
 
48 (49) 
49 (51) 
 
14 (54) 
12 (46) 
 
 
0.69 
 
44 (48) 
48 (52) 
 
18 (60) 
12 (40) 
 
 
0.25 
EBF 
Yes 
No 
Missing 
 
42 (55) 
27 (36) 
7 (9) 
 
23 (51) 
16 (36) 
6 (13) 
 
 
0.52 
0.85 
 
19 (20) 
68 (70) 
10 (10) 
 
3 (12) 
16 (61) 
7 (27) 
 
 
0.05 
0.56 
 
1 (1) 
83 (90) 
8 (9) 
 
0 (0) 
16 (53) 
14 (47) 
 
 
<0.0001 
0.66 
ABF 
Yes 
No 
Missing 
 
67 (88) 
2 (3) 
7 (9) 
 
38 (85) 
1 (2) 
6 (13) 
 
 
0.51 
0.92 
 
70 (72) 
21 (22) 
6 (6) 
 
15 (58) 
5 (19) 
6 (23) 
 
 
0.03 
0.85 
 
46 (50) 
42 (46) 
4 (4) 
 
9 (30) 
8 (27) 
13 (43) 
 
 
<0.0001 
0.96 
NVP at birth 
No 
Yes 
Missing 
 
4 (5) 
56 (74) 
16(21) 
 
2 (4) 
40 (89) 
3 (7) 
 
 
0.10 
0.69 
 
6 (6) 
75 (77) 
16 (16) 
 
1 (4) 
22 (85) 
3 (11) 
 
 
0.79 
0.61 
 
6 (7) 
70 (76) 
16 (17) 
 
0 (0) 
27 (90) 
3 (10) 
 
 
0.93 
0.15 
Maternal characteristics 
Age (mean) 28 29 0.22 28 29 0.23 28 29 0.23 
Maternal 
ARV prior to 
birth 
Yes 
No 
Missing 
 
 
 
50 (66) 
17 (23) 
9 (11) 
 
 
 
35 (78) 
6 (13) 
4 (9) 
 
 
 
 
0.24 
0.20 
 
 
 
70 (72) 
17 (18) 
10 (10) 
 
 
 
17 (65) 
6 (23) 
3 (12) 
 
 
 
 
0.59 
0.49 
 
 
 
62 (67) 
20 (22) 
10 (11) 
 
 
 
24 (80) 
3 (10) 
3 (10) 
 
 
 
 
0.34 
0.15 
Marital status 
Single  
Married  
 
63 (88) 
9 (12) 
 
38 (88) 
5 (12) 
 
 
0.89 
 
80 (87) 
12 (13) 
 
23 (92) 
2 (8) 
 
 
0.49 
 
76 (87) 
11 (13) 
 
26 (89) 
3 (11) 
 
 
0.74 
Education 
level 
> secondary  
< secondary  
 
 
15 (21) 
58 (79) 
 
 
11 (26) 
32 (74) 
 
 
 
0.56 
 
 
19 (21) 
73 (79) 
 
 
7 (28) 
18 (72) 
 
 
 
0.44 
 
 
20 (23) 
67 (77) 
 
 
6 (21) 
23 (79) 
 
 
 
0.79 
Access to 
water in 
home 
Yes 
No 
 
 
 
51 (73) 
19 (27) 
 
 
 
28 (67) 
14 (33) 
 
 
 
 
0.49 
 
 
 
63 (71) 
26 (29) 
 
 
 
17 (71) 
7 (29) 
 
 
 
 
0.99 
 
 
 
62 (73) 
23 (27) 
 
 
 
18 (64) 
10 (36) 
 
 
 
 
0.38 
Electricity in 
home 
Yes 
No 
 
 
49 (68) 
23 (32) 
 
 
25 (58) 
18 (42) 
 
 
 
0.28 
 
 
63 (68) 
29 (32) 
 
 
13 (52) 
12 (48) 
 
 
 
0.13 
 
 
59 (68) 
28 (32) 
 
 
16 (55) 
13 (45) 
 
 
 
0.22 
Building 
material of 
roof 
Iron/tiles 
Grass 
 
 
 
63 (89) 
8 (11) 
 
 
 
36 (84) 
7 (16) 
 
 
 
 
0.45 
 
 
 
76 (84) 
15 (16) 
 
 
 
24 (96) 
1 (4) 
 
 
 
 
0.11 
 
 
 
72 (84) 
14 (16) 
 
 
 
28 (96) 
1 (4) 
 
 
 
 
0.08 
**CC: Complete case population; EBF: Exclusive breastfeeding; ABF: Any breastfeeding   
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Table 18 (continued). Comparison of demographic characteristics in complete case population versus missing 
population: Determine 
 12 month 15 month 18 month 
 CC Missing  CC Missing  CC Missing  
 N (%) N (%) p-value N (%) N (%) p-value N (%) N (%) p-value 
Infant characteristics 
Gender 
Female 
Male 
 
44 (51) 
43 (49) 
 
19 (53) 
17 (47) 
 
 
0.83 
 
43 (57) 
33 (43) 
 
18 (40) 
27 (60) 
 
 
0.08 
 
35 (55) 
29 (45) 
 
31 (48) 
34 (52) 
 
 
0.43 
EBF 
Yes 
No 
Missing 
 
1 (1) 
80 (92) 
6 (7) 
 
0 (0) 
16 (44) 
20 (56) 
 
 
<0.0001 
0.66 
 
0 (0) 
68 (90) 
8 (10) 
 
0 (0) 
17 (38) 
28 (62) 
 
 
<0.0001 
- 
 
0 (0) 
60 (94) 
4 (6) 
 
0 (0) 
28 (43) 
37 (57) 
 
 
<0.0001 
- 
ABF 
Yes 
No 
Missing 
 
39 (45) 
42 (48) 
6 (7) 
 
8 (22) 
8 (22) 
20 (56) 
 
 
<0.0001 
0.89 
 
23 (30) 
45 (59) 
8 (11) 
 
9 (20) 
8 (18) 
28 (62) 
 
 
<0.0001 
0.15 
 
15 (23) 
47 (74) 
2 (3) 
 
8 (12) 
21 (32) 
36 (56) 
 
 
<0.0001 
0.73 
NVP at birth 
No 
Yes 
Missing 
 
5 (6) 
69 (79) 
13 (15) 
 
1 (3) 
28 (78) 
7 (19) 
 
 
0.39 
0.52 
 
4 (5) 
64 (84) 
8 (11) 
 
2 (4) 
32 (71) 
11 (25) 
 
 
0.08 
1.00 
 
3 (5) 
52 (81) 
9 (14) 
 
5 (8) 
48 (74) 
12 (18) 
 
 
0.86 
0.53 
Maternal characteristics 
Age (mean) 28 29 0.23 28 29 0.23 28 29 0.23 
Maternal 
ARV prior to 
birth 
Yes 
No 
Missing 
 
 
 
61 (70) 
18 (21) 
8 (9) 
 
 
 
26 (72) 
5 (14) 
5 (14) 
 
 
 
 
0.85 
0.44 
 
 
 
53 (69) 
17 (22) 
6 (8) 
 
 
 
32 (71) 
6 (13) 
7 (16) 
 
 
 
 
0.62 
0.31 
 
 
 
53 (83) 
9 (14) 
2 (3) 
 
 
 
40 (62) 
14 (22) 
11 (17) 
 
 
 
 
0.003 
0.13 
Marital status 
Single  
Married  
 
73 (89) 
9 (11) 
 
30 (86) 
5 (14) 
 
 
0.62 
 
62 (86) 
10 (14) 
 
39 (91) 
4 (9) 
 
 
0.49 
 
54 (87) 
8 (13) 
 
55 (90) 
6 (10) 
 
 
0.59 
Education 
level 
> secondary  
< secondary  
 
 
17 (21) 
65 (79) 
 
 
9 (26) 
26 (74) 
 
 
 
0.55 
 
 
17 (24) 
55 (76) 
 
 
9 (21) 
34 (79) 
 
 
 
0.74 
 
 
13 (21) 
49 (79) 
 
 
13 (21) 
48 (79) 
 
 
 
0.96 
Access to 
water in 
home 
Yes 
No 
 
 
 
59 (75) 
20 (25) 
 
 
 
21 (60) 
14 (40) 
 
 
 
 
0.12 
 
 
 
51 (73) 
19 (27) 
 
 
 
28 (67) 
14 (33) 
 
 
 
 
0.49 
 
 
 
43 (73) 
16 (27) 
 
 
 
42 (71) 
17 (29) 
 
 
 
 
0.84 
Electricity in 
home 
Yes 
No 
 
 
54 (66) 
28 (34) 
 
 
22 (63) 
13 (37) 
 
 
 
0.76 
 
 
47 (65) 
25 (35) 
 
 
27 (63) 
16 (37) 
 
 
 
0.79 
 
 
40 (65) 
22 (35) 
 
 
42 (69) 
19 (31) 
 
 
 
0.61 
Building 
material of 
roof 
Iron/tiles 
Grass 
 
 
 
67 (83) 
14 (17) 
 
 
 
34 (97) 
1 (3) 
 
 
 
 
0.03 
 
 
 
59 (83) 
12 (17) 
 
 
 
40 (93) 
3 (7) 
 
 
 
 
0.13 
 
 
 
52 (84) 
10 (16) 
 
 
 
53 (88) 
7 (12) 
 
 
 
 
0.48 
  **CC: Complete case population; EBF: Exclusive breastfeeding; ABF: Any breastfeeding
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Table 19. Comparison of demographic characteristics in complete case population versus missing population: 
Unigold 
 3 months 6 month 9 month 
 CC Missing  CC Missing  CC Missing  
 N (%) N (%) p-value N (%) N (%) p-value N (%) N (%) p-value 
Infant characteristics 
Gender 
Female 
Male 
 
38 (49) 
39 (51) 
 
23 (52) 
21 (48) 
 
 
0.76   0.32   
 
0.35 
EBF 
Yes 
No 
Missing   
0.28 
0.44 
 
19 (18) 
76 (72) 
10 (10) 
 
3 (17) 
8 (44) 
7 (29) 
 
 
 
0.03 
0.56 
 
1 (1) 
81 (89) 
9 (10) 
 
0 (0) 
18 (58) 
13 (42) 
<0.0001 
0.64 
ABF 
Yes 
No 
Missing   
0.46 
0.95 
77 (73) 
22 (21) 
 6 (6) 
8 (45) 
4 (22) 
6 (33) 
0.0008 
0.38 
45 (49) 
41 (45) 
5 (6) 
10 (32) 
9 (29) 
12 (39) 
0.0006 
0.98 
NVP at birth 
No 
Yes 
Missing 
 
4 (5) 
57 (74) 
16 (21) 
 
2 (5) 
39 (89) 
3 (7) 
 
 
 
0.11 
0.73   
0.48 
0.26   
0.54 
0.12 
Maternal characteristics 
Age (mean) 28 29 0.32 28 29 0.32 28 29 0.32 
Maternal 
ARV prior to 
birth 
Yes 
No 
Missing   
0.82 
0.82   
0.49 
0.93 
60 (66) 
20 (22) 
11 (12) 
26 (84) 
3 (10) 
2 (6) 
0.09 
0.10 
Marital status 
Single  
Married    0.51   0.41   0.69 
Education 
level 
> secondary  
< secondary    0.25   0.44   0.89 
Access to 
water in home 
Yes 
No   0.97   0.85   0.80 
Electricity in 
home 
Yes 
No   0.41 
 
 
8 (47) 
9 (53) 
 
 
68 (68) 
32 (32) 0.10   0.29 
Roof 
Iron/tiles 
Grass   0.79   0.31 
29 (97) 
1 (3) 
71 (84) 
14 (16) 0.07 
          **CC: Complete case population; EBF: Exclusive breastfeeding; ABF: Any breastfeeding
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Table 19 (continued). Comparison of demographic characteristics in complete case population versus missing 
population: Unigold 
 12 month 15 month 18 month 
 CC Missing  CC Missing  CC Missing  
 N (%) N (%) p-value N (%) N (%) p-value N (%) N (%) p-value 
Infant characteristics 
Gender 
Female 
Male   0.66 
 
44 (60) 
29 (40) 
 
17 (35) 
31 (65) 
 
 
0.01   0.44 
EBF 
Yes 
No 
Missing 
1 (1) 
83 (92) 
6 (7) 
0 (0) 
13 (39) 
20 (61) 
<0.0001 
0.69 
0(0) 
64 (88) 
9 (12) 
0 (0) 
21 (44) 
27 (56) 
<0.0001 
- 
0 (0) 
64 (94) 
4 (6) 
0 (0) 
24 (39) 
37 (61) 
 
 
<0.0001 
- 
ABF 
Yes 
No 
Missing 
42 (47) 
42 (47) 
6 (6) 
5 (15) 
8 (24) 
20 (61) 
<0.0001 
0.44 
23 (32) 
41 (56) 
9 (12) 
9 (19) 
12 (25) 
27 (56) 
<0.0001 
0.57 
17 (25) 
49 (72) 
2 (3) 
6 (10) 
19 (31) 
36 (59) 
<0.0001 
0.86 
NVP at birth 
No 
Yes 
Missing   
0.57 
0.58 
4 (5) 
61 (84) 
8 (11) 
2 (4) 
35 (73) 
11 (23) 
0.11 
0.88   
0.75 
0.31 
Maternal characteristics 
Age (mean) 28 29 0.32 28 29 0.32 28 29 0.32 
Maternal 
ARV prior to 
birth 
Yes 
No 
Missing   
0.80 
0.32   
0.21 
0.54 
55 (81) 
10 (15) 
3 (4) 
38 (62) 
13 (21) 
10 (16) 
0.009 
0.18 
Marital status 
Single  
Married    0.46   0.35   0.78 
Education 
level 
> secondary  
< secondary  
16 (19) 
69 (81) 
10 (31) 
22 (69) 0.16   0.79   0.67 
Access to 
water in 
home 
Yes 
No 
 
 
19 (59) 
13 (41) 
 
 
61 (74) 
21 (26) 0.12   0.41   0.80 
Electricity in 
home 
Yes 
No   0.44   0.87   0.99 
Roof 
Iron/tiles 
Grass 
31 (97) 
1 (3) 
70 (83) 
14 (17) 0.05   0.25   0.35 
           **CC: Complete case population; EBF: Exclusive breastfeeding; ABF: Any breastfeeding
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APPENDIX B. RESULTS: AIM 3 
 
Base case results 
 
Table 20. Base case results: Point-of-care results, total costs, and pediatric outcomes for early infant diagnosis 
algorithms 
 
  
Minimal testing strategies 
  6 month   9 month  
 DT UN Alere DT UN Alere 
Test results: 
TP 426 372 411 223 213 377 
FN 0 0 5 257 142 4 
FP 5,286 1,047 16 4,322 213 16 
TN 1,031 5,152 6,277 1,818 5,798 6,619 
Costs: 
Testing $220,839.44 $93,030.41 $249,780.17 $179,615.78 $56,904.26 $259,293.25 
Counseling $18,052.14 $11,364.86 $10,075.04 $16,109.78 $10,164.89 $10,448.69 
Healthcare  $231,283.92 $201,760.81 $223,104.99 $121,062.78 $115,514.89 $204,539.60 
Total costs $470,175.50 $306,156.08 $482,960.20 $316,788.34 $182,584.04 $474,281.54 
Costs/infant $47.02 $30.62 $48.30 $31.68 $18.20 $47.43 
Rank 8 3 10 6 1 9 
Outcomes:  
Missed diag. 1,293 1,402 1,353 1,321 1,507 1,190 
YLL 25,153 26,328 26,040 27,554 28,596 23,046 
YLD 272,551 284,553 281,880 299,822 309,210 250,233 
DALY 297,705 310,881 307,921 327,377 337,806 273,279 
Rank 15 19 18 20 21 12 
Aggressive strategies 
  918 month   612 month  
 DT UN Alere DT UN Alere 
Test results: 
TP 1,512 1,586 1,227 1,400 1,200 1,359 
FN 244 130 4 0 189 19 
FP 5,010 195 18 7,124 2,053 32 
TN 10,275 15,255 14,645 9,699 15,035 16,195 
Costs: 
Testing $281,075.05 $175,660.60 $599,814.32 $354,825.39 $235,797.89 $664,861.85 
Counseling $33,790.31 $26,884.09 $24,239.70 $38,437.99 $31,071.88 $26,869.50 
Healthcare  $820,714.74 $861,230.30 $666,079.50 $760,045.59 $651,476.89 $737,784.61 
Total costs $1,135,580.10 $1,063,774.99 $1,290,133.52 $1,153,308.98 $918,346.67 $1,429,515.96 
Costs/infant $113.56 $106.38 $129.01 $115.33 $91.81 $142.95 
Rank 18 15 19 16 13 20 
Outcomes:  
Missed diag. 584 503 473 462 483 459 
YLL 22,586 20,796 16,254 19,504 20,554 19,256 
YLD 250,935 231,606 180,770 218,103 230,213 215,025 
DALY 273,521 252,403 197,025 237,607 250,767 234,281 
Rank 13 11 2 8 10 7 
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Table 20 (continued). Base case results: Point-of-care results, total costs, and pediatric outcomes for early 
infant diagnosis algorithms 
Minimal testing strategies 
  12 month   15 month  
 DT UN Alere DT UN Alere 
Test results: 
TP 465 308 438 586 564 688 
FN 0 243 4 147 141 1 
FP 899 0 14 342 0 8 
TN 5,612 6,353 6,226 6,417 6,872 6,938 
Costs: 
Testing $69,379.84 $56,346.84 $249,681.72 $55,716.61 $69,730.75 $291,582.00 
Counseling $11,860.47 $10,158.83 $10,076.25 $11,939.74 $11,509.08 $11,801.72 
Healthcare  $252,520.93 $167,187.68 $237,820.59 $318,324.43 $305,966.19 $373,726.37 
Total costs $333,761.24 $233,693.35 $497,578.57 $385,980.78 $387,206.01 $677,110.09 
Costs/infant $33.38 $23.37 $49.76 $38.60 $38.72 $67.71 
Rank 4 2 11 7 5 12 
Outcomes:  
Missed diag. 1,163 1,151 1,313 733 704 689 
YLL 23,481 25,500 25,659 20,201 19,423 18,255 
YLD 255,245 278,594 277,974 223,359 215,003 201,700 
DALY 278,726 304,094 303,634 243,559 233,526 219,955 
Rank 14 17 16 9 6 5 
Aggressive strategies 
  615 month     
 DT UN Alere    
Test results: 
TP 1,504 1,262 1,393    
FN 146 142 12    
FP 6,544 2,053 33    
TN 9,902 14,640 16,427    
Costs: 
Testing $337,758.91 $235,440.08 $675,125.29    
Counseling $37,554.88 $30,637.45 $27,286.82    
Healthcare  $816,478.69 $684,898.36 $756,076.68    
Total costs $1,191,792.48 $950,975.89 $1,458,488.80    
Costs/infant $119.18 $95.08 $145.85    
Rank 17 14 21    
Outcomes:  
Missed diag. 160 163 228    
YLL 17,650 16,014 15,636    
YLD 200,342 182,118 176,952    
DALY 217,992 198,132 192,588    
Rank 4 3 1    
 99 
 
REFERENCES 
 
1. UNAIDS. 2013 Progress Report on the Global Plan towards the elimination of new HIV 
infections among children by 2015 and keeping their mothers alive2013. 
2. WHO. Guidelines on HIV and infant feeding. Principles and recommendations for infant feeding 
in the context of HIV and a summary of evidence. Geneva, Switzerland2010  
3. UNAIDS Report on the Global AIDS Epidemic 2011. 
4. WHO. Antiretroviral drugs for treating pregnancy women and preventing HIV infections in 
infants: Geneva, Switzerland.;2010. 
5. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the 
treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. 
Journal of acquired immune deficiency syndromes (1999). Apr 15 2002;29(5):484-494. 
6. Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analysis of late postnatal 
mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-
to-Child Transmission of HIV. Lancet. Aug 22 1998;352(9128):597-600. 
7. Van de Perre P. Mother-to-child transmission of HIV-1: the 'all mucosal' hypothesis as a 
predominant mechanism of transmission. AIDS. Jun 18 1999;13(9):1133-1138. 
8. WHO. Guidelines on HIV and infant feeding 2010. Geneva, Switzerland2010. 
9. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-
infected infants. The New England journal of medicine. Nov 20 2008;359(21):2233-2244. 
10. WHO. WHO recommendations on the diagnosis of HIV infection in infants and children. 2010; 
http://whqlibdoc.who.int/publications/2010/9789241599085_eng.pdf. Accessed October 5, 2013. 
11. Watson-Jones D, Balira R, Ross DA, Weiss HA, Mabey D. Missed Opportunities: Poor Linkage 
into Ongoing Care for HIV-Positive Pregnant Women in Mwanza, Tanzania. PLoS One. 
2012;7(7):e40091. 
12. Marcos Y, Ryan Phelps B, Bachman G. Community strategies that improve care and retention 
along the prevention of mother-to-child transmission of HIV cascade: a review. Journal of the 
International AIDS Society. 2012;15 Suppl 2:17394. 
13. Moodley D, Bobat RA, Coutsoudis A, Coovadia HM. Predicting perinatal human 
immunodeficiency virus infection by antibody patterns. The Pediatric infectious disease journal. 
Oct 1995;14(10):850-852. 
14. Sirinavin S, Atamasirikul K. Semiquantitative human immunodeficiency virus antibody tests in 
diagnosis of vertical infection. The Pediatric infectious disease journal. Dec 2000;19(12):1153-
1157. 
15. Parekh BS, Shaffer N, Coughlin R, et al. Dynamics of maternal IgG antibody decay and HIV-
specific antibody synthesis in infants born to seropositive mothers. The NYC Perinatal HIV 
Transmission Study Group. AIDS research and human retroviruses. Sep 1993;9(9):907-912. 
 100 
 
16. Gulia J, Kumwenda N, Li Q, Taha TE. HIV seroreversion time in HIV-1-uninfected children born 
to HIV-1-infected mothers in Malawi. Journal of acquired immune deficiency syndromes (1999). 
Nov 1 2007;46(3):332-337. 
17. Sherman GG, Lilian RR, Coovadia AH. The performance of 5 rapid HIV tests using whole blood 
in infants and children: selecting a test to achieve the clinical objective. The Pediatric infectious 
disease journal. Mar 2012;31(3):267-272. 
18. UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 
and keeping their mothers alive: 2011-2015. Joint United Nations Programme on 
HIV/AIDS2010. 
19. UNAIDS. Global Report: UNAIDS report on the global AIDS epidemic 20132013. 
20. UNAIDS. Together we will end AIDS2012. 
21. UNICEF. Towards Universal Access: Scaling up HIV services for women and children in the 
health sector – Progress Report 2008. New York2008. 
22. UNAIDS. World AIDS Day Report. 2012. 
23. WHO. PMTCT Strategic Vision 2010-1025: Preventing mother-to-child transmission of HIV to 
reach the UNGASS and Millinium Development Goals2010. 
24. Hassan AS, Sakwa EM, Nabwera HM, et al. Dynamics and constraints of early infant diagnosis 
of HIV infection in Rural Kenya. AIDS and behavior. Jan 2012;16(1):5-12. 
25. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected 
and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. Oct 2-8 
2004;364(9441):1236-1243. 
26. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, et al. Predictors of early mortality in a cohort of 
human immunodeficiency virus type 1-infected african children. The Pediatric infectious disease 
journal. Jun 2004;23(6):536-543. 
27. WHO. WHO recommendations on the diagnosis of HIV infection in infants and children. 2010. 
28. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. 
Pediatrics. Nov 2008;122(5):1127-1134. 
29. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for 
early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. The Journal of 
pediatrics. Jan 2012;160(1):60-66 e61. 
30. Read JS. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. 
Pediatrics. Dec 2007;120(6):e1547-1562. 
31. Painter TM, Diaby KL, Matia DM, et al. Sociodemographic factors associated with participation 
by HIV-1-positive pregnant women in an intervention to prevent mother-to-child transmission of 
HIV in Cote d'Ivoire. International journal of STD & AIDS. Mar 2005;16(3):237-242. 
 101 
 
32. Sherman GG, Jones SA, Coovadia AH, Urban MF, Bolton KD. PMTCT from research to reality--
results from a routine service. South African medical journal = Suid-Afrikaanse tydskrif vir 
geneeskunde. Apr 2004;94(4):289-292. 
33. Manzi M, Zachariah R, Teck R, et al. High acceptability of voluntary counselling and HIV-
testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission 
programme in rural Malawi: scaling-up requires a different way of acting. Tropical medicine & 
international health : TM & IH. Dec 2005;10(12):1242-1250. 
34. Mirkuzie AH, Hinderaker SG, Sisay MM, Moland KM, Morkve O. Current status of medication 
adherence and infant follow up in the prevention of mother to child HIV transmission programme 
in Addis Ababa: a cohort study. Journal of the International AIDS Society. 2011;14:50. 
35. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a 
systematic review. PLoS medicine. Jul 2011;8(7):e1001056. 
36. Okonji JA, Zeh C, Weidle PJ, et al. CD4, viral load response, and adherence among 
antiretroviral-naive breast-feeding women receiving triple antiretroviral prophylaxis for 
prevention of mother-to-child transmission of HIV in Kisumu, Kenya. Journal of acquired 
immune deficiency syndromes (1999). Oct 1 2012;61(2):249-257. 
37. Chetty T, Knight S, Giddy J, Crankshaw TL, Butler LM, Newell ML. A retrospective study of 
Human Immunodeficiency Virus transmission, mortality and loss to follow-up among infants in 
the first 18 months of life in a prevention of mother-to-child transmission programme in an urban 
hospital in KwaZulu-Natal, South Africa. BMC pediatrics. Sep 10 2012;12(1):146. 
38. Kurewa NE, Munjoma MM, Chirenje ZM, Rusakaniko S, Hussain A, Stray-Pedersen B. 
Compliance and loss to follow up of HIV negative and positive mothers recruited from a PMTCT 
programme in Zimbabwe. The Central African journal of medicine. May-Aug 2007;53(5-8):25-
30. 
39. Kurewa EN, Kandawasvika GQ, Mhlanga F, et al. Realities and Challenges of a Five Year 
Follow Up of Mother and Child Pairs on a PMTCT Program in Zimbabwe. The open AIDS 
journal. 2011;5:51-58. 
40. Kirsten I, Sewangi J, Kunz A, et al. Adherence to combination prophylaxis for prevention of 
mother-to-child-transmission of HIV in Tanzania. PLoS One. 2011;6(6):e21020. 
41. Nassali M, Nakanjako D, Kyabayinze D, Beyeza J, Okoth A, Mutyaba T. Access to HIV/AIDS 
care for mothers and children in sub-Saharan Africa: adherence to the postnatal PMTCT program. 
AIDS care. Sep 2009;21(9):1124-1131. 
42. Darak S, Panditrao M, Parchure R, Kulkarni V, Kulkarni S, Janssen F. Systematic review of 
public health research on prevention of mother-to-child transmission of HIV in India with focus 
on provision and utilization of cascade of PMTCT services. BMC Public Health. 2012;12:320. 
43. Becquet R, Marston M, Dabis F, et al. Children who acquire HIV infection perinatally are at 
higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. 
PLoS One. 2012;7(2):e28510. 
 102 
 
44. Phadke MA, Gadgil B, Bharucha KE, et al. Replacement-fed infants born to HIV-infected 
mothers in India have a high early postpartum rate of hospitalization. The Journal of nutrition. 
Oct 2003;133(10):3153-3157. 
45. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 
months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV 
transmission in Botswana: a randomized trial: the Mashi Study. JAMA : the journal of the 
American Medical Association. Aug 16 2006;296(7):794-805. 
46. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection 
during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet. 
Mar 31 2007;369(9567):1107-1116. 
47. Doherty T, Chopra M, Jackson D, Goga A, Colvin M, Persson LA. Effectiveness of the 
WHO/UNICEF guidelines on infant feeding for HIV-positive women: results from a prospective 
cohort study in South Africa. AIDS. Aug 20 2007;21(13):1791-1797. 
48. Jackson DJ, Chopra M, Doherty TM, et al. Operational effectiveness and 36 week HIV-free 
survival in the South African programme to prevent mother-to-child transmission of HIV-1. 
AIDS. Feb 19 2007;21(4):509-516. 
49. Onyango-Makumbi C, Bagenda D, Mwatha A, et al. Early Weaning of HIV-Exposed Uninfected 
Infants and Risk of Serious Gastroenteritis: Findings from Two Perinatal HIV Prevention Trials 
in Kampala, Uganda. Journal of acquired immune deficiency syndromes (1999). Sep 25 2009. 
50. Creek TL, Kim A, Lu L, et al. Hospitalization and mortality among primarily nonbreastfed 
children during a large outbreak of diarrhea and malnutrition in Botswana, 2006. Journal of 
acquired immune deficiency syndromes (1999). Jan 2010;53(1):14-19. 
51. Homsy J, Moore D, Barasa A, et al. Breastfeeding, mother-to-child HIV transmission, and 
mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in 
rural Uganda. Journal of acquired immune deficiency syndromes (1999). Jan 2010;53(1):28-35. 
52. Kafulafula G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and gastroenteritis-
associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected 
women in Malawi. Journal of acquired immune deficiency syndromes (1999). Jan 2010;53(1):6-
13. 
53. Arpadi S, Fawzy A, Aldrovandi GM, et al. Growth faltering due to breastfeeding cessation in 
uninfected children born to HIV-infected mothers in Zambia. The American journal of clinical 
nutrition. Aug 2009;90(2):344-353. 
54. Rollins NC, Becquet R, Bland RM, Coutsoudis A, Coovadia HM, Newell ML. Infant feeding, 
HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and 
prioritization within programmes. AIDS. Nov 12 2008;22(17):2349-2357. 
55. Iliff PJ, Piwoz EG, Tavengwa NV, et al. Early exclusive breastfeeding reduces the risk of 
postnatal HIV-1 transmission and increases HIV-free survival. AIDS. Apr 29 2005;19(7):699-
708. 
 103 
 
56. Kuhn L, Sinkala M, Kankasa C, et al. High uptake of exclusive breastfeeding and reduced early 
post-natal HIV transmission. PLoS One. 2007;2(12):e1363. 
57. de Paoli MM, Mkwanazi NB, Richter LM, Rollins N. Early cessation of breastfeeding to prevent 
postnatal transmission of HIV: a recommendation in need of guidance. Acta paediatrica (Oslo, 
Norway : 1992). Dec 2008;97(12):1663-1668. 
58. Becquet R, Leroy V, Ekouevi DK, et al. Complementary feeding adequacy in relation to 
nutritional status among early weaned breastfed children who are born to HIV-infected mothers: 
ANRS 1201/1202 Ditrame Plus, Abidjan, Cote d'Ivoire. Pediatrics. Apr 2006;117(4):e701-710. 
59. Lunney KM, Jenkins AL, Tavengwa NV, et al. HIV-positive poor women may stop breast-
feeding early to protect their infants from HIV infection although available replacement diets are 
grossly inadequate. The Journal of nutrition. Feb 2008;138(2):351-357. 
60. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce 
HIV-1 transmission. The New England journal of medicine. Jun 17 2010;362(24):2271-2281. 
61. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding 
in Botswana. The New England journal of medicine. Jun 17 2010;362(24):2282-2294. 
62. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of 
mother-to-child transmission of HIV infection. Cochrane database of systematic reviews 
(Online). 2011(7):CD003510. 
63. UNAIDS. Regional Fact Sheets: sub-Saharan Africa 
(http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/201
2_FS_regional_ssa_en.pdf). 2012. Accessed December 10, 2012. 
64. Dube Q, Dow A, Chirambo C, et al. Implementing early infant diagnosis of HIV infection at the 
primary care level: experiences and challenges in Malawi. Bulletin of the World Health 
Organization. Sep 1 2012;90(9):699-704. 
65. Health Mo. Prevention of Mother to Child Tranmission of HIV. Malawi2008. 
66. UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010. UNAIDS Global Report. 2010. 
67. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after 
pregnancy in low-income, middle-income, and high-income countries: a systematic review and 
meta-analysis. AIDS. Oct 23 2012;26(16):2039-2052. 
68. Kurewa NE, Gumbo FZ, Mapingure PM, et al. Predictors of attrition among children born in a 
PMTCT programme in Zimbabwe followed up over 5 years. Journal of tropical pediatrics. Oct 
2012;58(5):360-369. 
69. Stringer EM, Ekouevi DK, Coetzee D, et al. Coverage of nevirapine-based services to prevent 
mother-to-child HIV transmission in 4 African countries. JAMA : the journal of the American 
Medical Association. Jul 21 2010;304(3):293-302. 
 104 
 
70. BM B. Point-of-Care Rapid Tests for HIV antibody. 2003; 
http://www.cdc.gov/hiv/rapid_testing/materials/J.Lab_Med_20031.htm. Accessed October 7, 
2013. 
71. WHO. Rapid HIV tests: Guidelines for use in HIV testing and counseling services. Geneva, 
Switzerland2004. 
72. Delaney KP, Branson BM, Uniyal A, et al. Evaluation of the performance characteristics of 6 
rapid HIV antibody tests. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America. Jan 15 2011;52(2):257-263. 
73. Sherman GG, Driver GA, Coovadia AH. Evaluation of seven rapid HIV tests to detect HIV-
exposure and seroreversion during infancy. Journal of clinical virology : the official publication 
of the Pan American Society for Clinical Virology. Nov 2008;43(3):313-316. 
74. Opoku-Anane J, J K, al. e. Validity and acceptability of rapid HIV-1 tests in 9-month old infanst 
in Kenya. Abstract 613a. 1. 5th Conference on Retroviruses and Opportunistic Infections. Boston, 
Massachussetts.2008. 
75. Menzies NA, Homsy J, Chang Pitter JY, et al. Cost-effectiveness of routine rapid human 
immunodeficiency virus antibody testing before DNA-PCR testing for early diagnosis of infants 
in resource-limited settings. The Pediatric infectious disease journal. Sep 2009;28(9):819-825. 
76. Buchanan AM, Nadjm B, Amos B, et al. Utility of rapid antibody tests to exclude HIV-1 
infection among infants and children aged <18 months in a low-resource setting. Journal of 
clinical virology : the official publication of the Pan American Society for Clinical Virology. Nov 
2012;55(3):244-249. 
77. Claassen M, van Zyl GU, Korsman SN, Smit L, Cotton MF, Preiser W. Pitfalls with rapid HIV 
antibody testing in HIV-infected children in the Western Cape, South Africa. Journal of clinical 
virology : the official publication of the Pan American Society for Clinical Virology. Sep 
2006;37(1):68-71. 
78. Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection: a field evaluation of 
the determine(R) HIV-1/2 Ag/Ab combo test. J Infect Dis. Feb 15 2012;205(4):528-534. 
79. Pilcher CD, Louie B, Facente S, et al. Performance of Rapid Point-of-Care and Laboratory Tests 
for Acute and Established HIV Infection in San Francisco. PLoS One. 2013;8(12):e80629. 
80. Bhowan K, Sherman GG. Performance of the first fourth-generation rapid human 
immunodeficiency virus test in children. The Pediatric infectious disease journal. May 
2013;32(5):486-488. 
81. Zachary D, Mwenge L, Muyoyeta M, et al. Field comparison of OraQuick ADVANCE Rapid 
HIV-1/2 antibody test and two blood-based rapid HIV antibody tests in Zambia. BMC infectious 
diseases. 2012;12:183. 
82. Pant Pai N, Balram B, Shivkumar S, et al. Head-to-head comparison of accuracy of a rapid point-
of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. 
The Lancet infectious diseases. May 2012;12(5):373-380. 
 105 
 
83. Donovan BJ, Rublein JC, Leone PA, Pilcher CD. HIV infection: point-of-care testing. The Annals 
of pharmacotherapy. Apr 2004;38(4):670-676. 
84. Sherman GG, Lilian RR, Coovadia AH. Oral fluid tests for screening of human 
immunodeficiency virus-exposed infants. The Pediatric infectious disease journal. Feb 
2010;29(2):169-172. 
85. Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal 
interface. Reviews of reproduction. May 1999;4(2):81-89. 
86. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of 
immunoglobulins during human pregnancy. American journal of reproductive immunology (New 
York, N.Y. : 1989). Nov 1996;36(5):248-255. 
87. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental 
transfer in healthy and pathological pregnancies. Clinical & developmental immunology. 
2012;2012:985646. 
88. van den Berg JP, Westerbeek EA, van der Klis FR, Berbers GA, van Elburg RM. Transplacental 
transport of IgG antibodies to preterm infants: a review of the literature. Early human 
development. Feb 2011;87(2):67-72. 
89. Mantyjarvi R, Hirvonen T, Toivanen P. Maternal antibodies in human neonatal sera. 
Immunology. Mar 1970;18(3):449-451. 
90. Doroudchi M, Samsami Dehaghani A, Emad K, Ghaderi A. Placental transfer of rubella-specific 
IgG in fullterm and preterm newborns. International journal of gynaecology and obstetrics: the 
official organ of the International Federation of Gynaecology and Obstetrics. May 
2003;81(2):157-162. 
91. Okoko JB, Wesumperuma HL, Hart CA. The influence of prematurity and low birthweight on 
transplacental antibody transfer in a rural West African population. Tropical medicine & 
international health : TM & IH. Jul 2001;6(7):529-534. 
92. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or 
vaccine-induced maternal antibodies against measles in newborns. Vaccine. Aug 21 
2007;25(34):6296-6304. 
93. Wesumperuma HL, Perera AJ, Pharoah PO, Hart CA. The influence of prematurity and low 
birthweight on transplacental antibody transfer in Sri Lanka. Annals of tropical medicine and 
parasitology. Mar 1999;93(2):169-177. 
94. Bunders M, Pembrey L, Kuijpers T, Newell ML. Evidence of impact of maternal HIV infection 
on immunoglobulin levels in HIV-exposed uninfected children. AIDS research and human 
retroviruses. Sep 2010;26(9):967-975. 
95. Hartter HK, Oyedele OI, Dietz K, Kreis S, Hoffman JP, Muller CP. Placental transfer and decay 
of maternally acquired antimeasles antibodies in Nigerian children. The Pediatric infectious 
disease journal. Jul 2000;19(7):635-641. 
 106 
 
96. Okoko BJ, Wesuperuma LH, Ota MO, et al. Influence of placental malaria infection and maternal 
hypergammaglobulinaemia on materno-foetal transfer of measles and tetanus antibodies in a rural 
west African population. Journal of health, population, and nutrition. Jun 2001;19(2):59-65. 
97. de Moraes-Pinto MI, Verhoeff F, Chimsuku L, et al. Placental antibody transfer: influence of 
maternal HIV infection and placental malaria. Archives of disease in childhood. Fetal and 
neonatal edition. Nov 1998;79(3):F202-205. 
98. de Moraes-Pinto MI, Almeida AC, Kenj G, et al. Placental transfer and maternally acquired 
neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis. May 
1996;173(5):1077-1084. 
99. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and -nonspecific B cell responses are 
sensitive to combination antiretroviral therapy. The Journal of experimental medicine. Jul 20 
1998;188(2):233-245. 
100. Jones C, Pollock L, Barnett SM, Battersby A, Kampmann B. Specific antibodies against vaccine-
preventable infections: a mother-infant cohort study. BMJ open. 2013;3(4). 
101. Cumberland P, Shulman CE, Maple PA, et al. Maternal HIV infection and placental malaria 
reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect 
Dis. Aug 15 2007;196(4):550-557. 
102. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection 
and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA : the 
journal of the American Medical Association. Feb 9 2011;305(6):576-584. 
103. de Moraes-Pinto MI, Farhat CK, Carbonare SB, et al. Maternally acquired immunity in newborns 
from women infected by the human immunodeficiency virus. Acta paediatrica (Oslo, Norway : 
1992). Dec 1993;82(12):1034-1038. 
104. Moro L, Bardaji A, Nhampossa T, et al. Malaria and HIV infection in Mozambican pregnant 
women are associated with reduced transfer of antimalarial antibodies to the newborn. J Infect 
Dis. Sep 30 2014. 
105. Farquhar C, Nduati R, Haigwood N, et al. High maternal HIV-1 viral load during pregnancy is 
associated with reduced placental transfer of measles IgG antibody. Journal of acquired immune 
deficiency syndromes (1999). Dec 1 2005;40(4):494-497. 
106. Scott S, Cumberland P, Shulman CE, et al. Neonatal measles immunity in rural Kenya: the 
influence of HIV and placental malaria infections on placental transfer of antibodies and levels of 
antibody in maternal and cord serum samples. J Infect Dis. Jun 1 2005;191(11):1854-1860. 
107. Andiman WA, Simpson BJ, Olson B, Dember L, Silva TJ, Miller G. Rate of transmission of 
human immunodeficiency virus type 1 infection from mother to child and short-term outcome of 
neonatal infection. Results of a prospective cohort study. American journal of diseases of 
children (1960). Jul 1990;144(7):758-766. 
108. Arico M, Caselli D, Marconi M, et al. Immunoglobulin G3-specific antibodies as a marker for 
early diagnosis of HIV infection in children. AIDS. Nov 1991;5(11):1315-1318. 
 107 
 
109. Chantry CJ, Cooper ER, Pelton SI, Zorilla C, Hillyer GV, Diaz C. Seroreversion in human 
immunodeficiency virus-exposed but uninfected infants. The Pediatric infectious disease journal. 
May 1995;14(5):382-387. 
110. Sohn AH, Thanh TC, Thinh le Q, et al. Failure of human immunodeficiency virus enzyme 
immunoassay to rule out infection among polymerase chain reaction-negative Vietnamese infants 
at 12 months of age. The Pediatric infectious disease journal. Apr 2009;28(4):273-276. 
111. Van de Perre P. Transfer of antibody via mother's milk. Vaccine. Jul 28 2003;21(24):3374-3376. 
112. Sato H, Albrecht P, Reynolds DW, Stagno S, Ennis FA. Transfer of measles, mumps, and rubella 
antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization. 
American journal of diseases of children (1960). Dec 1979;133(12):1240-1243. 
113. Ogra SS, Ogra PL. Immunologic aspects of human colostrum and milk. I. Distribution 
characteristics and concentrations of immunoglobulins at different times after the onset of 
lactation. The Journal of pediatrics. Apr 1978;92(4):546-549. 
114. Islam SK, Ahmed L, Khan MN, Huque S, Begum A, Yunus AB. Immune components (IgA, IgM, 
IgG, immune cells) of colostrum of Bangladeshi mothers. Pediatrics international : official 
journal of the Japan Pediatric Society. Dec 2006;48(6):543-548. 
115. Mickleson KN, Moriarty KM. Immunoglobulin levels in human colostrum and milk. Journal of 
pediatric gastroenterology and nutrition. 1982;1(3):381-384. 
116. Gasparoni A, Avanzini A, Ravagni Probizer F, Chirico G, Rondini G, Severi F. IgG subclasses 
compared in maternal and cord serum and breast milk. Archives of disease in childhood. Jan 
1992;67(1 Spec No):41-43. 
117. Nicoara C, Zach K, Trachsel D, Germann D, Matter L. Decay of passively acquired maternal 
antibodies against measles, mumps, and rubella viruses. Clinical and diagnostic laboratory 
immunology. Nov 1999;6(6):868-871. 
118. Waaijenborg S, Hahne SJ, Mollema L, et al. Waning of maternal antibodies against measles, 
mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis. 
Jul 2013;208(1):10-16. 
119. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis 
antibodies in maternal delivery, cord, and infant serum. J Infect Dis. Jul 15 2004;190(2):335-340. 
120. de Francisco A, Hall AJ, Unicomb L, Chakraborty J, Yunus M, Sack RB. Maternal measles 
antibody decay in rural Bangladeshi infants--implications for vaccination schedules. Vaccine. Apr 
1998;16(6):564-568. 
121. Dabis F, Waldman RJ, Mann GF, Commenges D, Madzou G, Jones TS. Loss of maternal measles 
antibody during infancy in an African city. International journal of epidemiology. Mar 
1989;18(1):264-268. 
122. Kilic A, Altinkaynak S, Ertekin V, Inandi T. The duration of maternal measles antibodies in 
children. Journal of tropical pediatrics. Oct 2003;49(5):302-305. 
 108 
 
123. Black FL. Measles active and passive immunity in a worldwide perspective. Progress in medical 
virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale. 
1989;36:1-33. 
124. Kiepiela P, Coovadia HM, Loening WE, Coward P, Abdool Karim SS. Loss of maternal measles 
antibody in black South African infants in the first year of life--implications for age of 
vaccination. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. Feb 2 
1991;79(3):145-148. 
125. Simpson BJ, Andiman WA. Difficulties in assigning human immunodeficiency virus-1 infection 
and seroreversion status in a cohort of HIV-exposed in children using serologic criteria 
established by the Centers for Disease Control and Prevention. Pediatrics. May 1994;93(5):840-
842. 
126. Gutierrez M, Ludwig DA, Khan SS, et al. Has highly active antiretroviral therapy increased the 
time to seroreversion in HIV exposed but uninfected children? Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America. Nov 2012;55(9):1255-1261. 
127. Mother-to-child transmission of HIV infection. The European Collaborative Study. Lancet. Nov 5 
1988;2(8619):1039-1043. 
128. Alvarez-Uria G, Naik PK, Midde M, Kannan S, Reddy R. False negative HIV antibody test in 
HIV infected children who receive early antiretroviral treatment in a resource-limited setting. 
Infectious disease reports. Jan 2 2012;4(1):e6. 
129. Creek TL, Sherman GG, Nkengasong J, et al. Infant human immunodeficiency virus diagnosis in 
resource-limited settings: issues, technologies, and country experiences. American journal of 
obstetrics and gynecology. Sep 2007;197(3 Suppl):S64-71. 
130. Malawi Demographic and Health Survey2010. 
131. Giuliano M, Andreotti M, Liotta G, et al. Maternal antiretroviral therapy for the prevention of 
mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after 
delivery. PLoS One. 2013;8(7):e68950. 
132. Aalen O, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based 
on censored observations. Scandinavian Journal of Statistics. 1978;5(3):141-150. 
133. Coutsoudis A, Dabis F, Fawzi W, et al. Late postnatal transmission of HIV-1 in breast-fed 
children: an individual patient data meta-analysis. J Infect Dis. Jun 15 2004;189(12):2154-2166. 
134. Taha TE, Hoover DR, Kumwenda NI, et al. Late postnatal transmission of HIV-1 and associated 
factors. J Infect Dis. Jul 1 2007;196(1):10-14. 
135. Peto R. Experimental Survival Curves for Interval-Censored Data. Applied Statistics. 1973;22:86-
91. 
136. Turnbull BW. The Empirical Distribution Function with Arbitrarily Grouped, Censored and 
Truncated Data. Journal of the Royal Statistical Society. 1976;38:290-295. 
 109 
 
137. Wellner J, Zhan Y. A hybrid algorithm for computation of the nonparametric maximum 
likelihood estimator from censored data. JASA. 1997. 
138. WHO. The World Health Report, 2002 - Reducing Risks, Promoting Healthy Life. . Geneva, 
Switzerland.2002. 
139. Coffie PA, Ekouevi DK, Chaix ML, et al. Maternal 12-month response to antiretroviral therapy 
following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. 
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 
Feb 15 2008;46(4):611-621. 
140. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant 
HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 
transmission in the United States (revised November 3, 2000). HIV clinical trials. Jan-Feb 
2001;2(1):56-91. 
141. Shapiro RL, Lockman S, Thior I, et al. Low adherence to recommended infant feeding strategies 
among HIV-infected women: results from the pilot phase of a randomized trial to prevent mother-
to-child transmission in Botswana. AIDS education and prevention : official publication of the 
International Society for AIDS Education. Jun 2003;15(3):221-230. 
142. Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-
to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a 
clinical trial. PLoS medicine. Mar 2011;8(3):e1001015. 
143. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine 
regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of 
postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. 
Lancet. Jan 21 2012;379(9812):221-228. 
144. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in 
Zambia: feasibility and early outcomes. JAMA : the journal of the American Medical Association. 
Aug 16 2006;296(7):782-793. 
145. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Loss to follow-up and mortality among 
pregnant women referred to a community clinic for antiretroviral treatment. AIDS. Aug 20 
2008;22(13):1679-1681. 
146. Sibanda EL, Weller IV, Hakim JG, Cowan FM. The magnitude of loss to follow-up of HIV-
exposed infants along the prevention of mother-to-child HIV transmission continuum of care: a 
systematic review and meta-analysis. AIDS. Nov 13 2013;27(17):2787-2797. 
147. Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal antiretroviral therapy for 
HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. AIDS. Feb 20 
2014;28(4):589-598. 
148. WHO. WHO recommendations for routine immunization. Geneva, Switzerland.2010. 
149. Herce ME, Mtande T, Chimbwandira F, et al. Supporting Option B+ scale up and strengthening 
the prevention of mother-to-child transmission cascade in central Malawi: results from a serial 
cross-sectional study. BMC infectious diseases. 2015;15:328. 
 110 
 
150. Price AJ, Kayange M, Zaba B, et al. Uptake of prevention of mother-to-child-transmission using 
Option B+ in northern rural Malawi: a retrospective cohort study. Sex Transm Infect. Jun 
2014;90(4):309-314. 
151. UNICEF. Option B and B+: Key Considerations for Countries to Implement an Equity-focused 
Approach2012. 
152. UNICEF. State of the World's Children 2011, UNICEF: Global UNAIDS Response: Epidemic 
update and health sector progress towards Universal Access, Progress Report2012. 
153. Impact of an innovative approach to prevent mother-to-child transmission of HIV--Malawi, July 
2011-September 2012. MMWR. Morbidity and mortality weekly report. Mar 1 2013;62(8):148-
151. 
154. Marston M, Becquet R, Zaba B, et al. Net survival of perinatally and postnatally HIV-infected 
children: a pooled analysis of individual data from sub-Saharan Africa. International journal of 
epidemiology. Apr 2011;40(2):385-396. 
155. Global Health Observatory: World Health Organization. Country of Malawi. 
http://www.who.int/countries/mwi/en/. 2015. Accessed June 1st, 2015. 
156. Ciaranello AL, Myer L, Kelly K, et al. Point-of-care CD4 testing to inform selection of 
antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis. PLoS 
One. 2015;10(3):e0117751. 
157. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease 
and injury: disability weights measurement study for the Global Burden of Disease Study 2010. 
Lancet. Dec 15 2012;380(9859):2129-2143. 
158. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 
289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet. Dec 15 2012;380(9859):2163-2196. 
159. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 
causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. 
Lancet. Jan 10 2015;385(9963):117-171. 
160. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV 
status in Zimbabwe. The Pediatric infectious disease journal. Jun 2007;26(6):519-526. 
161. Ciaranello AL, Perez F, Engelsmann B, et al. Cost-effectiveness of World Health Organization 
2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. Feb 
2013;56(3):430-446. 
162. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination 
antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Annals of internal 
medicine. Aug 16 2011;155(4):209-216. 
 111 
 
163. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting 
antiretroviral treatment: collaborative analysis of cohort studies. PLoS medicine. 
2013;10(4):e1001418. 
164. Idele P, Gillespie A, Porth T, et al. Epidemiology of HIV and AIDS among adolescents: current 
status, inequities, and data gaps. Journal of acquired immune deficiency syndromes (1999). Jul 1 
2014;66 Suppl 2:S144-153. 
165. Pricing for HIV Viral Load Testing in Low- and Middle-Income Countries: Médecins Sans 
Frontières 2013. 
166. Stevens W, Sherman G, Downing R, et al. Role of the laboratory in ensuring global access to 
ARV treatment for HIV-infected children: consensus statement on the performance of laboratory 
assays for early infant diagnosis. The open AIDS journal. 2008;2:17-25. 
167. Binagwaho A, Pegurri E, Drobac PC, et al. Prevention of mother-to-child transmission of HIV: 
cost-effectiveness of antiretroviral regimens and feeding options in Rwanda. PLoS One. 
2013;8(2):e54180. 
168. Gopalappa C, Stover J, Shaffer N, Mahy M. The costs and benefits of Option B+ for the 
prevention of mother-to-child transmission of HIV. AIDS. Jan 2014;28 Suppl 1:S5-14. 
169. Yuan Y. Multiple imputation using SAS software. Journal of Statistical Software. 2011;45(6):1-
25. 
170. Hsiao N. Evaluation of the Alere q for point-of-care early infant HIV diagnosis in South Africa. 
CROI. Seattle, Washington2015. 
171. Jani IV, Meggi B, Mabunda N, et al. Accurate early infant HIV diagnosis in primary health 
clinics using a point-of-care nucleic acid test. Journal of acquired immune deficiency syndromes 
(1999). Sep 1 2014;67(1):e1-4. 
172. World Health Organization Global Health Observatory Data Repository. Malawi. 
http://apps.who.int/gho/data/?theme=main&vid=60980. 2015. Accessed June 30, 2015. 
173. WHO. The Global Burden of Disease Concept - World Health Organization. Geneza, 
Switzerland: World Health Organization;2003. 
174. Murray CJ, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality 
and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, 
MA: Harvard School of Public Health;1996. 
175. Gold M, Siegel J, Russell L. Cost-Effectiveness in Health and Medicine. New York: Oxford 
University Press; 1996. 
176. Muenning P. Cost-effectiveness Analysis in Health: A Practical Approach. San Francisco: John 
Wiley & Sons; 2008. 
177. The WHO report 2002. Reducing risks, promoting health life. Geneva, Switzerland: WHO;2002. 
 112 
 
178. Macroeconomics and health: investing in health for economic development. 
http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Accessed September 2nd, 2015. 
179. Fiscus SA, Pilcher CD, Miller WC, et al. Rapid, real-time detection of acute HIV infection in 
patients in Africa. J Infect Dis. Feb 1 2007;195(3):416-424. 
180. Powers KA, Miller WC, Pilcher CD, et al. Improved detection of acute HIV-1 infection in sub-
Saharan Africa: development of a risk score algorithm. AIDS. Oct 18 2007;21(16):2237-2242. 
181. Pavie J, Rachline A, Loze B, et al. Sensitivity of five rapid HIV tests on oral fluid or finger-stick 
whole blood: a real-time comparison in a healthcare setting. PLoS One. 2010;5(7):e11581. 
182. WHO. HIV and infant feeding: update based on the technical consultation held on behalf of the 
Inter-agency Team (IATT) on Prevention of HIV Infections in Pregnant Women, Mothers, and 
their Infants. Geneva, Switzerland, 25-27 October 2006.2007. 
183. Chiappini E, Galli L, Tovo PA, et al. Virologic, immunologic, and clinical benefits from early 
combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS. Jan 9 
2006;20(2):207-215. 
184. Prendergast A, Mphatswe W, Tudor-Williams G, et al. Early virological suppression with three-
class antiretroviral therapy in HIV-infected African infants. AIDS. Jul 11 2008;22(11):1333-1343. 
185. Parpia ZA, Elghanian R, Nabatiyan A, Hardie DR, Kelso DM. p24 antigen rapid test for 
diagnosis of acute pediatric HIV infection. Journal of acquired immune deficiency syndromes 
(1999). Dec 2010;55(4):413-419. 
186. Boyle DS, Lehman DA, Lillis L, et al. Rapid detection of HIV-1 proviral DNA for early infant 
diagnosis using recombinase polymerase amplification. mBio. 2013;4(2). 
187. International Monetary Fund (IMF) - World Economic Outlook2014. 
188. Phillips T, McNairy M, Zerbe A, Myer L, Abrams EJ. Postpartum transfer of care among HIV-
infected women initiating antiretroviral therapy during pregnancy. Journal of acquired immune 
deficiency syndromes (1999). Jul 28 2015. 
189. Shaffer N, Abrams EJ, Becquet R. Option B+ for prevention of mother-to-child transmission of 
HIV in resource-constrained settings: great promise but some early caution. AIDS. Feb 20 
2014;28(4):599-601. 
190. Stinson K, Myer L. Barriers to initiating antiretroviral therapy during pregnancy: a qualitative 
study of women attending services in Cape Town, South Africa. African journal of AIDS 
research : AJAR. Mar 2012;11(1):65-73. 
191. Finocchario-Kessler S, Clark KF, Khamadi S, Gautney BJ, Okoth V, Goggin K. Progress Toward 
Eliminating Mother to Child Transmission of HIV in Kenya: Review of Treatment Guideline 
Uptake and Pediatric Transmission at Four Government Hospitals Between 2010 and 2012. AIDS 
and behavior. Apr 23 2015. 
 113 
 
192. Becquet R, Bland R, Leroy V, et al. Duration, pattern of breastfeeding and postnatal transmission 
of HIV: pooled analysis of individual data from West and South African cohorts. PLoS One. 
2009;4(10):e7397. 
193. Feucht UD, Meyer A, Thomas WN, Forsyth BW, Kruger M. Early diagnosis is critical to ensure 
good outcomes in HIV-infected children: outlining barriers to care. AIDS care. Aug 14 2015:1-
11. 
 
 
